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Thesis abstract 
Monoclonal antibodies (mAbs) have an invaluable role in the treatment of cancers, 
auto-immune and inflammatory conditions. Since their advent, approximately 80 
antibodies and antibody-based therapeutic products have gained marketing approval, 
quickly earning their positions in the list of top ten selling prescription products 
worldwide. One of the major challenges associated with the development of mAbs and 
novel antibody-based therapies, is protein aggregation - a degradation phenomenon 
which results in ‘clumping’ of proteins together, and subsequent loss of protein activity. 
Furthermore, antibody aggregates have been associated with immunogenic reactions 
experienced by patients undergoing immunotherapy with antibody products. 
Preventing antibody aggregation has major implications for the future of 
biopharmaceutical development; not only are immunogenic reactions minimised, the 
shelf-life of therapeutic antibodies is significantly increased thus reducing 
manufacturing costs, there is increased flexibility in the type of antibody formulations 
that can be manufactured - including non-invasive options - and the half-life of 
antibodies in vivo may be increased. Other types of degradation can also occur 
including deamidation, oxidation and fragmentation, although less commonly.  
We tackled the challenge of protein aggregation via two main approaches – 1) 
investigating novel additives and formulation approaches to suppress protein 
aggregation of model proteins and antibodies; 2) engineering structural changes to 
antibodies to enhance their stability and resistance to aggregation without 
compromising their therapeutic function.  Protein unfolding and aggregation was 
accelerated by incubation at elevated temperatures or by using chemical denaturants 
and characterised using intrinsic and extrinsic fluorescence, size-exclusion-HPLC and 
light scattering techniques. This orthogonal approach allowed us to probe the 
conformational and colloidal stability of the protein at every step in the aggregation 
process.  
Successful approaches discovered in our work include the use of novel stabilizing 
additives such as ionic liquids and an approach to engineering antibodies with 
additional glycosylation to strategically improve their conformational stability. The work 
described in this thesis paves the way for the development of next-generation 
therapeutic antibodies, or biobetters, which are resistant to aggregation. 
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Thesis introduction 
Chapter 1 of this thesis explores current developments in the field of antibody therapy, 
the types of degradation processes that affect antibodies and their formulations, the 
development of biobetter antibodies engineered with improved biophysical properties, 
and the outlook of the antibody therapeutic landscape. This chapter was published in 
the Editor’s issue of Advanced Drug Delivery Reviews: 
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V. (2017). The state-of-play and 
future of antibody therapeutics. Advanced Drug Delivery Reviews, 122:2-19. 
Amongst the many degradation processes affecting antibodies discussed in chapter 
1, protein aggregation is one of the most common and challenging. One consequence 
of this degradation process is reduced flexibility in the types of formulations that can 
be developed and administered. As such, many biologics such as antibodies are 
administered via diluted infusion bags, resulting in added inconvenience to the patient. 
In chapter 2, we investigated the combination use of two amino acids (arginine and 
glutamic acid) as synergistic stabilizing additives for an inhalable dry powder protein 
formulation. The study found that the hypothesised synergistic effect of these additives 
was not observed for the protein tested. It was concluded that the synergy of these 
amino acids was protein and concentration-specific. Chapter 2 was published in the 
Pharmaceutical Development and Technology journal: 
Reslan, M., Demir, Y., Trout, B., Chan, H., Kayser, V. (2017). Lack of a synergistic 
effect of arginine-glutamic acid on the physical stability of spray-dried bovine serum 
albumin. Pharmaceutical Development and Technology, 22:785-791. 
In chapter 3 we replaced H2O as the solvent for a protein formulation with deuterium 
oxide (D2O) to induce in hydrogen-deuterium exchange and deuteration of the protein. 
This was hypothesised to enhance protein stability as the protein’s intra-molecular 
interactions are strengthened by deuterium. We observed a modest improvement in 
the stability of the protein tested, however, the rate of aggregation was also increased. 
The work described in this chapter was published in the Pharmaceutical Development 
and Technology journal:  
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Reslan, M., Kayser, V. (2016). The effect of deuterium oxide on the conformational 
stability and aggregation of bovine serum albumin. Pharmaceutical Development and 
Technology, 1-7. 
Rapid developments in the field of ionic liquids and their widespread applications 
prompted a literature review of their use as potential stabilizers of proteins, an area of 
research which had not yet received its deserved attention. In chapter 4, we 
summarised the literature available on the effect of ionic liquids on protein stability and 
screened for biocompatible ionic liquids with potential application for the stabilization 
of therapeutic antibodies. This invited review was published in the Biophysical 
Reviews journal:  
Reslan, M., Kayser, V. (2018). Ionic liquids as biocompatible stabilizers of proteins. 
Biophysical Reviews. doi:10.1007/s12551-018-0407-6 
Monoclonal antibodies (mAbs) are multi-domain proteins with more complex 
aggregation pathways than smaller, globular proteins. To aid the development of 
rational approaches to stabilise mAbs, a mechanistic understanding of the aggregation 
process is needed. In chapter 5, we thoroughly studied the aggregation kinetics of 
trastuzumab - a marketed therapeutic mAb - and developed a simple model to 
characterise the process of aggregation connecting data from accelerated studies at 
elevated temperature to long-term storage at lower temperature. This study was 
prepared for publication to the European Journal of Pharmaceutics and 
Biopharmaceutics:  
Reslan, M., Kayser, V. (2018). Analysis of the aggregation kinetics of Herceptin® 
(trastuzumab). European Journal of Pharmaceutics and Biopharmaceutics. 
In chapter 6, we formulated trastuzumab at high concentrations with a biocompatible 
ionic liquid – choline dihydrogen phosphate (CDHP) – discovered during our previous 
literature search (chapter 4). At ~50% w/v concentrations of CDHP, we were 
successful in stabilizing trastuzumab at concentrations 3-fold higher (60 mg/mL) than 
the concentration of the marketed product. The complex effect of different 
concentrations of CDHP on the stability of trastuzumab was detailed in this chapter, 
including its effect on the conformational stability of each domain and the process of 
aggregation. Chapter 6 was published as a communication article at Chemical 
Communications:  
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Reslan, M., Vijayaraghavan R., Macfarlane D. R., Kayser, V. (2018). Choline ionic 
liquid enhances the stability of Herceptin® (trastuzumab). Chemical Communications, 
54:10622-10625.  
Antibody engineering is another approach utilised to prevent protein aggregation and 
enhance antibody stability. In chapter 7, We developed and described a cost-effective, 
simple and high-yielding protocol to express, purify and characterise therapeutic 
antibodies in preparation for our antibody engineering work. Chapter 7 was published 
in the Journal of Visualized Experiments:  
Elgundi, Z., Sifniotis, V., Reslan, M., Cruz, E., Kayser, V. (2017). Laboratory Scale 
Production and Purification of a Therapeutic Antibody. Journal of Visualized 
Experiments, 119: e55153. 
In chapter 8, we rationally engineered blockbuster antibody adalimumab with 
additional N-linked glycans to stabilize an aggregation-prone region in the Fab domain. 
Amongst the mutants tested, several had significantly enhanced conformational 
stability in the Fab domain, attributed to the added pair of glycans. The binding affinity 
of the mutants to the antigen and Fc receptors was also checked to characterise any 
change in therapeutic function. Determination of the aggregation-prone region was 
based on computational methods, highlighting the significant role of computational 
tools for the future development of next-generation antibodies. Chapter 8 was 
prepared for publication to the European Journal of Pharmaceutics and 
Biopharmaceutics:  
Reslan, M., Sifniotis, V., Cruz, E., Sumer-Bayraktar, Z., Kayser, V. (2018). Enhancing 
the stability of adalimumab by engineering additional glycosylation motifs. European 
Journal of Pharmaceutics and Biopharmaceutics. 
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CHAPTER 1 
 
“The State-of-Play and Future of Antibody 
Therapeutics” 
 
Graphical abstract 
 
 
Chapter 1 was published in the Editor’s issue of Advanced Drug Delivery 
Reviews: 
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., Kayser, V. (2017). The 
state-of-play and future of antibody therapeutics. Advanced Drug 
Delivery Reviews, 122:2-19. 
Several sections were not included in the thesis introduction as they 
were outside the scope of this thesis. Additionally, minor content has 
been updated with new developments since publication in 2017. 
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Abstract 
It has been over four decades since the development of monoclonal antibodies (mAbs) 
using a hybridoma cell line was first reported. Since then approximately 80 therapeutic 
antibodies have been marketed, mostly as oncology, autoimmune and inflammatory 
therapeutics. Innovations in antibody engineering are providing the opportunity to 
design biobetter antibodies with improved biophysical properties to maximize efficacy. 
The manufacturing process of antibodies is also moving forward with advancements 
relating to host cell production and purification processes. Studies into the physical 
and chemical degradation pathways of antibodies are contributing to the design of 
more stable proteins guided by computational tools. Moreover, the delivery and 
pharmacokinetics of antibody-based therapeutics are improving as optimized 
formulations are pursued through the implementation of recent innovations in the field. 
1. Introduction 
 
Over the past twenty years, therapeutic antibodies have rapidly become the leading 
product within the biopharmaceutical market. In 2013, therapeutic antibodies 
represented 50% of the $140 billion taken by the biopharmaceutical market with sales 
growing from $39 billion in 2008 to $75 billion in 2013 [1]. There are currently more 
than 70 therapeutic antibodies approved for established markets such as the United 
States and Europe with over three hundred antibody-based products in clinical 
development [1-3]. Therapeutic antibodies are no longer full-length, naked mouse 
antibodies; advancements in antibody engineering technologies, novel antigen 
discovery strategies and progress in deciphering disease pathways have all generated 
robust interest, resources and investment in antibody development.  In this review, we 
will discuss developments in the field of therapeutic antibodies, the growth of 
biosimilars and pay particular attention to targeting degradation pathways of 
antibodies to produce more stable biobetter antibodies and formulations. 
2. Antibody discovery strategies 
 
The generation of early antibodies relied on the immunization of mice or other 
mammals with the desired antigen target. This resulted in multiple antibodies directed 
at different epitopes of the antigen secreted by a mixed population of B cells with each 
cell secreting only one specific antibody (i.e. polyclonal).  Unfortunately, secreting B 
cells can only replicate a limited number of times, therefore rendering mass production 
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all but impossible.  The ground-breaking hybridoma technology developed by Kohler 
and Milstein allowed antibody secreting cells from the spleen of immunized animals to 
be fused with immortalized non-antibody secreting cells, thus resulting in cells that 
would divide continuously when cultivated in permissive conditions [4, 5].  Although 
the first recombinant antibodies were produced using this technology, including the 
first approved therapeutic antibody muromonab-CD3 (Orthoclone OKT®3) in 1986 for 
preventing kidney transplant rejection, hybridoma production presented some 
drawbacks.  Hybridomas can be labor intensive, low yielding or genetically unstable 
[6].  More importantly though, the antibody sequences originated from an immunized 
animal and consequently had the potential of triggering an immune response in 
humans.  Therefore, further improvements were needed to yield antibodies more 
human-like and safe.  These technologies have evolved from chimeric antibodies that 
is, grafting essential mouse amino acids needed for antigen binding onto a human 
antibody framework [7, 8] to both in vitro and in vivo techniques for generating 
humanized antibodies.   
The XenoMouse™ (Abgenix) and HuMab-Mouse® (Medarex) are transgenic mice 
developed in parallel and in both, the endogenous murine heavy and kappa light chain 
genes are inactivated and replaced with the equivalent human germline sequences [9, 
10].  Injection of antigens into these mice leads to development of ‘fully human’ 
antibodies that have undergone mouse somatic hypermutation and selection to 
relatively high affinity.  Validation of this technology came with the regulatory approval 
of panitumumab (Vectibix®) in 2006; a fully human antibody directed against 
epidermal growth factor receptor (EGFR) as treatment for advanced colorectal cancer 
[11].  Since then, RANK ligand-specific denosumab (Prolia®) has been approved for 
bone loss and TNF-specific golimumab (Simponi®) for rheumatoid arthritis.   
An in vitro method for generating fully human antibodies can be accomplished by 
cloning and screening large libraries of sufficiently diverse human antibody genes in 
combination with display technology.  The concept of display technology provides a 
direct physical link between a gene (genotype) and the encoding antibody fragment 
(phenotype) to allow selection of genes that encode a protein with the desired binding 
function.  Phage display technology remains the most widely used in vitro method for 
the display of large repertoires and for the selection of high affinity antibodies to 
biologically relevant targets [6].  Phage display involves the expression of proteins on 
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the surface of filamentous phage via fusion with phage coat protein with the genetic 
sequence packaged within, linking phenotype to genotype selection.  When combined 
with antibody libraries, phage display allows for rapid in vitro selection of antigen-
specific antibodies and recovery of their corresponding coding sequence [12-14].  This 
system is highly effective, robust and amenable to high throughput processes for 
screening of >1010 specificities [15].  The diversity of phage display libraries is 
distinguishable by source and design: naïve [16], immune [12], synthetic [17] and 
semi-synthetic [18].  The technology was first demonstrated for a single chain variable 
fragment (scFv) [13] with screening of other formats also introduced including human 
antigen binding fragments (Fabs) [19], domain antibodies [20], camelid domain 
antibodies [21], single domain shark antibodies [22], diabodies [23] and even whole 
IgG [24].  The first approved human antibody isolated by phage display technology 
was adalimumab (Humira®) which binds the cytokine TNF.  This antibody was first 
selected as a scFv expressed on the surface of phage and was further engineered in 
human IgG1 format, providing major validation for phage display technologies [25].  
Adalimumab remains the most lucrative antibody product generating global sales of 
$18 billion in 2017 [1, 26].  The number of phage display-derived candidates currently 
in clinical development further demonstrates the value of phage display as an 
established and reliable drug discovery platform [27].   
3. Manufacture of antibodies 
 
Therapeutic antibodies are mainly produced in mammalian host cell lines because of 
their ability to introduce post-translational modifications.  Chinese hamster ovary 
(CHO) cells remain the most widely used cell line for the manufacture of antibodies 
(20 of 39 FDA approved), followed by SP2/0 (8/39) and NS0 (7/39) mouse cell lines 
and hybridomas (2/28). Two of the three Fabs are produced in the bacterial strain 
Escherichia coli.  As the clinical success of therapeutic antibodies grows, alternative 
and more cost-effective production platforms are being pursued including microbial 
hosts and plant systems.  Microbial cells such as bacteria and yeast possess many 
advantages including fast growth, well-characterised genetics and low cultivation 
costs.   
Antibody production in bacterial systems has focused on fragments due to the lack of 
post-translation glycosylation required on the Fc region of full length IgG antibodies, 
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specifically required for efficient FcγR interactions.  A major advancement was recently 
achieved with the expression of active, full-length IgG in the cytoplasm of E. coli to 
generate ‘cyclonals’.  Robinson et al. used an engineered strain with an oxidative 
cytoplasmic environment to facilitate and promote the formation of disulphide bonds 
and efficient IgG folding and assembly [28].  Moreover, molecular engineering of 
cyclonal Fc domains with previously identified Fc mutations enabled FcγR interactions 
[29-31].  Conversely, yeast expression offers the advantages of post-translational 
modifications, disulphide bond formation as well as secretion of correctly-folded 
proteins.  Antibody yields surpassing mammalian systems have been reported for a 
glyco-engineered strain of P. pastoris capable of producing human N-linked 
glycoproteins [32, 33].  Additionally, a series of experiments have demonstrated 
production of IgG at industrial scale to be robust and commercially viable [34].  The 
potential of yeast expression systems has not yet been fully realised with the most 
advanced antibodies otelixizumab (refer to Fc engineered section) and clazakizumab 
completing Phase II trials for psoriatic arthritis and rheumatoid arthritis. 
Plant systems are also generating interest as an alternative production platform due 
to the absence of mammalian pathogens but too are subject to disadvantages given 
the different glycosylation profile to humans, subcellular localisation issues and 
decreased yield because of proteolytic degradation.  Nevertheless, several antibodies 
have reached clinical development.  For instance, CaroRX is an antibody that targets 
Streptococcus mutans and used for treating cavities, produced in Nicotiana tabacum 
and approved for use in Europe [35].  MB66 (or MAPP66) contains a combination of 
three monoclonal antibodies produced in Nictiana benthamiana designed to block 
distinct mechanisms of HIV which has entered Phase I trials.  The clear advantages 
of using plant systems is the low cost, scalability and relative ease to deploy in 
developing countries [36, 37].  Interestingly, a biosimilar of trastuzumab produced in 
N. benthamiana is entering Phase I clinical trials.  An efficacy study in mice has shown 
that biosimilar trastuzumab was as effective as originator trastuzumab (Herceptin®) in 
reducing the size and growth rate of breast cancer tumours [38]. 
The choice of expression system therefore depends on many factors in order to 
guarantee cost-effective high yields and meet safety criteria; from discovery stages 
with the precise sequence and mode of action of the specific antibody to development 
of the manufacturing cell line.  Manufacturing cell lines to yield a therapeutic antibody 
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are initially generated by vector construction and transfection.  A variety of different 
expression systems and transfection methods exist [39]. Following transfection, cells 
are subjected to a selection procedure where stable cell lines are cloned and 
expanded.  Several strategies have since evolved from the limiting dilution approach 
that utilise automated cell sorting equipment [40, 41].  The screening and selection of 
stable clones with desired growth and production characteristics is a critical albeit time-
consuming step in the process. Once conditions are defined, the process is often 
transferred to a pilot scale to test scalability and produce material for preclinical 
toxicology studies.  Larger scale manufacturing for production of clinical material is 
performed under current good manufacturing practices (cGMP) regulations involving 
either fed-batch or continuous perfusion culture [42, 43].  For validation purposes, 
three (United States) or five (Europe) consecutive full-scale culture runs are required 
for BLA approval [44]. 
Therapeutic antibodies must have very high purity and be sterile, with the 
concentration of host cell proteins reduced to parts per million (ppm), DNA to parts per 
billion (ppb) and virus levels to less than one virus particle per million doses [45, 46].  
The stringent purification of antibodies from mammalian cells is typically accomplished 
using a three column chromatography process; protein A affinity chromatography as 
an initial capture step followed by cation exchange (CEX) and anion exchange (AEX) 
chromatography [47].  These are followed by a virus clearance step after which the 
purified product is concentrated and diafiltered into the final formulation buffer.  While 
the antibody is primarily captured during the affinity step, the consecutive ion 
exchange processes act as ‘polishing’ steps to remove impurities such as host cell 
protein, DNA, aggregates, endotoxin, adventitious and endogenous viruses [44].  With 
the growing demand and increasing market competition, attention is now being 
focused on reducing manufacturing costs and improving process efficiency.  For 
example, Protein A affinity chromatography contributes a major cost to the purification 
process, therefore improved chromatography matrices, specifically non-affinity 
methods are gaining popularity such as; hydrophobic charge induction 
chromatography (HCIC), high performance tangential flow filtration (HPTFF) and MEP 
HyperCel [48-51]. 
4. Biobetter antibodies 
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Between 2015-2018 (June) close to 30 mAbs have received marketing approval by 
the US Food and Drug Administration (FDA) (Table 1), with the rate of approvals 
steadily increasing each year. Despite its success, antibody-based therapy still 
presents a long list of important shortcomings that need to be overcome to fully exploit 
their full therapeutic potential. Typical drawbacks in antibody-based therapy include 
limited efficacy due to poor tissue and tumor penetration, low in vivo efficacy, 
cumbersome administration, antibody aggregation, solubility as well as high 
production costs [52].  
Table 1. Novel full-length monoclonal antibodies and fragments approved by the 
FDA in recent years 
Name Commerc
ial Name 
Company Target Indication 
(FDA 
approved) 
Format 
APPROVED BY FDA IN 2015 
Secukinumab Costentyx
® 
Novartis IL-17 Psoriasis IgG1 
(fully 
human) 
Dinutuximab Unituxin® United 
Therapeutics 
Corporation 
GD2 Neuroblastom
a (pediatric 
patients) 
IgG1 
(chimeric
) 
Alirocumab Praulent® Sanofi PCSK9 Hyperlipidemi
a 
IgG1 
(fully 
human) 
Evolocumab Repatha® Amgen PCSK9 Hyperlipidemi
a 
IgG2 
(fully 
human) 
Idarucizumab Praxbind
® 
Boehringer 
Ingelheim 
Dabigatr
an 
Anticoagulatio
n reversal 
Fab 
fragment 
(humanis
ed) 
Mepolizumab Nucala® Glaxo Smith 
Kline 
IL-5 Asthma IgG1 
(humanis
ed) 
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Necitumumab Portrazza
® 
Eli Lilly EGFR NSCLC IgG1 
(fully 
human) 
Daratumumab Darzalex
® 
Janssen 
Biotech 
CD38 Multiple 
myeloma 
IgG1 
(fully 
human) 
APPROVED BY FDA IN 2016 
Reslizumab Cinqair® Teva IL-5 Asthma IgG4 
(humanis
ed) 
Ixekizumab Taltz® Eli Lilly IL-17a Psoriasis IgG4 
(humanis
ed) 
Obiltoxaximab Anthim® Elusys 
Therapeutics 
Bacillus 
anthrax 
Anthrax IgG3 
(humanis
ed) 
Olaratumab Lartruvo® Eli Lilly PDGFR
-α 
Soft tissue 
sarcoma 
IgG1 
(fully 
human) 
Atezolizumab Tecentriq
® 
Roche/ 
Genentech 
PD-L1 NSCLC, 
bladder 
cancers 
IgG1 
(humanis
ed) 
Bezlotoxumab Zinplava® Merck Clostridi
um 
difficile 
toxin B 
Prevention of 
recurrent C. 
difficile 
infection 
IgG1 
(fully 
human) 
APPROVED BY FDA in 2017 
Brodalumab Silliq® Valeant 
Pharmaceutic
als 
IL-17R Psoriasis IgG1 
(fully 
human) 
Ocrelizumab Ocrevus® Genentech/ 
Roche 
CD20 Multiple 
Sclerosis 
IgG1 
(humanis
ed) 
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Durvalumab Imfinzi® AstraZeneca PD-L1R Urothelial and 
NSCLC 
IgG1 
(fully 
human) 
Sarilumab Kevzara® Regeneron/ 
Sanofi 
IL-6R Rheumatoid 
arthritis 
IgG1 
(fully 
human) 
Guselkumab Tremfya® Janssen 
Biotech/ 
Johnson & 
Johnson 
IL-
23/p19 
Psoriasis IgG1 
(fully 
human) 
Benralizumab Fasenra® Astra Zeneca IL-5R Asthma IgG1 
(humanis
ed) 
Dupilumab Dupixent
® 
Regeneron/ 
Sanofi 
IL-4R Atopic 
Dermatitis 
IgG4 
(fully 
human) 
Avelumab Bavencio
® 
Pfizer/ Merck PD-L1 NSCLC, 
gastric and 
Merkel-cell 
carcinoma 
IgG1 
(fully 
human) 
APPROVED BY FDA in 2018 (as of June) 
Ibalizumab-
uiyk 
Trogarzo
® 
TaiMed 
Biologics/ 
Theratechnol
ogies 
CD4 Multi-drug 
resistant HIV-
1 
IgG4 
(humanis
ed) 
Tildrakizumab-
asmn 
Ilumya® Sun 
Pharmaceutic
al Industries/ 
Merck 
IL-
23/p19 
Plaque 
psoriasis 
IgG1 
(humanis
ed) 
Burosumab-
twza 
Crysvita® Ultragenyx 
Pharmaceutic
al 
FGF-23 X-linked 
hypophosphat
emia 
IgG1 
(fully 
human) 
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Erenumab-
aooe 
Aimovig® Novartis/ 
Amgen 
CGRPR Prevention of 
migraines 
IgG2 
(fully 
human) 
Abbreviations: GD = disialoganglioside; NSCLC = non-small cell lung cancer; PCSK 
= proprotein convertase subtilisin/kexin; EGFR = epidermal growth factor receptor; 
PD-L = programmed death-ligand; PDGFR = platelet-derived growth factor receptor; 
IL = interleukin; CD = cluster of differentiation; FGF = fibroblast growth factor; 
CGRPR = calcitonin gene-related peptide receptor 
The use of antibody engineering to improve the properties of therapeutic antibodies 
has advanced greatly in the last decades giving rise to a varied set of novel formats 
that offer enhanced attributes for therapeutic and research purposes. These novel 
molecules are often referred to as biobetters or next-generation antibodies and include 
platforms such as: engineered antibodies for enhanced effector functions, antibody 
drug-conjugates (ADC), multi-specific antibodies and single-domain antibody 
fragments (sdAb or nanobodies®) (Fig. 1) [53, 54]. While full-length and IgG1 
antibodies still dominate, novel formats such as bispecifics and ADCs are starting to 
enter the market. In 2017, inotuzumab ozogamicin an anti-CD22 humanized IgG4 
antibody conjugated to calicheamicin was approved for acute lymphoblastic leukemia 
(ALL). The FDA also approved emicizumab, a bispecific IgG4 mAb targeting factor IXa 
and X [55]. 
A biobetter can have modifications to its chemical structure such as humanization, 
fusion/conjugation or be glyco-engineered to be less immunogenic or more efficacious. 
For instance, anti-CD20 ocrelizumab which was approved by the FDA in 2017 for 
multiple sclerosis, is a humanized version of rituximab (Rituxan®).  A biobetter may 
be modified to have an improved formulation for improved treatment regimen so 
treatment is less evasive or have a simplified manufacturing process.  This was 
demonstrated with novel subcutaneous (SC) formulations of trastuzumab 
(Herceptin®) and rituximab (Mabthera®) developed by co-formulating the antibody 
with hyaluronidase, an enzyme that increases the absorption and distribution of the 
injected product [56].  A biobetter may be engineered to have higher target affinity, 
bind at a different epitope or stronger effector function to enhance efficacy and 
potentially reduce any off-target side effects.  Any such improvement means that the   
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Figure 1. Schematic representation of biobetter antibody formats being pursued for 
clinical development. (a) Schematic structure of an IgG1 antibody 
with glycosylation sites at asparagine 297 (Asn-297) in CH2 domains indicated by 
hexagons. The general structure of N-linked glycosylation is shown inset; core 
structures indicated by solid lines and variable structures by dotted lines comprising 
of Fucose (Fuc), N-Acetylglucosamine(GlcNAc), Mannose (Man), Galactose (Gal) 
or N-Acetylneuraminic acid (Neu5Ac). Glyco-engineering of antibodies can involve 
defucosylation which refers to the removal of core fucose to enhance Fc-
mediated effector functions. (b) Schematic structure of an antibody drug conjugate 
(ado-trastuzumab emtansine; Kadcyla®) including N-maleimidomethyl) cyclohexane-
1-carboxylate (MCC) linker and maytansinoid 1 (DM1) payload. (c) Prominent 
bispecific formats in development including: Triomab or Trifunctional antibody, Dual 
variable domain immunoglobulin (DVD-Ig), Dock-and-Lock (DNL) antigen binding 
fragments (Fabs), Bispecific T cell engager (BITE), Dual affinity re-targeting (DART) 
molecule, Tandem diabody (tandAb) and Immune-mobilizing monoclonal T cell 
receptors against cancer (ImmTAC). 
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therapeutic has been modified and incomparable to the original therapeutic; it is 
therefore classified as a new biological therapeutic and requires more laborious testing 
to obtain regulatory approval before market entry.   
4.1. Fc engineered antibodies for enhanced effector functions 
 
Antibody engineering has sought to improve the effector function of antibodies via the 
Fc region; namely ADCC, complement dependent cytotoxicity (CDC) and PK profile. 
Specifically, this has been mostly explored through modifications in the amino acid 
sequence or the glycosylation pattern in the Fc region to enhance the affinity towards 
Fcγ receptors (FcγR) on effector cells [53, 57]. The most prominent and successful 
technology so far has been the glycosylation approach, which has seen nearly twenty 
glyco-engineered antibodies enter clinical trials with three already approved for clinical 
use [58-60]. The first success came with the approval of mogamulizumab (Poteligeo®) 
in Japan in 2012, developed using the POTELLIGENT (Kyowa Hakko Kirin) platform 
which is indicated for CC-chemokine receptor 4 (CCR4)-expressing T cell leukaemia-
lymphoma and peripheral T cell lymphoma (PTCL) in adult patients [61].  
An ADCC enhanced version of rituximab, obinituzumab (Gazyva®) gained approval 
by the FDA in 2013 under breakthrough therapy designation [62]. Obinituzumab is an 
anti-CD20 monoclonal antibody that was originated by GlycArt Biotechnology (now 
GlycoMAb) and is approved for CCL [59]. Both POTELLIGENT® and GlycArt 
platforms are based on the manufacture of products using engineered cell lines that 
yield defucosylated antibodies; a structural modification that removes the core 1,6 
fucose from the N-glycans attached to asparagine at amino acid position 297 of human 
IgG1 thereby greatly enhancing the affinity towards FcγRIII, and increasing ADCC 
induction by NK cells (Fig. 1a) [63, 64].  NK cells are not abundant in the tumor site, 
and human endogenous IgG can inhibit the elicitation of ADCC by therapeutic 
antibodies [65] therefore, increasing the affinity towards FcγRIII to preferentially 
interact with the therapeutic antibody is a valuable approach to improve the efficacy 
profile. This approach was demonstrated by Zhang et al. [66] by producing an anti-
HER2 antibody with an identical sequence to trastuzumab but with superior binding 
affinity to FcyRIIIa and greater ADCC activity [66]. The antibody was produced using 
glyco-engineered Pichia pastoris and the differences were presumed to be due to 
absence of fucose in the N-glycans attached to the IgG1 product. Benralizumab is 
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another example of a defucosylated IgG1 mAb which received marketing approval by 
the FDA in 2017 for maintenance treatment of severe asthma [55].  
Whereas the glyco-engineering approach generates defucosylated antibodies with 
FcγRIIIa-specific affinity improvement, variants generated by mutagenesis of Fc 
amino acid sequence can be enhanced for multiple FcγR interactions.  A number of 
publications have identified specific Fc mutations to improve binding to the activating 
receptor FcγIIIa and reduce binding to the inhibitory receptor FcγIIb with 
corresponding improvement to ADCC activity [67-69].  The XmAb® concept is one 
such example that was investigated as an anti-CD30 in Phase I trials for Hodgkin 
lymphoma. 
In an alternative approach, aglycosylated antibodies (without glycan structures) can 
be engineered to display effector functions that are distinct from those of glycosylated 
counterparts [29, 31, 70, 71].  The use of aglycosylated therapeutic antibodies offers 
manufacturing advantages by bypassing glycosylation and hence production can be 
performed in prokaryotic hosts.  On the other hand, the importance of glycosylation on 
the structural stability of antibodies has been demonstrated [72, 73].  The first 
aglycosylated antibody to enter clinical trials, produced in yeast, is humanized rat-
derived IgG1 otelixizumab directed against CD3 which is being assessed in Phase II 
trials for new onset autoimmune type I diabetes mellitus. 
5. Physical and chemical degradation of antibodies 
 
During manufacturing and storage, therapeutic antibodies are at risk of degradation 
via several pathways.  Though these reactions may be kept under control by 
appropriate storage and formulation conditions of the final product, degradation that 
occurs during culture, downstream processing and in vivo cannot be controlled 
sufficiently.  These degradation events may affect antigen recognition, hamper 
functionality and in severe cases lead to immunogenic responses [74-78].  Each 
antibody molecule seems to have a unique personality related to its requirements for 
stability; a phenomenon derived from the fact that differences in the CDR between 
antibodies are primarily dictated by the surface exposed amino acids that define 
antigen specificity [77].  The identification of degradation prone or unstable regions 
early in the antibody development process would ideally permit re-engineering of these 
problematic areas [79-82]. This approach is aided by recent developments in 
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computational modelling tools that predict regions of interest susceptible to physical, 
chemical degradation or influence other biophysical properties of antibodies.  In the 
next section, degradation pathways commonly observed in therapeutic antibodies and 
an overview of predictive tools are discussed. 
5.1. Aggregation  
 
Protein aggregation is the most common and significant type of physical degradation 
associated with therapeutic antibodies, often leading to reduced activity and in some 
cases, formation of immunogenic products [83, 84].  Initial preparations of therapeutic 
antibodies were administered by intravenous (IV) infusion formulated at protein 
concentrations (1-25 mg/ml). As antibody-based therapeutics have become more 
widely used, high concentration formulations that allow SC injection (>50 mg/ml) 
became desirable giving rise to aggregation issues. Proteins are folded in such a way 
as to internalize hydrophobic regions and surface expose more hydrophilic regions.  
As protein-protein contact frequency increases at high concentrations, the opportunity 
for aggregation formation increases proportionally. Changes in extrinsic conditions 
including temperature, pH, salt, shaking, viscosity and concentration can transiently 
expose hydrophobic regions which in doing so promotes protein-protein interactions 
that lead to aggregation events [85-88].  Non-covalent aggregates can be formed via 
hydrophobic and/or electrostatic interactions and may be reversible, while covalent 
aggregates are usually formed by disulphide bonds and are difficult to reverse. 
Mechanisms of protein aggregation include: (1) aggregation of native state monomers; 
(2) aggregation of monomers with a modified conformation (non-native); (3) 
aggregation of chemically-modified monomers; (4) aggregation via a nucleation-
dependant process; and (5) surface-induced aggregation via adsorption of protein to 
glass-liquid or air-liquid interfaces [89, 90].  
5.2. Denaturation 
 
Protein denaturation refers to the partial or complete unfolding of the native three-
dimensional folded protein structure.  A denatured antibody often loses its tertiary and 
perhaps secondary structure leading to loss of binding affinity and activity if an active 
site domain is affected, and may expose aggregation-prone regions leading to further 
degradation [86, 91, 92].  Several intermediate states may exist between the folded 
native structure of an antibody molecule and the denatured state, with some 
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intermediates thought to act as precursors or ‘nuclei’, attracting other protein species 
to exposed hydrophobic sites and forming irreversible aggregates.  Denaturation may 
be induced by a number of stress conditions that arise during antibody manufacture 
including changes in solution pH or temperature, use of organic solvents or chaotropes, 
high salt concentrations, or shear force [85, 86, 93]. In general, the CH3 domain of an 
antibody is often the most stable against denaturation at high temperatures (highest 
Tm) while the CH2 domain is least stable and denatures first (lowest Tm) [94].  
5.3. Fragmentation 
 
Fragmentation of therapeutic antibodies can be a product of enzymatic or non-
enzymatic hydrolysis that occurs at the peptide backbone of a number of regions, such 
as the hinge region, the CH2-CH3 interface or a region containing aspartic acid (Asp) 
or tryptophan (Trp) residues [85].  Asp-associated hydrolysis is affected by pH and the 
n+1 residue; for instance, a serine (Ser), valine (Val) or tyrosine (Tyr) adjacent to an 
Asp may increase the rate of Asp-hydrolysis.  Hinge region hydrolysis can occur in the 
absence of Asp and occurs most commonly in the IgG1 isoform [85, 95, 96]. The rate 
of hydrolysis is dependent on the flexibility the peptide sequence at the hinge and 
occurs within a narrow range of residues. Hinge hydrolysis rates are affected by 
solution pH, with a minimum rate of hydrolysis observed near pH 6, and higher rates 
at a lower or higher pH [85, 96]. Fragmentation of full-length antibodies is a common 
occurrence and generally, cleaved forms are present in such low amounts that effect 
on efficacy would not likely be seen.     
5.4. Deamidation 
 
Deamidation is the most common chemical degradation pathway of therapeutic 
antibodies and results from the hydrolysis of the amide side-chain of amino acids 
glutamine (Gln) or asparagine (Asn) [85, 89, 97, 98].  Hydrolysis of the side-chain can 
occur at acidic pH (pH <4) resulting in the conversion of Asn to Asp and Gln to glutamic 
acid (Glu) [85]. However, at higher pH, deamidation occurs predominantly (and more 
slowly) via the formation of a cyclic imide intermediate   For Asn, the cyclic intermediate 
(succinimide) leads to either the formation of Asp or an isomer of Asp. A similar 
process results in the deamidation of Gln to Glu; although Gln deamidation is much 
less frequent, due to the lower stability of the 6-membered cyclic intermediate formed.  
In short, deamidation events lead to more acidic forms of the antibody through the 
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acquisition of additional carboxylic acid groups. Conversely, it is also possible for Asp 
residues to undergo modification to a succinimide intermediate that produces a basic 
form of the antibody by removal of a carboxylic acid group [97].   
Several factors can affect the rate of deamidation. For instance, Asn residues are more 
prone to deamidation if they are present in solvent-accessible or structurally-flexible 
regions, especially if followed by a small or flexible residue such as Gly, Ser, threonine 
(Thr) or Asn [85, 99].  Deamidation rate is also affected by extrinsic conditions 
including pH, temperature, buffer composition and concentration [100]. Gln 
deamidation is thought to be less common than Asp deamidation due to the lower 
stability of the 6-membered cyclic ring intermediate, which results in a much slower 
reaction rate [85]. Although Gln deamidation occurs less frequently, a study found that 
following incubation at pH 9, 7.8% of Gln82 of a recombinant IgG1 mAb had 
undergone deamidation, despite no deamidation of this residue occurring at neutral 
pH [98]. 
Deamidation of therapeutic antibodies is well characterised both in vitro and in vivo, 
and has been shown to decrease the potency, activity and stability of antibodies [97, 
99-103]. The deamidation events appear to be highly selective for individual antibodies.  
For example, Harris et al. performed accelerated stability studies at elevated 
temperatures with rhuMAB HER2 antibody and found three labile Asn residues in the 
CDR region (Asn55, Asn30 and Asn102) [97]. These residues either formed aspartate, 
isoasparatate or a stable succinimide intermediate, resulting in a total of 7 species of 
the antibody being resolved. Deamidation of these Asn residues was shown to 
significantly affect the specific in vitro activity and potency of rhuMAb HER2.  
5.5. Oxidation 
 
Oxidation is another common degradation pathway which can occur during antibody 
production, formulation or storage. A number of amino acid residues may be affected, 
including methionine (Met), cysteine (Cys), histidine (His), tyrosine (Tyr) and Trp [85]. 
Specific Met residues within the Fc region (up to four residues) are prone to oxidation 
resulting in production of methionine sulfoxide [89, 104, 105].  Oxidation of these 
residues may affect the stability of an antibody, Fc-mediated effector function or 
Protein A binding affinity which is often used for purification from cell culture 
supernatant [106]. Wang et al. demonstrated that oxidation of Met252 can result in >4-
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fold reduction in the half-life of an antibody in transgenic mice expressing human Fc 
neonatal receptor (FcRn). However, this was only observed when 80% of the antibody 
existed in the oxidized form, and not at 40% [107].   
Oxidation can be dependent on intrinsic factors such as the degree of surface exposed 
residues as well as extrinsic factors including buffer composition, light exposure and 
pH, although Met oxidation appears to be almost pH-independent [85, 106, 108]. 
Oxidative stress has been observed during antibody production in mammalian 
expression systems where the formation of reactive oxygen species as a result of 
hypoxic conditions caused fragmentation of an IgG1 antibody [109]. 
Tryptophan oxidation of antibodies has been reported following light exposure. 
Sreedhara et al. [104] found that light induced oxidation of surface exposed Trp 
residues (Trp53, Trp108 and Trp94) in the Fab region of an IgG1 antibody leading to 
a loss in potency accompanied with a solution colour change [104]. In another example, 
oxidation of Trp residue in the H3 CDR loop (Trp135) of a humanized anti-respiratory 
syncytial virus (RSV) therapeutic antibody resulted in loss of antigen binding and 
biological function [110]. 
6. Computational design tools 
 
In recent years, computational methods used to simulate and develop structural 
models of proteins have transformed into practical design tools for the development of 
biobetter and next-generation antibody therapeutics [80, 111]. Current computational 
design tools have evolved to allow rapid identification of specific amino acid 
sequences or regions on a protein of interest, that contribute to its observed in vivo 
properties such as binding affinity, efficacy, stability and half-life [111].  
Some of the early computational tools used for protein modelling include TANGO, 
PAGE, AGGRESCAN, PASTA and Zyggregator all of which rely on the sequence of 
the protein of interest (Table 2) [81, 112-117]. These computational tools use force 
fields such as CHARMM or AMBER and exploit chemical properties of the amino acids 
such as hydrophobicity, β-sheet propensity, charge, and aromatic content to predict 
aggregation hot-spots and residues susceptible to chemical degradation. In some 
cases, multiple tools can be used in combination to improve the predictive power.  For 
example, Wang et al. combined TANGO and PAGE to identify aggregation-prone 
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motifs and residues susceptible to deamidation or oxidation of 22 commercial and 20 
non-commercial therapeutic antibodies [118].  
Table 2. A representative list of computational tools for prediction of protein 
aggregation hot spots. 
Name Properties 
Sequence-based methods 
TANGO 
[112] 
Determines the secondary structure formation propensity 
Aggrescan 
[113] 
Uses amino acid aggregation propensity value 
Zyggregator 
[115] 
Compares a new peptide sequence to the database 
PASTA 
[116] 
Predicts amyloid structure aggregation by looking into 
sequences that are likely to stabilize the cross-beta core of 
fibrils 
PAGE 
[117] 
Uses physicochemical properties for prediction 
Structure-based methods 
SAP   
[81] 
Determines spatial effective surface accessible area 
LIP   
[119] 
Measures ratio of polar surface area to apolar surface area 
of buried interfaces 
AGGRESCAN3D 
[120] 
Based on original AGGRESCAN server with input from 3D 
structure and spatial arrangement of residues 
 
Some structure-based computational tools have also been developed. One such 
method, Spatial Aggregation Propensity (SAP), predicts surface exposed aggregation-
prone regions of a protein based on hydrophobicity, dynamic fluctuations and solvent 
accessibility of residues and regions [80]. The tool has been used to simulate entire 
antibodies and develop IgG1 antibody variants with enhanced physical stability to the 
wild type, by performing single or multiple mutations in either the Fab or Fc regions 
[80, 82]. 
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Another method developed by Angarica and Sancho [119] predicts aggregation 
propensity based on the packing density and polarity ratio (ratio of polar surface area 
to apolar surface area) of buried interfaces [119]. The tool was designed to 
characterise “Light Interfaces of high Polarity” (LIPs) considered to be intrinsically 
unstable cores. The technology shows promise as a tool for engineering antibody 
variants with increased aggregation-resistance, especially as a complimentary method 
to surface- or sequence-based tools mentioned above.  
One of the most recent developments in computational modelling is the evolution of 
AGGRESCAN to AGGRESCAN3D (A3D), an improved server which addresses many 
of the limitations of AGGRESCAN and other sequence-based methods. A3D takes 
into account the three-dimensional structure of the protein and the spatial arrangement 
of the residues when the protein is in its native folded state [120]. With the 
incorporation of a mutation module that allows the easy modelling of the detected 
aggregation-prone and surrounding residues, A3D looks to be a promising tool for 
predicting problematic regions and the same time, allowing for re-design of more 
stable proteins.  
7. Optimization of antibody bioavailability and delivery 
 
Antibody-based therapies are predominantly delivered intravenously (IV), though an 
increasing number are now being formulated and administered subcutaneously (SC). 
While the IV route offers 100% bioavailability, systemic distribution and physiological 
barriers greatly reduce the actual concentration of antibody achieved in target tissues 
[121]. What is more, IV infusions are time-consuming and inconvenient. Ideally, an 
antibody formulation should be non-invasive and increase local bioavailability.  Limited 
alternatives have been implemented in the clinic since formulation requirements for 
such delivery often pose significant hurdles. For other parenteral administration routes, 
such as SC or intramuscular (IM), the most common limitation is poor antibody 
solubility at the high concentrations required, given that maximum volume of injection 
is restricted to 2 ml and 5 ml, respectively.  When compared to IV formulations which 
range from 1-25 mg/ml, SC and IM products often require concentrations >100 mg/ml 
to deliver an effective dose [122].  Furthermore, these delivery routes involve an 
absorption step to enable systemic circulation. Two main approaches are being 
pursued to optimize bioavailability: 1) the design of aggregation-resistant antibodies 
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with higher solubility to prevent precipitation at higher concentrations; 2) the use of 
polymer matrix systems to develop controlled release formulations and improve PK 
profile. 
As discussed in the previous section, the design of aggregation-resistant antibodies 
albeit challenging, has become possible with the implementation of computational 
tools and increasing understanding of antibody structure and degradation pathways. 
Formulation stability has also been improved by using stabilizing additives such as 
salts (e.g. citrates, sulfates), amino acids (e.g. glycine, alanine) and sugars (e.g. 
sorbitol, sucrose, trehalose) [85, 123-125]. The development of SC and IM products 
has been successful in the last decade because of the formulation of large doses in 
significantly smaller volumes without aggregation issues [56].  SC and IM formulations 
have significantly improved patient convenience enabling self-administration through 
the use of pre-filled syringes, a feature that is highly advantageous for treatment of 
chronic diseases.  A novel approach to improving SC formulation and PK has been 
proposed by Yang et al. whereby, crystalline antibody preparations of infliximab 
(Remicade®) and trastuzumab (Herceptin®) were formulated at 200 mg/ml while 
maintaining low viscosities suitable for this delivery route [126].  Animal studies in rats 
showed a 2-fold increase of antibody half-life compared to non-crystallized antibody, 
demonstrating the potential of crystalline preparations as controlled release systems.  
Alginate polymers have also been explored for controlled release.  Schweizer et al. 
[127] developed two polyanionic alginate matrices loaded with antibody through 
electrostatic interactions [127].  Both matrices were delivered to rats subcutaneously 
as hydrogels. After comparison with its liquid antibody counterpart, no significant 
differences in bioavailability were reported.  
For many pathologies, local delivery could increase efficacy and reduce systemic 
exposure. In such cases, administration routes such as oral, topical, respiratory and 
intraocular become highly relevant. Controlled release systems based on polymer 
matrices are also being tested in preclinical studies for these delivery routes [121, 128]. 
For instance, liposomes and chitosan-alginate microparticles have been employed for 
oral delivery in order to protect antibodies from gastric inactivation and allow release 
in the small intestine [129, 130]. This is being explored in combination with the 
conjugation of targeting ligands to improve delivery and absorption in the gastro-
intestinal tract.  [131].  For topical application, a hydrofiber dressing/adhesive sheet 
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has been used to apply infliximab as a gel formulation for wound healing with 
improvements in 7/8 patients tested [132].  In another example, a Phase I trial has 
been completed with positive results for BIL-010t, a topically administered, sheep 
antibody therapy to treat Basal Cell Carcinoma (BCC).  BIL-010t ointment was self-
applied for 28 days; it was noted that 13/20 patients had decreases in the sizes of their 
lesions with only mild localized skin reactions reported.  The respiratory route has been 
extensively studied for treatment of chronic obstructive pulmonary disease, lung 
cancer, asthma and other pulmonary pathologies. Liposomes and microspheres have 
shown potential to increase bioavailability of respiratory delivery by preventing 
proteolysis [133]. The PEGylation of antibody fragments was shown to increase lung 
lumen residence time in a murine model through decreased clearance of alveolar 
macrophages and increased mucoadhesion [134].  Other strategies being investigated 
to deliver antibodies via the respiratory tract include IgG-loaded lipid microparticles 
and nano-micelles [135-137]. The most advanced molecule in clinical development is 
ALX-0171, an anti-RSV nanobody administered through inhalation; demonstrating a 
positive safety and tolerability profile in a first-in-infant Phase I/II study with an anti-
viral effect observed [138].   
Overall, the IV route will likely remain the most prominent administration route in 
development due to ease of formulation. Still, the improvement of local bioavailability 
is an obvious requirement to fulfil the potential of antibody-based therapy, both in 
terms of efficacy and patient convenience. As such, strategies such as pursuing 
alternative administration routes and developing appropriate controlled release 
systems will gain relevance as their therapeutic potential continues to be explored in 
preclinical studies.  
8. Conclusion 
 
Antibody-based therapeutics have evolved from murine antibodies to humanized and 
fully human antibodies, developed with innovative technologies such as transgenic 
mice and phage display.  In the coming years, next-generation antibodies with 
improved properties and formats including ADC and bispecifics are expected to gain 
popularity as biobetter antibody therapeutics. The advancement of next-generation 
biobetters is critical to address the shortcomings confronted with the use of these 
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antibodies such as poor efficacy and stability and most importantly, to provide greater 
patient benefit. 
Acknowledgements  
The authors would like to acknowledge the School of Pharmacy of the University of 
Sydney for financial contribution. E. Cruz acknowledges the Ministry of Science, 
Technology and Telecommunications of the Republic of Costa Rica for postgraduate 
scholarship. M. Reslan is a recipient of the Research Training Stipend provided by the 
University of Sydney on behalf of the Department of Education and Training to support 
his research training.  
Disclosures 
The authors declare that they have no competing financial interests. 
References 
[1] D.M. Ecker, S.D. Jones, H.L. Levine, The therapeutic monoclonal antibody market, 
mAbs, 7 (2015) 9-14. 
[2] R.E. Kontermann, U. Brinkmann, Bispecific antibodies, Drug Discovery Today, 20 
(2015) 838-847. 
[3] P.M. Drake, D. Rabuka, An emerging playbook for antibody-drug conjugates: 
lessons from the laboratory and clinic suggest a strategy for improving efficacy and 
safety, Current Opinion in Chemical Biology, 28 (2015) 174-180. 
[4] G. Kohler, C. Milstein, Continuous cultures of fused cells secreting antibody of 
predefined specificity, Nature, 256 (1975) 495-497. 
[5] G. Kohler, C. Milstein, Derivation of specific antibody-producing tissue culture and 
tumor lines by cell fusion, European Journal of Immunology, 6 (1976) 511-519. 
[6] W. Li, N.B. Caberoy, New perspective for phage display as an efficient and versatile 
technology of functional proteomics, Applied Microbiology and Biotechnology, 85 
(2010) 909-919. 
[7] P.T. Jones, P.H. Dear, J. Foote, M.S. Neuberger, G. Winter, Replacing the 
complementarity-determining regions in a human antibody with those from a mouse, 
Nature, 321 (1986) 522-525. 
[8] L. Riechmann, M. Clark, H. Waldmann, G. Winter, Reshaping human antibodies 
for therapy, Nature, 332 (1988) 323-327. 
23 
 
[9] N. Lonberg, Human antibodies from transgenic animals, Nature Biotechnology, 23 
(2005) 1117-1125. 
[10] C.T. Scott, Mice with a human touch, Nature Biotechnology, 25 (2007) 1075-1077. 
[11] A. Jakobovits, R. Amado, X. Yang, L. Roskos, G. Schwab, From XenoMouse 
technology to panitumumab, the first fully human antibody product from transgenic 
mice, Nature Biotechnology, 25 (2007) 1134-1143. 
[12] W.D. Huse, L. Sastry, S.A. Iverson, A.S. Kang, M. Alting-Mees, D.R. Burton, S.J. 
Benkovic, R.A. Lerner, Generation of a large combinatorial library of the 
immunoglobulin repertoire in phage lambda, Science, 246 (1989) 1275-1281. 
[13] J. McCafferty, A.D. Griffiths, G. Winter, D.J. Chiswell, Phage antibodies: 
filamentous phage displaying antibody variable domains, Nature, 348 (1990) 552-554. 
[14] C.F. Barbas, 3rd, A.S. Kang, R.A. Lerner, S.J. Benkovic, Assembly of 
combinatorial antibody libraries on phage surfaces: the gene III site, Proceedings of 
the National Academy of Sciences, 88 (1991) 7978-7982. 
[15] D.J. Schofield, A.R. Pope, V. Clementel, J. Buckell, S.D.J. Chapple, K.F. Clarke, 
J.S. Conquer, A.M. Crofts, S.R.E. Crowther, M.R. Dyson, G. Flack, G.J. Griffin, Y. 
Hooks, W.J. Howat, A. Kolb-Kokocinski, S. Kunze, C.D. Martin, G.L. Maslen, J.N. 
Mitchell, M. O'Sullivan, R.L. Perera, W. Roake, S.P. Shadbolt, K.J. Vincent, A. Warford, 
W.E. Wilson, J. Xie, J.L. Young, J. McCafferty, Application of phage display to high 
throughput antibody generation and characterization, Genome Biology, 8 (2007). 
[16] J.D. Marks, H.R. Hoogenboom, T.P. Bonnert, J. McCafferty, A.D. Griffiths, G. 
Winter, By-passing immunization.  Human antibodies from V-gene libraries displayed 
on phage, Journal of Molecular Biology, 222 (1991) 581-597. 
[17] C.F.I. Barbas, J.D. Bain, D.M. Hoekstra, R.A. Lerner, Semisynthetic combinatorial 
antibody libraries: a chemical solution to the diversity problem, Proceedings of the 
National Academy of Sciences, 89 (1992) 4457-4461. 
[18] H.R. Hoogenboom, G. Winter, By-passing immunisation.  Human antibodies from 
synthetic repertoires of germline VH gene segments rearranged in vitro., Journal of 
Molecular Biology, 227 (1992) 381-388. 
[19] H.R. Hoogenboom, A.D. Griffiths, K.S. Johnson, D.J. Chiswell, P. Hudson, G. 
Winter, Multi-subunit proteins on the surface of filamentous phage: methodologies for 
displaying antibody (Fab) heavy and light chains, Nucleic Acids Research, 19 (1991) 
4133-4137. 
24 
 
[20] J. Davies, L. Riechmann, An antibody variable heavy domain with a lox-Cre site 
integrated into its coding region: bacterial recombination within a single polypeptide 
chain, FEBS Letters, 377 (1995) 92-96. 
[21] M.M. Harmsen, H.J. De Haard, Properties, production, and applications of camelid 
single-domain antibody fragments, Applied Microbiology and Biotechnology, 77 (2007) 
13-22. 
[22] S.D. Nuttall, U.V. Krishnan, L. Doughty, K. Pearson, M.T. Ryan, N.J. Hoogenraad, 
M. Hattarki, J.A. Carmichael, R.A. Irving, P.J. Hudson, Isolation and characterization 
of an IgNAR variable domain specific for the human mitochondrial translocase 
receptor Tom70, European Journal of Biochemistry, 270 (2003) 3543-3554. 
[23] K. Nakano, T. Kojima, K. Kasutani, C. Senoh, O. Natori, S. Ishii, H. Tsunoda, K. 
Hattori, Effective screening method of agonistic diabodies based on autocrine growth, 
Journal of Immunological Methods, 347 (2009) 31-35. 
[24] Y. Mazor, T. Van Blarcom, R. Mabry, B.L. Iverson, G. Georgiou, Isolation of 
engineered, full-length antibodies from libraries expressed in Escherichia coli, Nature 
Biotechnology, 25 (2007) 563-565. 
[25] L.S. Jespers, A. Roberts, S.M. Mahler, G. Winter, H.R. Hoogenboom, Guiding the 
selection of human antibodies from phage display repertoires to a single epitope of an 
antigen, Biotechnology (N Y), 12 (1994) 899-903. 
[26] L. Urquhart, Top drugs and companies by sales in 2017, Nature Reviews Drug 
Discovery, 17 (2018) 232. 
[27] A.E. Nixon, D.J. Sexton, R.C. Ladner, Drugs derived from phage display: from 
candidate identification to clinical practice, mAbs, 6 (2014) 73-85. 
[28] M.P. Robinson, N. Ke, J. Lobstein, C. Peterson, A. Szkodny, T.J. Mansell, C. 
Tuckey, P.D. Riggs, P.A. Colussi, C.J. Noren, C.H. Taron, M.P. DeLisa, M. Berkmen, 
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria, 
Nature Communications, 6 (2015) 8072. 
[29] S.L. Sazinsky, R.G. Ott, N.W. Silver, B. Tidor, J.V. Ravetch, K.D. Wittrup, 
Aglycosylated immunoglobulin G1 variants productively engage activating Fc 
receptors, Proceedings of the National Academy of Sciences, 105 (2008) 20167-
20172. 
[30] S.T. Jung, W. Kelton, T.H. Kang, D.T. Ng, J.T. Andersen, I. Sandlie, C.A. Sarkar, 
G. Georgiou, Effective phagocytosis of low Her2 tumor cell lines with engineered, 
25 
 
aglycosylated IgG displaying high FcgammaRIIa affinity and selectivity, ACS Chemical 
Biology, 8 (2013) 368-375. 
[31] S.T. Jung, S.T. Reddy, T.H. Kang, M.J. Borrok, I. Sandlie, P.W. Tucker, G. 
Georgiou, Aglycosylated IgG variants expressed in bacteria that selectively bind 
FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells, Proceedings of 
the National Academy of Sciences, 107 (2010) 604-609. 
[32] H. Li, N. Sethuraman, T.A. Stadheim, D. Zha, B. Prinz, N. Ballew, P. Bobrowicz, 
B.K. Choi, W.J. Cook, M. Cukan, N.R. Houston-Cummings, R. Davidson, B. Gong, 
S.R. Hamilton, J.P. Hoopes, Y. Jiang, N. Kim, R. Mansfield, J.H. Nett, S. Rios, R. 
Strawbridge, S. Wildt, T.U. Gerngross, Optimization of humanized IgGs in 
glycoengineered Pichia pastoris, Nature Biotechnology, 24 (2006) 210-215. 
[33] T.I. Potgieter, S.D. Kersey, M.R. Mallem, A.C. Nylen, M. d'Anjou, Antibody 
expression kinetics in glycoengineered Pichia pastoris, Biotechnology and 
Bioengineering, 106 (2010) 918-927. 
[34] J. Ye, J. Ly, K. Watts, A. Hsu, A. Walker, K. McLaughlin, M. Berdichevsky, B. 
Prinz, D. Sean Kersey, M. d'Anjou, D. Pollard, T. Potgieter, Optimization of a 
glycoengineered Pichia pastoris cultivation process for commercial antibody 
production, Biotechnology Progress, 27 (2011) 1744-1750. 
[35] J.K. Ma, T. Lehner, P. Stabila, C.I. Fux, A. Hiatt, Assembly of monoclonal 
antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants, 
European Journal of Immunology, 24 (1994) 131-138. 
[36] B. De Muynck, C. Navarre, M. Boutry, Production of antibodies in plants: status 
after twenty years, Plant Biotechnology Journal, 8 (2010) 529-563. 
[37] G. Moussavou, K. Ko, J.H. Lee, Y.K. Choo, Production of monoclonal antibodies 
in plants for cancer immunotherapy, BioMed Research International, 2015 (2015) 
306164. 
[38] B.M. Grohs, Y. Niu, L.J. Veldhuis, S. Trabelsi, F. Garabagi, J.A. Hassell, M.D. 
McLean, J.C. Hall, Plant-produced trastuzumab inhibits the growth of HER2 positive 
cancer cells, Journal of Agricultural and Food Chemistry, 58 (2010) 10056-10063. 
[39] F.M. Wurm, Production of recombinant protein therapeutics in cultivated 
mammalian cells, Nature Biotechnology, 22 (2004) 1393-1398. 
[40] S.M. Browne, M. Al-Rubeai, Selection methods for high-producing mammalian 
cell lines, Trends in Biotechnology, 25 (2007) 425-432. 
26 
 
[41] S. Shi, R.G. Condon, L. Deng, J. Saunders, F. Hung, Y.S. Tsao, Z. Liu, A high-
throughput automated platform for the development of manufacturing cell lines for 
protein therapeutics, Journal of Visualized Experiments, (2011). 
[42] M. Chartrain, L. Chu, Development and production of commercial therapeutic 
monoclonal antibodies in Mammalian cell expression systems: an overview of the 
current upstream technologies, Current Pharmaceutical Biotechnology, 9 (2008) 447-
467. 
[43] L. Chu, D.K. Robinson, Industrial choices for protein production by large-scale cell 
culture, Current Opinion in Biotechnology, 12 (2001) 180-187. 
[44] H.F. Liu, J. Ma, C. Winter, R. Bayer, Recovery and purification process 
development for monoclonal antibody production, mAbs, 2 (2010) 480-499. 
[45] J.R. Birch, A.J. Racher, Antibody production, Advanced Drug Delivery Reviews, 
58 (2006) 671-685. 
[46] S.D. Jones, P. Seymour, H.L. Levine, CMC Activities for Development of MAbs,  
Contract Pharma, 2010, pp. 60-63. 
[47] R.L. Fahrner, H.L. Knudsen, C.D. Basey, W. Galan, D. Feuerhelm, M. Vanderlaan, 
G.S. Blank, Industrial purification of pharmaceutical antibodies: development, 
operation, and validation of chromatography processes, Biotechnology and Genetic 
Engineering Reviews, 18 (2001) 301-327. 
[48] W. Schwart, D. Judd, M. Wysocki, L. Guerrier, E. Birck-Wilson, E. Boschetti, 
Comparison of hydrophobic charge induction chromatography with affinity 
chromatography on protein A for harvest and purification of antibodies, Journal of 
Chromatography A, 908 (2001) 251-263. 
[49] R. van Reis, S. Gadam, L.N. Frautschy, S. Orlando, E.M. Goodrich, S. Saksena, 
R. Kuriyel, C.M. Simpson, S. Pearl, A.L. Zydney, High performance tangential flow 
filtration, Biotechnology and Bioengineering, 56 (1997) 71-82. 
[50] B. Lebreton, A. Brown, R. van Reis, Application of high-performance tangential 
flow filtration (HPTFF) to the purification of a human pharmaceutical antibody fragment 
expressed in Escherichia coli, Biotechnology and Bioengineering, 100 (2008) 964-974. 
[51] T. Arakawa, M. Futatsumori-Sugai, K. Tsumoto, Y. Kita, H. Sato, D. Ejima, MEP 
HyperCel chromatography II: binding, washing and elution, Protein Expression and 
Purification, 71 (2010) 168-173. 
27 
 
[52] P. Chames, M. Van Regenmortel, E. Weiss, D. Baty, Therapeutic antibodies: 
successes, limitations and hopes for the future, British Journal of Pharmacology, 157 
(2009) 220-233. 
[53] R. Niwa, M. Satoh, The current status and prospects of antibody engineering for 
therapeutic use: focus on glycoengineering technology, Journal of Pharmaceutical 
Sciences, 104 (2015) 930-941. 
[54] J.B. Evans, B.A. Syed, From the analyst's couch: Next-generation antibodies, Nat 
Rev Drug Discov, 13 (2014) 413-414. 
[55] H. Kaplon, J.M. Reichert, Antibodies to watch in 2018, mAbs, 10 (2018) 183-203. 
[56] O. Shpilberg, C. Jackisch, Subcutaneous administration of rituximab (MabThera) 
and trastuzumab (Herceptin) using hyaluronidase, British Journal of Cancer, 109 
(2013) 1556-1561. 
[57] S. Derer, C. Kellner, S. Berger, T. Valerius, M. Peipp, Fc engineering: design, 
expression, and functional characterization of antibody variants with improved effector 
function, Methods Mol Biol, 907 (2012) 519-536. 
[58] A. Beck, J.M. Reichert, Marketing approval of mogamulizumab: a triumph for 
glyco-engineering, mAbs, 4 (2012) 419-425. 
[59] M. Sachdeva, S. Dhingra, Obinutuzumab: A FDA approved monoclonal antibody 
in the treatment of untreated chronic lymphocytic leukemia, Int J Appl Basic Med Res, 
5 (2015) 54-57. 
[60] M. Ratner, Genentech's glyco-engineered antibody to succeed Rituxan, Nature 
Biotechnology, 32 (2014) 6+. 
[61] J.M. Subramaniam, G. Whiteside, K. McKeage, J.C. Croxtall, Mogamulizumab: 
first global approval, Drugs, 72 (2012) 1293-1298. 
[62] A.K. Kakkar, S. Balakrishnan, Obinutuzumab for chronic lymphocytic leukemia: 
promise of the first treatment approved with breakthrough therapy designation, J Oncol 
Pharm Pract, 21 (2015) 358-363. 
[63] S.D. Liu, C. Chalouni, J.C. Young, T.T. Junttila, M.X. Sliwkowski, J.B. Lowe, 
Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling 
components to intensify processes promoting ADCC, Cancer Immunol Res, 3 (2015) 
173-183. 
[64] T. Mizushima, H. Yagi, E. Takemoto, M. Shibata-Koyama, Y. Isoda, S. Iida, K. 
Masuda, M. Satoh, K. Kato, Structural basis for improved efficacy of therapeutic 
antibodies on defucosylation of their Fc glycans, Genes to Cells, 16 (2011) 1071-1080. 
28 
 
[65] S. Preithner, S. Elm, S. Lippold, M. Locher, A. Wolf, A.J. da Silva, P.A. Baeuerle, 
N.S. Prang, High concentrations of therapeutic IgG1 antibodies are needed to 
compensate for inhibition of antibody-dependent cellular cytotoxicity by excess 
endogenous immunoglobulin G, Mol Immunol, 43 (2006) 1183-1193. 
[66] N. Zhang, L. Liu, C. Dan Dumitru, N.R.H. Cummings, M. Cukan, Y. Jiang, Y. Li, 
F. Li, T. Mitchell, M.R. Mallem, Y. Ou, R.N. Patel, K. Vo, H. Wang, I. Burnina, B.-K. 
Choi, H.E. Huber, T.A. Stadheim, D. Zha, Glycoengineered Pichia produced anti-
HER2 is comparable to trastuzumab in preclinical study, mAbs, 3 (2011) 289-298. 
[67] R.L. Shields, A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, 
A. Stadlen, B. Li, J.A. Fox, L.G. Presta, High resolution mapping of the binding site on 
human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design 
of IgG1 variants with improved binding to the Fc gamma R, The Journal of Biological 
Chemistry, 276 (2001) 6591-6604. 
[68] G.A. Lazar, W. Dang, S. Karki, O. Vafa, J.S. Peng, L. Hyun, C. Chan, H.S. Chung, 
A. Eivazi, S.C. Yoder, J. Vielmetter, D.F. Carmichael, R.J. Hayes, B.I. Dahiyat, 
Engineered antibody Fc variants with enhanced effector function, Proceedings of the 
National Academy of Sciences, 103 (2006) 4005-4010. 
[69] J.B. Stavenhagen, S. Gorlatov, N. Tuaillon, C.T. Rankin, H. Li, S. Burke, L. Huang, 
S. Vijh, S. Johnson, E. Bonvini, S. Koenig, Fc optimization of therapeutic antibodies 
enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo 
via low-affinity activating Fcgamma receptors, Cancer Research, 67 (2007) 8882-8890. 
[70] M.J. Borrok, S.T. Jung, T.H. Kang, A.F. Monzingo, G. Georgiou, Revisiting the 
role of glycosylation in the structure of human IgG Fc, ACS Chemical Biology, 7 (2012) 
1596-1602. 
[71] R. Stewart, G. Thom, M. Levens, G. Guler-Gane, R. Holgate, P.M. Rudd, C. 
Webster, L. Jermutus, J. Lund, A variant human IgG1-Fc mediates improved ADCC, 
Protein Engineering Design and Selection, 24 (2011) 671-678. 
[72] V. Kayser, N. Chennamsetty, V. Voynov, K. Forrer, B. Helk, B.L. Trout, 
Glycosylation influences on the aggregation propensity of therapeutic monoclonal 
antibodies, Biotechnology Journal, 6 (2011) 38-44. 
[73] Y. Mimura, S. Church, R. Ghirlando, P.R. Ashton, S. Dong, M. Goodall, J. Lund, 
R. Jefferis, The influence of glycosylation on the thermal stability and effector function 
expression of human IgG1-Fc: properties of a series of truncated glycoforms, 
Molecular Immunology, 37 (2000) 697-706. 
29 
 
[74] M.K. Joubert, M. Hokom, C. Eakin, L. Zhou, M. Deshpande, M.P. Baker, T.J. 
Goletz, B.A. Kerwin, N. Chirmule, L.O. Narhi, V. Jawa, Highly aggregated antibody 
therapeutics can enhance the in vitro innate and late-stage T-cell immune responses, 
The Journal of Biological Chemistry, 287 (2012) 25266-25279. 
[75] S. Hermeling, D.J. Crommelin, H. Schellekens, W. Jiskoot, Structure-
immunogenicity relationships of therapeutic proteins, Pharmaceutical Research, 21 
(2004) 897-903. 
[76] D.S. Rehder, D. Chelius, A. McAuley, T.M. Dillon, G. Xiao, J. Crouse-Zeineddini, 
L. Vardanyan, N. Perico, V. Mukku, D.N. Brems, M. Matsumura, P.V. Bondarenko, 
Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor 
immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity, 
Biochemistry, 47 (2008) 2518-2530. 
[77] A.L. Daugherty, R.J. Mrsny, Formulation and delivery issues for monoclonal 
antibody therapeutics, Adv Drug Deliv Rev, 58 (2006) 686-706. 
[78] Y. Yan, H. Wei, Y. Fu, S. Jusuf, M. Zeng, R. Ludwig, S.R. Krystek, G. Chen, L. 
Tao, T.K. Das, Isomerization and Oxidation in the Complementarity-Determining 
Regions of a Monoclonal Antibody: A Study of the Modification–Structure–Function 
Correlations by Hydrogen–Deuterium Exchange Mass Spectrometry, Analytical 
Chemistry, 88 (2016) 2041-2050. 
[79] B. Moorthy, B. Xie, E. Moussa, L. Iyer, S. Chandrasekhar, J. Panchal, E. Topp, 
Structure of Monoclonal Antibodies, in: A. Rosenberg, B. Demeule (Eds.) Biobetters, 
Springer New York2015, pp. 81-89. 
[80] N. Chennamsetty, V. Voynov, V. Kayser, B. Helk, B.L. Trout, Design of therapeutic 
proteins with enhanced stability, Proceedings of the National Academy of Sciences, 
106 (2009) 11937-11942. 
[81] N. Chennamsetty, V. Voynov, V. Kayser, B. Helk, B.L. Trout, Prediction of 
aggregation prone regions of therapeutic proteins, The Journal of Physical Chemistry 
B, 114 (2010) 6614-6624. 
[82] F. Courtois, C.P. Schneider, N.J. Agrawal, B.L. Trout, Rational Design of 
Biobetters with Enhanced Stability, Journal of Pharmaceutical Sciences, 104 (2015) 
2433-2440. 
[83] M. Ahmadi, C.J. Bryson, E.A. Cloake, K. Welch, V. Filipe, S. Romeijn, A. Hawe, 
W. Jiskoot, M.P. Baker, M.H. Fogg, Small Amounts of Sub-Visible Aggregates 
30 
 
Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics, 
Pharmaceutical Research, 32 (2015) 1383-1394. 
[84] J. Bessa, S. Boeckle, H. Beck, T. Buckel, S. Schlicht, M. Ebeling, A. Kiialainen, A. 
Koulov, B. Boll, T. Weiser, T. Singer, A.G. Rolink, A. Iglesias, The Immunogenicity of 
Antibody Aggregates in a Novel Transgenic Mouse Model, Pharmaceutical Research, 
32 (2015) 2344-2359. 
[85] M.C. Manning, D.K. Chou, B.M. Murphy, R.W. Payne, D.S. Katayama, Stability of 
Protein Pharmaceuticals: An Update, Pharmaceutical Research, 27 (2010) 544-575. 
[86] E. Sahin, A.O. Grillo, M.D. Perkins, C.J. Roberts, Comparative effects of pH and 
ionic strength on protein–protein interactions, unfolding, and aggregation for IgG1 
antibodies, Journal of Pharmaceutical Sciences, 99 (2010) 4830-4848. 
[87] P. Arosio, S. Rima, M. Morbidelli, Aggregation Mechanism of an IgG2 and two 
IgG1 Monoclonal Antibodies at low pH: From Oligomers to Larger Aggregates, 
Pharmaceutical Research, 30 (2013) 641-654. 
[88] S.N. Telikepalli, O.S. Kumru, C. Kalonia, R. Esfandiary, S.B. Joshi, C.R. Middaugh, 
D.B. Volkin, Structural Characterization of IgG1 mAb Aggregates and Particles 
Generated Under Various Stress Conditions, Journal of Pharmaceutical Sciences, 103 
(2014) 796-809. 
[89] F. Depreter, G. Pilcer, K. Amighi, Inhaled proteins: Challenges and perspectives, 
International Journal of Pharmaceutics, 447 (2013) 251-280. 
[90] V. Kayser, N. Chennamsetty, V. Voynov, B. Helk, K. Forrer, B.L. Trout, Evaluation 
of a non-Arrhenius model for therapeutic monoclonal antibody aggregation, Journal of 
Pharmaceutical Sciences, 100 (2011) 2526-2542. 
[91] N. Kim, R.L. Remmele Jr, D. Liu, V.I. Razinkov, E.J. Fernandez, C.J. Roberts, 
Aggregation of anti-streptavidin immunoglobulin gamma‐1 involves Fab unfolding and 
competing growth pathways mediated by pH and salt concentration, Biophysical 
Chemistry, 172 (2013) 26-36. 
[92] H. Wu, R. Kroe-Barrett, S. Singh, A.S. Robinson, C.J. Roberts, Competing 
aggregation pathways for monoclonal antibodies, FEBS Letters, 588 (2014) 936-941. 
[93] S.B. Mehta, J.S. Bee, T.W. Randolph, J.F. Carpenter, Partial Unfolding of a 
Monoclonal Antibody: Role of a Single Domain in Driving Protein Aggregation, 
Biochemistry, 53 (2014) 3367-3377. 
31 
 
[94] V.I. Razinkov, M.J. Treuheit, G.W. Becker, Accelerated Formulation Development 
of Monoclonal Antibodies (mAbs) and mAb-Based Modalities: Review of Methods and 
Tools, Journal of Biomolecular Screening, 20 (2015) 468-483. 
[95] H. Liu, G. Gaza-Bulseco, J. Sun, Characterization of the stability of a fully human 
monoclonal IgG after prolonged incubation at elevated temperature, Journal of 
Chromatography B, 837 (2006) 35-43. 
[96] J. Vlasak, R. Ionescu, Fragmentation of monoclonal antibodies, mAbs, 3 (2011) 
253-263. 
[97] R.J. Harris, B. Kabakoff, F.D. Macchi, F.J. Shen, M. Kwong, J.D. Andya, S.J. Shire, 
N. Bjork, K. Totpal, A.B. Chen, Identification of multiple sources of charge 
heterogeneity in a recombinant antibody, Journal of Chromatography B: Biomedical 
Sciences and Applications, 752 (2001) 233-245. 
[98] H. Liu, G. Gaza-Bulseco, C. Chumsae, Glutamine deamidation of a recombinant 
monoclonal antibody, Rapid Communications in Mass Spectrometry, 22 (2008) 4081-
4088. 
[99] Y.T. Zhang, J. Hu, A.L. Pace, R. Wong, Y.J. Wang, Y.-H. Kao, Characterization 
of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange 
chromatography and peptide mapping, Journal of Chromatography B, 965 (2014) 65-
71. 
[100] A.L. Pace, R.L. Wong, Y.T. Zhang, Y.-H. Kao, Y.J. Wang, Asparagine 
deamidation dependence on buffer type, pH, and temperature, Journal of 
Pharmaceutical Sciences, 102 (2013) 1712-1723. 
[101] L. Yi, N. Beckley, B. Gikanga, J. Zhang, Y.J. Wang, H.-W. Chih, V.K. Sharma, 
Isomerization of Asp–Asp motif in model peptides and a Monoclonal Antibody Fab 
Fragment, Journal of Pharmaceutical Sciences, 102 (2013) 947-959. 
[102] V. Timm, P. Gruber, M. Wasiliu, H. Lindhofer, D. Chelius, Identification and 
characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid 
antibodies, Journal of Chromatography B, 878 (2010) 777-784. 
[103] L. Huang, J. Lu, V.J. Wroblewski, J.M. Beals, R.M. Riggin, In Vivo Deamidation 
Characterization of Monoclonal Antibody by LC/MS/MS, Analytical Chemistry, 77 
(2005) 1432-1439. 
[104] A. Sreedhara, J. Yin, M. Joyce, K. Lau, A.T. Wecksler, G. Deperalta, L. Yi, Y. 
John Wang, B. Kabakoff, R.S.K. Kishore, Effect of ambient light on IgG1 monoclonal 
32 
 
antibodies during drug product processing and development, European Journal of 
Pharmaceutics and Biopharmaceutics, 100 (2016) 38-46. 
[105] A. Sreedhara, K. Lau, C. Li, B. Hosken, F. Macchi, D. Zhan, A. Shen, D. 
Steinmann, C. Schöneich, Y. Lentz, Role of Surface Exposed Tryptophan as Substrate 
Generators for the Antibody Catalyzed Water Oxidation Pathway, Molecular 
Pharmaceutics, 10 (2013) 278-288. 
[106] R. Torosantucci, C. Schöneich, W. Jiskoot, Oxidation of Therapeutic Proteins 
and Peptides: Structural and Biological Consequences, Pharmaceutical Research, 31 
(2014) 541-553. 
[107] W. Wang, J. Vlasak, Y. Li, P. Pristatsky, Y. Fang, T. Pittman, J. Roman, Y. Wang, 
T. Prueksaritanont, R. Ionescu, Impact of methionine oxidation in human IgG1 Fc on 
serum half-life of monoclonal antibodies, Mol Immunol, 48 (2011) 860-866. 
[108] W. Wang, S. Singh, D.L. Zeng, K. King, S. Nema, Antibody structure, instability, 
and formulation, Journal of Pharmaceutical Sciences, 96 (2007) 1-26. 
[109] B. Yan, Z. Yates, A. Balland, G.R. Kleemann, Human IgG1 Hinge Fragmentation 
as the Result of H2O2-mediated Radical Cleavage, Journal of Biological Chemistry, 
284 (2009) 35390-35402. 
[110] Z. Wei, J. Feng, H.-Y. Lin, S. Mullapudi, E. Bishop, G.I. Tous, J. Casas-Finet, F. 
Hakki, R. Strouse, M.A. Schenerman, Identification of a Single Tryptophan Residue 
as Critical for Binding Activity in a Humanized Monoclonal Antibody against 
Respiratory Syncytial Virus, Analytical Chemistry, 79 (2007) 2797-2805. 
[111] C.J. Wilson, Rational protein design: developing next-generation biological 
therapeutics and nanobiotechnological tools, Wiley Interdisciplinary Reviews: 
Nanomedicine and Nanobiotechnology, 7 (2015) 330-341. 
[112] N. Cerda-Costa, A. Esteras-Chopo, F.X. Aviles, L. Serrano, V. Villegas, Early 
kinetics of amyloid fibril formation reveals conformational reorganisation of initial 
aggregates, Journal of Molecular Biology, 366 (2007) 1351. 
[113] N. de Groot, I. Pallares, F. Aviles, J. Vendrell, S. Ventura, Prediction of "hot 
spots" of aggregation in disease-linked polypeptides, BMC Structural Biology, 5 (2005) 
18. 
[114] U. Ogmen, O. Keskin, S. Aytuna, R. Nussinoiv, A. Gursoy, PRISM: Protein 
interactions by structural matching, Nucleic Acids Research, 33 (2005) W331-W336. 
[115] G.G. Tartaglia, M. Vendruscolo, The Zyggregator method for predicting protein 
aggregation propensities, Chemical Society Reviews, 37 (2008) 1395-1401. 
33 
 
[116] A. Trovato, F. Seno, S.C.E. Tosatto, The PASTA server for protein aggregation 
prediction, Protein Engineering Design and Selection, (2007) gzm042. 
[117] G.G. Tartaglia, A. Cavalli, R. Pellarin, A. Caflisch, Prediction of aggregation rate 
and aggregation-prone segments in polypeptide sequences, Protein Science, 14 
(2005) 2723-2734. 
[118] X. Wang, T.K. Das, S.K. Singh, S. Kumar, Potential aggregation prone regions 
in biotherapeutics, mAbs, 1 (2009) 254-267. 
[119] V.E. Angarica, J. Sancho, Protein Dynamics Governed by Interfaces of High 
Polarity and Low Packing Density, PLoS ONE, 7 (2012) e48212. 
[120] R. Zambrano, M. Jamroz, A. Szczasiuk, J. Pujols, S. Kmiecik, S. Ventura, 
AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein 
structures, Nucleic Acids Research, 43 (2015) W306-W313. 
[121] D. Schweizer, T. Serno, A. Goepferich, Controlled release of therapeutic 
antibody formats, European Journal of Pharmaceutics and Biopharmaceutics, 88 
(2014) 291-309. 
[122] A.L. Daugherty, R.J. Mrsny, Formulation and delivery issues for monoclonal 
antibody therapeutics, Advanced Drug Delivery Reviews, 58 (2006) 686-706. 
[123] L. Chang, D. Shepherd, J. Sun, X. Tang, M.J. Pikal, Effect of sorbitol and residual 
moisture on the stability of lyophilized antibodies: Implications for the mechanism of 
protein stabilization in the solid state, Journal of Pharmaceutical Sciences, 94 (2005) 
1445-1455. 
[124] L. Platts, R.J. Falconer, Controlling protein stability: Mechanisms revealed using 
formulations of arginine, glycine and guanidinium HCl with three globular proteins, 
International Journal of Pharmaceutics, 486 (2015) 131-135. 
[125] S. Ohtake, Y. Kita, T. Arakawa, Interactions of formulation excipients with 
proteins in solution and in the dried state, Adv Drug Deliv Rev, 63 (2011) 1053-1073. 
[126] M.X. Yang, B. Shenoy, M. Disttler, R. Patel, M. McGrath, S. Pechenov, A.L. 
Margolin, Crystalline monoclonal antibodies for subcutaneous delivery, Proceedings 
of the National Academy of Sciences, 100 (2003) 6934-6939. 
[127] D. Schweizer, K. Schonhammer, M. Jahn, A. Gopferich, Protein-polyanion 
interactions for the controlled release of monoclonal antibodies, Biomacromolecules, 
14 (2013) 75-83. 
[128] D.W. Grainger, Controlled-release and local delivery of therapeutic antibodies, 
Expert Opinion on Biological Therapy, 4 (2004) 1029-1044. 
34 
 
[129] M. Shimizu, Y. Miwa, K. Hashimoto, A. Goto, Encapsulation of chicken egg yolk 
immunoglobulin G (IgY) by liposomes, Bioscience Biotechnology and Biochemistry, 
57 (1993) 1445-1449. 
[130] X.Y. Li, L.J. Jin, T.A. McAllister, K. Stanford, J.Y. Xu, Y.N. Lu, Y.H. Zhen, Y.X. 
Sun, Y.P. Xu, Chitosan-alginate microcapsules for oral delivery of egg yolk 
immunoglobulin (IgY), Journal of Agricultural and Food Chemistry, 55 (2007) 2911-
2917. 
[131] Y. Yun, Y.W. Cho, K. Park, Nanoparticles for oral delivery: Targeted 
nanoparticles with peptidic ligands for oral protein delivery, Advanced Drug Delivery 
Reviews, 65 (2013) 822-832. 
[132] M. Streit, Z. Beleznay, L.R. Braathen, Topical application of the tumour necrosis 
factor-alpha antibody infliximab improves healing of chronic wounds, International 
Wound Journal, 3 (2006) 171-179. 
[133] M. Smola, T. Vandamme, A. Sokolowski, Nanocarriers as pulmonary drug 
delivery systems to treat and to diagnose respiratory and non respiratory diseases, 
International Journal of Nanomedicine, 3 (2008) 1-19. 
[134] S.J. Koussoroplis, G. Paulissen, D. Tyteca, H. Goldansaz, J. Todoroff, C. Barilly, 
C. Uyttenhove, J. Van Snick, D. Cataldo, R. Vanbever, PEGylation of antibody 
fragments greatly increases their local residence time following delivery to the 
respiratory tract, Journal of Controlled Release, 187 (2014) 91-100. 
[135] L. Dellamary, D.J. Smith, A. Bloom, S. Bot, G.R. Guo, H. Deshmuk, M. Costello, 
A. Bot, Rational design of solid aerosols for immunoglobulin delivery by modulation of 
aerodynamic and release characteristics, Journal of Controlled Release, 95 (2004) 
489-500. 
[136] A.I. Bot, T.E. Tarara, D.J. Smith, S.R. Bot, C.M. Woods, J.G. Weers, Novel lipid-
based hollow-porous microparticles as a platform for immunoglobulin delivery to the 
respiratory tract, Pharmaceutical Research, 17 (2000) 275-283. 
[137] I.M. El-Sherbiny, N.M. El-Baz, M.H. Yacoub, Inhaled nano- and microparticles 
for drug delivery, Global Cardiology Science and Practice, 2015 (2015) 2. 
[138] L. Detalle, T. Stohr, C. Palomo, P.A. Piedra, B.E. Gilbert, V. Mas, A. Millar, U.F. 
Power, C. Stortelers, K. Allosery, J.A. Melero, E. Depla, Generation and 
Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the 
Treatment of Respiratory Syncytial Virus Infection, Antimicrobial Agents and 
Chemotherapy, 60 (2016) 6-13. 
35 
 
CHAPTER 2 
 
 
 
“Lack of a Synergistic Effect of Arginine-Glutamic 
Acid on the Physical Stability of Spray-Dried 
Bovine Serum Albumin” 
 
 
 
Chapter 2 was published in the Pharmaceutical Development and 
Technology journal: 
Reslan, M., Demir, Y., Trout, B., Chan, H., Kayser, V. (2017). Lack of a 
synergistic effect of arginine-glutamic acid on the physical stability of 
spray-dried bovine serum albumin. Pharmaceutical Development and 
Technology, 22:785-791. 
 
 
 
 
 
 
 
36 
 
Abstract 
Improving the physical stability of spray-dried proteins is essential for enabling 
pulmonary delivery of biotherapeutics as a non-invasive alternative to injections. 
Recently, a novel combination of two amino acids - L-arginine (L-Arg) and L-glutamic 
acid (L-Glu), has been reported to have synergistic protein-stabilizing effects on 
various protein solutions. Using spray-dried bovine serum albumin (BSA) reconstituted 
in solution as a model protein, we investigated the synergistic effect of these amino 
acids on the physical stability of proteins.  
Five BSA solutions were prepared: (1) BSA with no amino acids (control); (2) with 50 
mM L-Arg; (3) with 200 mM L-Arg, (4) with 50 mM L-Glu; and (5) with 25:25 mM of 
Arg:Glu. All solutions were spray-dried and accelerated studies at high temperatures 
were performed. Following accelerated studies, monomer BSA loss was measured 
using SE-HPLC. 
We found that L-Arg significantly improved the physical stability of spray-dried BSA 
even at low concentrations, however, when combined with L-Glu, was ineffective at 
reducing monomer BSA loss. Our findings demonstrate the limitations in using Arg-
Glu for the stabilization of spray-dried BSA. Furthermore, we found that a low 
concentration of L-Glu enhanced monomer BSA loss. These findings may have 
significant implications on the design of future biotherapeutic formulations 
1. Introduction 
 
The majority of current and emerging biotherapeutics are delivered parenterally due 
to their poor oral bioavailability and short half-lives in the gastrointestinal tract [1-3]. 
However, due to poor patient compliance to parenteral treatment and the increased 
likelihood of treatment failure, the development of non-invasive protein formulations 
has become critical [1, 4]. In recent years, following the success of insulin inhalers, 
pulmonary delivery of proteins has been recognized as a viable non-invasive 
alternative for the treatment of local and systemic conditions [5, 6]. The advantages of 
the pulmonary route include: improved compliance, potential to reduce dose and 
adverse effects, increased biological half-life, and enhanced efficacy for local lung 
diseases [2, 7].  
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For any biotherapeutic formulation, protein aggregation is particularly problematic as 
it leads to loss of protein activity and can induce an undesired immunogenic response 
in a patient [8, 9]. One method currently employed to suppress aggregation involves 
the addition of protein-stabilizing excipients to the formulation, such as various sugars 
- trehalose, sucrose and maltose; amino acids – arginine and leucine; and surfactants 
– tween 80 and poloxamer [4, 10-12]. In order for non-invasive formulations – such as 
inhalers - to become more practical, the physical stability of proteins must be 
enhanced further, without excessive use of excipients to maximize the potency of the 
formulation.  
Recently, a combination of arginine and glutamic acid in equimolar concentrations has 
been used to stabilize a number of proteins prepared in aqueous solutions [9, 13, 14]. 
It was shown that the combination of the two amino acids had a synergistic effect on 
the suppression of protein aggregation in concentrations ranging from 50-200 mM [13, 
14]. While the effect of amino acids on protein stability has been studied extensively, 
only a limited number of proteins have been tested with the Arg-Glu combination. 
Furthermore, the mechanism underlying the Arg-Glu synergy is poorly understood; 
thus, more research is required to understand the significance of these findings for the 
development of biotherapeutics. The aim of this study is to investigate the potential 
synergistic effects of L-Arg and L-Glu on the physical stability of protein formulations, 
using spray-dried BSA reconstituted in solution as a model system. BSA has good 
thermal stability and is widely used to model protein aggregation as it is well-
characterized and readily available. Findings from our study may contribute to the use 
of a novel combination of amino acids as an effective protein-stabilizing excipient 
system for the formulation of therapeutically important proteins.  
We used a 50 mM L-Glu concentration, due to the limited solubility of L-Glu. We 
observed minimal protein degradation due to spray-drying for all formulations. L-Arg 
suppressed heat-induced monomer loss of spray-dried BSA as previously reported 
[15, 16], however L-Glu enhanced monomer BSA loss, while the combination of Arg-
Glu neither suppressed nor facilitated monomer loss. Our findings suggest that the 
synergistic mechanism observed in previous studies is protein-specific and it is 
possible that a minimum threshold concentration is required to observe synergistic 
action.  
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2. Materials and methods 
 
2.1. Materials 
 
Bovine serum albumin (Fraction V, A7906), L-arginine (A5006, reagent grade, ≥98%) 
and L-glutamic acid (G1251, ReagentPlus®, ≥99%) were purchased from Sigma 
Aldrich, Castle Hill, Australia. di-potassium hydrogen phosphate (105101, 
EMPROVE® Ph Eur, BP, E 340 grade) and potassium dihydrogen phosphate 
(104873, EMSURE® ISO grade) were purchased from Merck Millipore, MA, USA. 
2.2. Preparation of BSA samples 
All samples were prepared from a 40 mg/ml stock solution of BSA in 15 mM potassium 
phosphate buffer to a final [BSA] of 4 mg/mL. A 55.6 mM stock solution of L-Glu was 
used to make BG1 and BAG1 to a final [L-Glu] of 50 mM and 25 mM, respectively. A 
200 mM stock solution of L-Arg was used to make BA1, BA2 and BAG1 to final [L-Arg] 
of 50 mM, 200 mM and 25 mM respectively (Table 1). 50 mL of each formulation was 
prepared and stored at 4 °C. All samples used in the study were adjusted to pH 6.5.  
Table 1. Summary of preparations used in the study. 
Samples  [BSA] 
(mg/mL) 
[L-arginine] 
(mM) 
[L-glutamic acid] 
(mM) 
[Potassium 
phosphate] (mM) 
BSA (Control) 4 - - 15 
BA1 4 50 - 15 
BAG1 4 25 25 15 
BG1 4 - 50 15 
BA2 4 200 - 15 
 
2.3. Spray-drying 
All samples were spray dried using a Buchi Mini Spray-Dryer B-290 in open loop 
setting using compressed air. The operating conditions were: inlet temperature of 60 
°C, outlet temperature of 39 °C, aspirator at 100%, liquid feed rate at 2.2 mL/min and 
an atomizing airflow of 742 NL/hr. 
2.4. Laser diffraction (LD) 
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The particle size distribution of dry powders was measured by laser diffraction using 
a Malvern Mastersizer 2000 (Malvern, Worcestershire, UK). Approximately 5 mg of 
spray-dried powder was analyzed for each BSA sample, three times. The refractive 
index of BSA particles was 1.45 and the absorption value was 0.1. Size was assessed 
by the volume-weighted mean diameter and D0.1, D0.5 and D0.9, which represent the 
diameter at which, 10%, 50% and 90% of the volume distribution of particles 
(respectively), fall below. Size distribution was assessed by the span, which is a 
measure of the broadness of the distribution, calculated as (D0.9−D0.1)/D0.5. 
2.5. Accelerated studies at elevated temperature  
Accelerated studies at high temperatures were conducted as previously described 
[17]. Incubation of dry powders in the solid state was not feasible due to the powders 
sticking to the tubes at elevated temperatures, leading to significant loss of sample 
when dissolving the powders for SE-HPLC. Thus spray-dried BSA powders were first 
dissolved in 15 mM potassium phosphate buffer to a final [BSA] of 0.85 mg/mL, then 
100 µL aliquots were incubated in a Thermal Cycler 2720 (Applied Biosystems, CA, 
USA) at 65 °C for 1 and 2 hours, and 70 °C for 15 and 30 minutes. Following 
incubation, the physical stability of the BSA samples was analyzed using size 
exclusion-high performance liquid chromatography (SE-HPLC). 
2.6. SE-HPLC 
 
Size exclusion-high performance liquid chromatography was used to quantify 
monomer loss of BSA following accelerated temperature studies. Analysis was 
performed using an Agilent 1200 Liquid Chromatography system with a TSKgel Super 
SW3000 column, at 22 °C, with 150 mM potassium phosphate mobile phase, at pH 
6.5, and flow rate set at 0.2 mL/min. 85 µg of BSA was injected in each run (100 µL).  
Monomer peaks were detected at 280 nm by an in-line UV signal detector. The area 
under the curve (AUC) of the monomer peak was averaged over three runs and the 
mean monomer % was calculated for each sample. The standard deviation (SD) was 
plotted as error bars in the figures.  
3. Results 
3.1. Particle size distribution of powders by LD 
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The addition of L-Arg prior to spray-drying had no significant effect on the mean 
particle size of the spray-dried powders (Table 2), however the addition of L-Glu 
reduced the size of the particles generated from 2.75 ± 0.14 to 2.11 ± 0.16 µm (± SD), 
even when combined with arginine (BAG1; 2.27 ± 0.01 µm; Table 2). Despite the 
differences in the mean particle sizes, the particle size distribution of the powders was 
relatively comparable with a span ranging from 1.30 (BA1) to 1.71 (BG1) and D0.5 from 
1.90 (BG1) to 2.68 (BA2) (Table 2).  
Table 2. Size distribution data of the spray-dried powders. 
Powder Volume-weighted mean (µm) ± SD D0.1 D0.5 D0.9 Span 
BSA 2.75 ± 0.14 1.01 2.48 4.91 1.57  
BA1  2.59 ± 0.05 1.21 2.38 4.30  1.30 
BAG1 2.27 ± 0.01 0.86 2.04 4.04  1.56  
BA2 2.87 ± 0.16 0.70 2.68 5.21 1.69 
BG1 2.11 ± 0.16 0.66  1.90 3.89 1.71 
 
3.2. SE-HPLC analysis of monomer BSA loss following spray-drying and 
accelerated temperature studies  
 
SE-HPLC was used to measure changes in monomer BSA content following spray-
drying and incubation at high temperatures (Fig. 1-7; Tables 3 and 4). Mean monomer 
% content and % loss of all samples following spray-drying and heat-treatment can be 
found in Tables 3 and 4. Since BSA exists predominantly in the monomer state, a loss 
of monomer AUC would indicate that the protein sample has either fragmented or 
formed aggregates. After spray-drying, a monomer loss between 1.1-2.8% is observed 
for all samples, except BA1 which had the lowest monomer loss (0.4%; Fig. 1 and 2; 
Table 3). Interestingly, the highest monomer loss post-spray drying was observed with 
BAG1 (2.8%), while the other formulations maintained a comparable monomer loss of 
~1%. Incubation at 65 °C for 1 hour caused a significant decrease in monomer % for 
all samples (19-37% loss), except BA2 with only a 4.7% loss (Fig. 3 and 7; Table 4). 
Following incubation at 65 °C for 2 hours, all samples have a significantly lower 
monomer % (5.9-42.2% loss) when compared to the untreated control, however the 
smallest reductions in monomer % are observed with BA1 (23%) and BA2 (5.9%) (Fig. 
4 and 7; Table 4). This trend continues for samples incubated at 70 °C for 15 minutes; 
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the highest monomer loss is observed with BG1 (51.4%), followed by BAG1 (45.5%), 
BSA-only (44.8%), BA1 (36.9%) and BA2 (16.5%) (Fig. 5 and 7; Table 4). Likewise, 
following incubation at 70 °C for 30 minutes, the highest monomer loss is observed 
with BG1 (54.2%), followed by BAG1 (49.9%), BSA-only (48.8%), BA1 (37.3%) and 
BA2 (22.7%) (Fig. 6 and 7; Table 4). 
 
Table 3. Mean monomer % loss of BSA samples following spray-drying. 
Sample 
Monomer 
BSA BAG1 BG1 BA1 BA2 
% % 
loss 
% % 
loss 
% % 
loss 
% % 
loss 
% % 
loss 
Pre-Spray 78.0 0 78.0 0 78.0 0 78.0 0 78.0 0 
Post-Spray 76.9 1.1 75.2 2.8 76.9 1.1 77.6 0.4 76.3 1.7 
Figure 1. Representative SE-HPLC chromatogram of BSA and spray-dried BSA, 
BAG1, BG1, BA1 and BA2. [BSA] of all samples is 0.85 mg/mL. BAG1 = BSA + 5.3 
mM L-Arg + 5.3 mM L-Glu; BG1 = BSA + 10.6 mM L-Glu; BA1 = BSA + 10.6 mM L-
Arg; BA2 = BSA + 42.5 mM L-Arg. Inset figure represents a magnified region of the 
chromatogram between 10-25 minutes. 
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Figure 2. Mean monomer % of BSA samples following spray-drying.  “BSA Pre-Spray” 
represents the monomer % for a BSA solution that has not been spray-dried. [BSA] of 
all samples is 0.85 mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = BSA 
+ 10.6 mM L-Glu; BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. The 
error bars represent the SD. 
 
Figure 3. Representative SE-HPLC chromatogram of spray-dried BSA, BAG1, BG1, 
BA1 and BA2 following incubation at 65 °C for 60 minutes. [BSA] of all samples is 0.85 
mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = BSA + 10.6 mM L-Glu; 
BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. Inset figure represents a 
magnified region of the chromatogram between 9-25 minutes. 
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Figure 4. Representative SE-HPLC chromatogram of spray-dried BSA, BAG1, BG1, 
BA1 and BA2 following incubation at 65 °C for 120 minutes. [BSA] of all samples is 0.85 
mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = BSA + 10.6 mM L-Glu; 
BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. Inset figure represents a 
magnified region of the chromatogram between 9-25 minutes. 
 
Figure 5. Representative SE-HPLC chromatogram of spray-dried BSA, BAG1, BG1, 
BA1 and BA2 following incubation at 70 °C for 15 minutes. [BSA] of all samples is 0.85 
mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = BSA + 10.6 mM L-Glu; 
BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. Inset figure represents a 
magnified region of the chromatogram between 9-26 minutes. 
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Figure 6. Representative SE-HPLC chromatogram of spray-dried BSA, BAG1, BG1, 
BA1 and BA2 following incubation at 70 °C for 30 minutes. [BSA] of all samples is 0.85 
mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = BSA + 10.6 mM L-Glu; 
BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. Inset figure represents a 
magnified region of the chromatogram between 9-26 minutes. 
Figure 7. Mean relative monomer % of spray-dried BSA samples, prior to, and 
following incubation at 65 °C for 1 and 2 hours and 70 °C for 15 and 30 minutes. The 
“Untreated (Control)” represents a spray-dried sample prior to heat-treatment. [BSA] 
of all samples is 0.85 mg/mL. BAG1 = BSA + 5.3 mM L-Arg + 5.3 mM L-Glu; BG1 = 
BSA + 10.6 mM L-Glu; BA1 = BSA + 10.6 mM L-Arg; BA2 = BSA + 42.5 mM L-Arg. 
The error bars represent the SD. 
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When compared to BSA-only, BG1 has a significantly lower monomer % while BA1 
and BA2 have a significantly higher monomer %, following all incubation conditions 
(Fig. 3-7; Table 4). For example, following incubation at 70 °C for 30 minutes, the 
monomer BSA content of BSA-only, BG1, BA1 and BA2 is 28.1%, 22.7%, 40.3% and 
53.6%, respectively (Fig. 6 and 7; Table 4). There is no significant difference between 
BSA-only and BAG1 at any incubation conditions except at 65 °C after 2 hours, where 
BSA-only has a significantly higher monomer % (48.7% vs. 41.1%; Fig. 4 and 7; Table 
4).  
From the SE-HPLC chromatograms, a significant amount of the injected sample into 
the column is not recovered following heat-treatment as the total AUC decreases with 
incubation temperature. The low protein recovery is likely due to loss of aggregates 
that became trapped in the column owing to their large size. With this in mind, even 
though it appears that BA2 has the highest amount of aggregates after heat-treatment 
at all incubation conditions (Fig. 3-6), the total recovered protein with the BA2 sample 
is significantly higher than all other heat-treated samples (BSA, BAG1, BG1 and BA1) 
indicating that BA2 formed mostly smaller aggregates.  
All samples containing amino acids had enlarged fragment peaks between ~19-26 
minutes. BA2 had the largest fragment peak at ~24 minutes and the size of the peak 
remained unchanged following all incubation conditions (Fig. 3-6). Since L-Arg and L-
Glu solutions eluted between 19-26 minutes in preliminary tests (data not shown), the 
Table 4. Mean monomer % loss of BSA samples following incubation at 65 °C for 
1 and 2 hours and 70 °C for 15 and 30 minutes. 
Sample 
Monomer 
BSA BAG1 BG1 BA1 BA2 
% % 
loss 
% % 
loss 
% % 
loss 
% % 
loss 
% % 
loss 
Post-Spray  76.9 0 75.2 0 76.9 0 77.6 0 76.3 0 
65 °C 1 h 48.8 28.1 47.3 27.9 40.1 36.8 58.3 19.3 71.6 4.7 
65 °C 2 h 48.7 28.2 41.1 34.1 34.7 42.2 54.6 23.0 70.4 5.9 
70 °C 15 min 32.1 44.8 29.7 45.5 25.5 51.4 40.7 36.9 59.8 16.5 
70 °C 30 min 28.1 48.8 25.3 49.9 22.7 54.2 40.3 37.3 53.6 22.7 
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peaks observed were attributed to overlaps between the free amino acids, salt and the 
fragment BSA peaks, and therefore, were not considered in the final assessment of 
the physical stability of the samples. 
4. Discussion 
4.1. Particle size of BSA powders with amino acids 
 
Particle size of spray-dried BSA was unchanged with the addition of L-Arg, however 
was significantly lowered when L-Glu was used. Faghihi, et al. [18] also found that 
spray-dried Immunoglobulin G (IgG) with 20% or 50% w/w arginine, did not 
significantly affect the size of particles produced when compared with excipient-free 
IgG. Conversely, they found that leucine, phenylalanine, cysteine and glycine 
significantly decreased the particle size of spray-dried IgG powders. They proposed 
that these amino acids would reside at the surface of IgG for extended periods of time 
due to either hydrophobicity or side-chain interactions, reducing agglomeration of IgG 
during spray-drying and thus resulting in smaller particle sizes. A similar phenomenon 
could be occurring here with L-Glu in our study. Firstly, BSA surface (pI 4.7) is 
expected to be predominantly negatively-charged at pH 6.5, and hence, the 
negatively-charged side chain of L-Glu is likely neutralizing the remaining positively-
charged surface residues on BSA; increasing the net negative surface charge of BSA. 
 
This would result in reduced agglomeration, due to increased electrostatic repulsion 
during particle formation, thereby causing the formation of smaller-sized BSA particles. 
Nonetheless, all samples prepared in our study maintained a satisfactory particle size 
for pulmonary delivery, (Table 3) and thus may be a feasible approach for the 
development and delivery of spray-dried biotherapeutics.  We did not investigate the 
deposition performance of our powders since it is not the focus of our study.  
 
4.2. Effect of spray-drying on protein stability 
 
Spray-drying can introduce thermal and shear stress which can have unfavourable 
effects on the stability of protein powders [4, 19]. However, this is highly dependent on 
the protein studied and the spray-drying conditions used, particularly the inlet air 
temperature [20]. In our study, we chose a thermally stable protein and used a low 
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inlet temperature (60 °C) to ensure that the spray-drying process has a minimal effect 
on the stability of the powders, thus eliminating the contribution of the spray-drying 
process to changes observed following accelerated temperature studies. 
Nonetheless, BAG1 enhanced monomer loss during spray-drying when compared 
with the control and other formulations tested. Since this was not observed for BG1 
nor BA1, the effect may be concentration-dependant, with lower concentrations 
facilitating protein aggregation during spray-drying. Despite this, monomer loss 
following spray-drying was still < 3% (Fig. 1 and 2; Table 3) and we consider such a 
loss to be not clinically or therapeutically significant.  
 
4.3. Accelerated studies at high temperatures 
 
We found that the addition of L-Arg at concentrations of 50 and 200 mM, significantly 
suppressed monomer loss of BSA, with a more prominent effect when higher [L-Arg] 
was used (Fig. 3-7; Table 4). Furthermore, using 200 mM of L-Arg may have 
suppressed the formation of insoluble aggregates or aggregates too large to be eluted 
with SE-HPLC, as there were higher amounts of smaller soluble aggregates eluting 
following heat-treatment and a higher total AUC (Fig. 3-6). Ajmera and Scherließ [21] 
investigated the effects of various amino acids including L-Arg on the enzymatic 
activity of catalase. In a 1:1 and 2:1 mass ratio with catalase, L-Arg significantly 
suppressed loss of activity of spray-dried catalase following storage at elevated 
temperate/humidity. However, Faghihi, et al. [18] found that the effects of L-Arg on IgG 
stability were not as significant. While the spray-dried powder containing 20 or 50% 
w/w L-Arg had a significantly lower soluble aggregate % than pure IgG, the 
aggregation rate constant was higher following storage for 2 months at 45 °C [18]. 
Shah, et al. [16] and Vagenende, et al. [22] illustrated that the relationship between 
the [L-Arg] added and changes in protein stability is non-linear; therefore it is likely that 
the concentrations of L-Arg used in our study lie on the high-end of the concentration-
effect curve, where increasing [L-Arg] enhances its protein-stabilizing effect; while the 
[L-Arg] added to stabilize IgG [18] lies at the lower-end of the concentration-effect 
curve, where increasing [L-Arg] facilitates protein destabilization. Furthermore, 
Shiraki, et al. [15] found that lysozyme formulated with L-Arg had significantly higher 
soluble protein content following heat-induced degradation.  These findings correlate 
well with our findings – higher protein content recovered in our SE-HPLC experiments 
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for samples containing L-Arg - thus suggesting that L-Arg suppresses the formation of 
insoluble or large aggregates.  
On the other hand, we found that the addition of L-Glu alone increased monomer BSA 
loss significantly, even at the low concentration tested (Fig. 3-7; Table 4). Golovanov, 
et al. [23] reported no significant changes in protein solubility with the addition of L-
Glu in concentrations of up to 50 mM for various proteins tested. Shiraki, et al. [15] 
tested the effects of L-Glu on the stability of several proteins including lysozyme and 
found that adding 50 mM of L-Glu resulted in a higher concentration of soluble protein 
following heat-treatment than the controls with no amino acids, with the exception of 
myoglobin, which had a lower protein concentration than the control. On the other 
hand, L-Glu was found to decrease soluble protein concentration of reduced 
carboxymethyl lysozyme that was denatured with urea and diluted 10-fold to induce 
aggregation [15]. The same findings were reported with L-Aspartic acid (L-Asp), which 
is also a negatively charged amino acid [15]. Based on the overall findings, it was 
concluded that the effect of negatively charged residues such as L-Glu and L-Asp on 
protein stability, depends on the nature of the equilibrium between the native and 
unfolded state and is determined by specific side-chain interactions with the protein 
[15]. This may explain why L-Glu promotes the aggregation of some proteins such as 
BSA or myoglobin, while suppressing aggregation of other proteins. It also explains 
why the effect observed varies according to the stress conditions applied [15].  
In addition, contrary to the findings of previous studies, [13, 14, 23] the combination of 
Arg-Glu did not display synergistic-protein stabilizing effects for spray-dried BSA (Fig. 
3-7; Table 4). Based on our findings, there are two possible scenarios; either the two 
amino acids interacted with each other and had no significant interactions with BSA, 
or each amino acid interacted with BSA separately (L-Arg suppressing aggregation; 
L-Glu promoting aggregation), and the net effect was neutral.  There are a number of 
potential reasons for this; firstly, the synergy of Arg-Glu may be concentration-
dependent and may not be effective for stabilizing spray-dried BSA in the low 
concentration we used - thus, for inhaled formulations where excipient concentration 
must be minimized, the use of these amino acids in high concentrations may not be 
feasible; secondly, the Arg-Glu interaction with proteins may be specific to the protein 
being tested, and may not be beneficial to BSA. The negative interaction between L-
Glu and BSA observed in our study, may have contributed to the lack of effect 
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observed with the combination of Arg-Glu. Further research into the mechanism of 
destabilization of proteins by L-Glu is required to provide better understanding of the 
Arg-Glu synergy reported previously [13, 14, 23]. 
 
5. Conclusion 
 
Our study investigated the synergistic effects of arginine and glutamic acid on the 
physical stability of spray-dried BSA. We found that the use of L-Arg alone, at low 
concentrations, improved the physical stability of BSA following heat-treatment, and 
the effect was more significant with higher concentrations of L-Arg.  On the other hand, 
it was found that L-Glu facilitated monomer BSA loss when added alone, after heat-
treatment. Finally, the combination of Arg-Glu in low concentrations neither enhanced 
nor worsened the physical stability of spray-dried BSA.  
Our findings illustrate that the effect of L-Glu on protein stability varies according to 
the protein used, and the nature of the equilibrium conditions that govern the refolding 
or unfolding of a protein. Furthermore, how L-Glu interacts with the tested protein may 
determine whether the combination of Arg-Glu enhances the physical stability of a 
protein or not. Since the addition of these amino acids maintained acceptable particle 
size after spray-drying, they represent potential formulation approaches for the 
pulmonary delivery of proteins that are beneficially affected by the use of these amino 
acids. However, further investigation is required to provide insight into the mechanism 
of destabilization of BSA by L-Glu, and how this may affect the synergistic effects of 
Arg-Glu on protein stability. 
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CHAPTER 3 
 
 
 
“The Effect of Deuterium Oxide on the 
Conformational Stability and Aggregation of 
Bovine Serum Albumin” 
 
 
Chapter 3 was published in the Pharmaceutical Development and 
Technology journal: 
Reslan, M., Kayser, V. (2016). The effect of deuterium oxide on the 
conformational stability and aggregation of bovine serum albumin. 
Pharmaceutical Development and Technology, 1-7. 
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Abstract 
Protein aggregation is a significant problem affecting the integrity of proteins and is a 
major hindrance to the development of biopharmaceutical products. Deuterium oxide 
(D2O), widely used in protein characterization studies, has been shown to promote 
protein aggregation when used as a substitute for water in most buffered protein 
solutions; however, a few studies have reported minor improvements in melting point 
temperatures for some proteins. Our study aims to investigate the effect of D2O on 
protein stability, using bovine serum albumin (BSA) as a model. We performed 
accelerated stability studies at high temperatures and assessed the physical and 
conformational stability of BSA using fluorescence spectroscopy, dynamic light 
scattering (DLS) and size-exclusion high performance liquid chromatography. Our 
findings reveal that D2O enhances the conformational stability of monomeric BSA, 
reducing monomer loss and formation of small aggregates at high temperatures. 
There is also an increase in the formation of larger aggregates probed by thioflavin T, 
however the increase is not considered significant based on DLS results. Our findings 
demonstrate that exchanging water with D2O can improve the stability of proteins in 
solution, by maintaining the stability of the monomeric form, which may be beneficial 
for the long-term storage of some biological products.  
1. Introduction 
 
Protein aggregation is a common and highly problematic degradative process affecting 
the long-term stability and integrity of a biological product and has been implicated in 
debilitating neurodegenerative diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s  [1-4]. Our understanding of the aggregation process of biological 
products has developed tremendously in recent years, and is typically addressed by 
formulating purified proteins in aqueous buffers with various additives such as amino 
acids and surfactants which partially improve their long-term storage stability [3, 5-8]. 
However, as this approach alone is often inadequate, many biological products require 
additional steps such as lyophilization to form a dry powder, affording 1-2 years of 
shelf-life [5].  
Over a decade ago, it was found that exchanging the solvent from water (H2O) to 
deuterium oxide (D2O) in various biological systems, affected the physical stability of 
different proteins studied [9-19]. The general consensus was that D2O promoted 
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protein aggregation. Lee and Berns [10], reported that C-Phycocyanin formed a higher 
amount of hexamer aggregates in D2O buffer when compared with H2O buffer. It was 
suggested that D2O enhances hydrophobic forces thought to contribute to the 
formation of the hexamer. Henderson, et al. [11], found that D2O stabilized lactate 
dehydrogenase (LDH) at low ionic strength and inhibited monomer dissociation into 
subunits; however, for bovine liver glutamate dehydrogenase (GDH), D2O promoted 
monomer association into larger polymers especially at larger concentrations. Since 
the studies were performed at a low temperature (8 °C), where the contribution of 
hydrophobic interactions is minimal, the findings were attributed to the greater strength 
of deuterium bonding to hydrogen bonding and the resultant strengthening of water 
bridges, which contributed to either decreased dissociation (LDH) or increased 
association (GDH), depending on the protein [11].  
A series of other studies were performed with β-lactoglobulin [12], salmonella flagellin 
[13] and formyltetrahydrofolate synthetase [14] all of which found an increased extent 
of association in D2O compared with H2O, either due to increased hydrophobic 
interactions or formation of deuterium bonds, or both. A few studies reported that D2O 
improved the melting point temperature of some proteins [13, 17], however the 
changes were not considered significant.  
The effect of D2O on protein stability is either facilitated by hydrogen-deuterium 
exchange of solvent-accessible NH or OH protons and, or a difference in the solvent-
isotope effect/hydration shell due to the slightly heavier deuterium atom. In a study by 
Cioni and Strambini [19] they claimed that the effects observed were predominantly 
due to the latter of the two, at least for the majority of the proteins used in their study.  
Nonetheless, the majority of previous work suggests that D2O promotes protein 
aggregation by promoting hydrophobic interactions. Whether D2O has the potential to 
stabilize proteins is unclear. D2O is widely used in NMR, mass spectrometry and 
neutron scattering experiments for protein characterization and may be useful as a 
storage solution if found to improve the physical or conformational stability of proteins.  
Hereby, we investigated the effect of D2O on protein aggregation propensity and 
conformational stability using BSA as a model protein. BSA is widely used in protein 
aggregation studies as it is well-characterized and readily available. Our results 
suggest that a simple exchange of solvents from H2O to D2O may increase its long-
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term stability, without considerably increasing aggregation, by reducing the formation 
of small aggregates that are precursors of larger aggregates. 
2. Materials and Methods 
 
Bovine serum albumin (BSA; Fraction V, A7906), deuterium oxide (D2O; 99.9 atom % 
D, 151882), 8-Anilino-1-naphthalenesulfonic acid (ANS; >97% HPLC grade, A1028), 
N-Acetyl-L-tryptophanamide (NATA; A6501), and Thioflavin T (ThT; T3516) were 
purchased from Sigma Aldrich (Castle Hill, Australia). Millex-GV syringe filter units 
(0.22 µm, PVDF, 33 mm, gamma sterilized, SLGV033RS), di-potassium hydrogen 
phosphate (EMPROVE® Ph Eur, BP, E 340 grade, 105101) and potassium 
dihydrogen phosphate (EMSURE® ISO grade, 104873) were purchased from Merck 
Millipore (MA, USA). Dimethyl sulfoxide (UNIVAR analytical grade, 2225) was 
purchased from Ajax Finechem (Taren Point, Australia). 
2.1. Preparation of samples 
 
5 mg/mL BSA solutions were prepared by dissolving BSA in double distilled H2O 
(referred to as H2O from here onwards) or D2O. Samples were filter-sterilized using a 
0.22 μm syringe filter and stored at 4 °C. The pH of BSA samples in H2O was 6.7, 
while the pD of samples in D2O was 7.1 (based on the equation: pD = pH measured + 
0.4 [20]). 
ANS and ThT dyes were prepared as 20 mM stock solutions in dimethyl sulfoxide 
(DMSO) and H2O, respectively, and stored frozen at -20 °C. For dye binding studies, 
the stocks were diluted with either H2O or D2O to a working concentration of 300 μM. 
Working stock solutions were freshly prepared for each set of experiments.  
2.2. Accelerated stability studies at elevated temperatures 
 
Accelerated studies at elevated temperatures were conducted as previously described 
[8].100 μL aliquots of BSA solutions at a concentration of 5 mg/mL were incubated in 
a Thermal Cycler 2720 (Applied Biosystems, CA, USA) at 55, 60, 65 and 70 °C for 
various durations. Samples were immediately diluted and stored on ice following 
incubation, to 1 mg/mL for size exclusion-high performance liquid chromatography 
(SE-HPLC), 0.5 mg/mL for dynamic light scattering (DLS) and to 0.2 mg/mL for UV-
vis absorbance and fluorescence studies, with either H2O or D2O.  
2.3. Fluorescence Spectroscopy 
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Fluorescence measurements were performed using the Spectrophotometer Fluorolog 
3 FL3-22 (HORIBA Jobin Yvon, Kyoto, Japan). BSA samples were diluted to 0.2 
mg/mL in H2O or D2O and analyzed in an ultra-micro fluorescence quartz cuvette from 
Hellma at right-angled detection mode. NATA samples were diluted to 7.5 μg/mL for 
analysis. Data was analyzed using Igor Pro 6 software.  
2.4. Tryptophan and NATA fluorescence 
 
Tryptophan fluorescence of BSA was used to characterize BSA conformational 
stability by comparing differences in maximum fluorescence intensity and the 
maximum emission wavelength, which provide information on the environment 
surrounding the tryptophan residues. A decrease in tryptophan fluorescence and an 
increase in maximum emission wavelength usually suggest that there is increased 
solvent exposure near the tryptophan residue(s), which may be due to unfolding. On 
the other hand, a decrease in the maximum emission wavelength is due to the 
formation of a more hydrophobic local environment near the tryptophan residue(s) 
which may occur due to protein aggregation [21].  
Fluorescence of NATA, an analogue of tryptophan, was measured to determine if D2O 
had any solvent effects on tryptophan fluorescence, independent of its effect on the 
conformational stability of BSA.  
Tryptophan fluorescence of BSA and NATA was detected in the emission wavelength 
range of 300-500 nm with an excitation wavelength of 295 nm. Both excitation and 
emission slit sizes were set at 3 nm. Samples were corrected by blank subtraction of 
H2O or D2O. All measurements were performed in triplicates and averaged, and the 
standard deviation (SD) was calculated.  
2.5. ANS and ThT fluorescence 
ANS fluorescence was used to determine the degree of solvent accessibility and 
unfolding following incubation at high temperatures. A significant increase in maximum 
ANS fluorescence is usually indicative of protein unfolding [22]. ANS fluorescence was 
detected in the emission wavelength range of 400-600 nm with an excitation 
wavelength of 385 nm. Both excitation and emission slit sizes were set at 2 nm.  
ThT fluorescence was used to measure the degree of BSA aggregation following 
incubation at high temperatures. A significant increase in maximum ThT fluorescence 
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is usually associated with the formation of protein aggregates [22]. ThT emission was 
detected in the emission wavelength range of 425-600 nm with an excitation 
wavelength of 415 nm. Both excitation and emission slit sizes were set at 3 nm.  
For both dyes, 5 µL of dye from a working stock of 300 µM was added to 495 µL of 
each sample to a final concentration of 3 µM. All samples were then incubated at room 
temperature for 20 minutes before analysis to allow for dye binding. Samples were 
corrected by blank subtraction of H2O or D2O (for dye-only samples) or a BSA sample 
dissolved in the respective solvent with no dye (for samples containing dye and BSA). 
All dye fluorescence measurements were performed in triplicates and averaged, and 
the SD was calculated.  
2.6. SE-HPLC 
Size exclusion-high performance liquid chromatography (SE-HPLC) was used to 
measure monomer loss of BSA following accelerated temperature studies. Analysis 
was performed using an Agilent 1200 Liquid Chromatography system (Agilent 
Technologies, California, USA) with a TSKgel Super SW3000 column (Tosoh 
Bioscience, Tokyo, Japan) at 22 °C, using a 150 mM potassium phosphate mobile 
phase, at pH 6.5, and a flow rate of 0.2 mL/min. 5 μL of each BSA sample at a 
concentration of 1 mg/mL was injected.  Monomer peaks were detected using an in-
line UV signal detector set at 280 nm. The area under the curve (AUC) of the monomer 
peak was averaged over three runs and the mean monomer % was calculated for 
each sample. The SD was plotted as error bars in the figures.  
2.7. DLS 
Monomer and aggregate size distributions of BSA samples were analysed by dynamic 
light scattering (DLS) using the Malvern Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). The intensities of different-sized peaks were analysed 
qualitatively and compared across formulations for relative changes in monomer and 
aggregate intensities. Intermediates were defined as small-sized ‘aggregates’ that 
were distinct from the monomer or large aggregate population. The size range 
measured in each figure (x-axis) was modified to 1 nm – 1 μm as no particles were 
detected outside that range. The refractive index of BSA in H2O or D2O was set at 1.33 
and the absorption value was 0.1. The viscosity of H2O was set at 0.8879 mPa/s and 
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of D2O at 1.095 mPa/s. Samples were diluted to 0.5 mg/mL in their respective solvents 
and measured three times each, in disposable plastic cuvettes at 25 °C.  
2.8. UV-Vis Spectroscopy 
UV-Vis absorbance was used to determine the concentration of soluble protein 
following accelerated temperature studies. Absorbance was measured at 280 nm over 
a wavelength range of 220-350 nm using a Shimadzu UV-2600 spectrophotometer 
(Shimadzu, Japan). Samples were corrected by blank subtraction of the respective 
solvent (H2O or D2O). Data was not included as the absorbance of all samples 
remained unchanged following incubation, and therefore no change in soluble protein 
concentration was observed.  
3. Results 
 
3.1. NATA and Tryptophan emission 
  
Maximum NATA fluorescence at room temperature is almost 20% higher in D2O 
compared with H2O (Fig. 1A inset). Following incubation at 55 °C, NATA fluorescence 
decreases slightly in both H2O and D2O but remains ~20% higher in D2O (Fig. 1A). At 
60 °C, the fluorescence in both solvents is relatively unchanged. Following incubation 
at 65 and 70 °C, there is a slight increase in fluorescence in both solvents, however 
the ratio of NATA fluorescence in D2O to H2O decreases slightly to a difference of 
~10% (Fig. 1A).   
The maximum tryptophan fluorescence of BSA in H2O and D2O is the same at room 
temperature (Fig. 1B). Upon incubation at 55 °C for 2 hours, both samples have a 
decreased maximum fluorescence, with a larger decrease observed in the H2O 
sample (Fig. 1B). This trend continues for 60, 65 and 70 °C – as the temperature 
become harsher, the maximum fluorescence continues to decrease - but the 
fluorescence of BSA dissolved in D2O is consistently higher (Fig. 1B). From the ratio 
of tryptophan fluorescence of BSA in D2O to BSA in H2O, it can be determined that 
the difference ranges from approximately 10-16%, with the highest difference 
observed at 65 °C and the lowest at 70 °C (Fig. 1B inset). This difference is similar to 
that observed with NATA, except at room temperature, since D2O does not appear to 
affect tryptophan fluorescence of BSA (Fig. 1A and B).   
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The maximum tryptophan emission wavelength of BSA in H2O gradually shifts from 
Figure 1. Maximum fluorescence emission spectra of NATA and BSA samples in H2O 
or D2O at 25 °C and following incubation at 55 °C (2 hours), 60 °C (1 hour), 65 °C (1 
hour) and 70 °C (30 minutes). (A) Intrinsic fluorescence of NATA samples; (B) 
Tryptophan fluorescence of BSA samples; (C) Tryptophan maximum emission 
wavelength of BSA samples (D) Fluorescence of 3 μM ANS added following 
incubation; (E) Fluorescence of 3 μM Thioflavin T added following incubation.  Insets: 
the fluorescence ratios of the respective samples in each figure, calculated by dividing 
the fluorescence of D2O samples with H2O samples. Error bars represent the SD.  
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~337 to ~332 nm following incubation at 55, 60, 65 and 70 °C (Fig. 1C). A similar shift 
is observed for BSA in D2O, from ~336 nm at room temperature to ~331 nm following 
incubation at 70 °C. The difference between the max emission wavelengths of BSA in 
H2O to BSA in D2O at the different conditions suggests that the shift is slightly greater 
with increasing temperature for samples dissolved in D2O, although this difference is 
not significant (Fig. 1C). 
3.2. ANS Emission 
 
The maximum fluorescence of ANS dye dissolved in H2O or D2O is minimal at room 
temperature in the absence of BSA (Fig. 1D). Interestingly, the fluorescence of ANS 
dye dissolved in D2O is approximately 2-fold higher than that dissolved in H2O (Fig. 
1D inset). When BSA is added, ANS fluorescence increases significantly and is 
highest at room temperature in both solvents (Fig. 1D). The maximum fluorescence of 
ANS bound to BSA in D2O remains higher by approximately 1.5-fold at room 
temperature (Fig. 1D inset). The maximum ANS fluorescence remains relatively 
unchanged following incubation at 55 °C, 60 °C and 65 °C in both H2O and D2O (Fig. 
1D). Likewise, the ratio of maximum ANS intensity also remains relatively unchanged, 
only increasing slightly to approximately 1.6-fold at 55 °C and 60 °C then decreasing 
back to 1.4-fold at 65 °C (Fig. 1D inset). Following incubation at 70 °C, the maximum 
fluorescence of ANS bound to BSA dissolved in H2O or D2O significantly decreases 
and is lowest at this temperature (Fig. 1D). The ratio of ANS fluorescence is also 
lowest at 70 °C, decreasing to ~1.3-fold higher for samples dissolved in D2O (Fig. 1D 
inset).   
3.3. ThT Emission 
 
The maximum fluorescence of ThT in H2O or D2O is minimal at room temperature, and 
almost identical when dissolved in either solvent (Fig. 1E). At 25 °C, BSA dissolved in 
H2O or D2O with ThT has low ThT fluorescence, and the fluorescence of ThT in D2O 
is ~0.8-fold that of BSA dissolved in H2O (Fig. 1E). After incubation at 55 °C, there is 
a small increase in the maximum fluorescence of ThT for BSA samples in both 
solvents, with a 1.2-fold higher fluorescence for BSA dissolved in D2O (Fig. 1E). 
Following incubation at 60 °C, the maximum ThT fluorescence continues to increase 
for BSA in D2O, but remains relatively unchanged for BSA in H2O (Fig. 1E).  The ThT 
fluorescence is approximately 1.4-fold higher at 60 °C for BSA in D2O (Fig. 1E inset). 
61 
 
A significant increase in ThT fluorescence is observed for BSA in D2O following 
incubation at 65 °C and again at 70 °C (Fig. 1E). The same trend is observed for BSA 
in H2O, however the increase in ThT fluorescence following incubation at 65 and 70 °C 
is not as prominent as the increase observed for BSA in D2O (Fig. 1E). At 65 °C, the 
maximum fluorescence of ThT bound to BSA in D2O is 2.1-fold higher and at 70 °C it 
is 2.2-fold higher than the fluorescence of ThT bound to BSA in H2O (Fig. 1E).  
3.4. SE-HPLC 
 
Following incubation at 55 °C, monomer loss is minimal in both BSA samples (Fig. 2 
and 3). Although BSA in H2O has a slightly higher mean monomer % at 55 °C, the SD 
is large and the difference is not significant (Fig. 3). There are minor losses after 
incubation at 60 °C, but again the difference between the monomer % of BSA in H2O 
and BSA in D2O remains insignificant (Fig. 2 and 3). A large decrease in monomer % 
is observed following incubation at 65 °C - the relative monomer % of BSA in H2O 
decreases to ~75% while for BSA in D2O the monomer % remains significantly higher 
at ~85% (Fig. 2 and 3).  Likewise, following incubation at 70 °C, there is a large 
decrease in monomer % for both samples, dropping to ~35% for BSA in H2O and 
~40% for BSA in D2O. Again, BSA in D2O retains a higher monomer % (~5% higher) 
following heat-treatment at 70 °C (Fig. 2 and 3). We did not compare the changes in 
aggregate peaks, as the larger aggregates formed following incubation did not elute, 
possibly due to their size. Thus, we relied on ThT fluorescence and DLS results to 
compare aggregate populations.   
Figure 2. Representative SE-HPLC chromatograms of BSA samples in (A) H2O or (B) 
D2O, measured at 25 °C (control) and following incubation at 55 °C (2 hours), 60 °C 
(1 hour), 65 °C (1 hour) and 70 °C (30 minutes).   
62 
 
3.5. DLS 
 
At room temperature, there is no significant difference between the size distribution of 
BSA species in H2O compared with D2O (Fig. 4A). Monomer species at ~ 5 nm have 
the highest relative intensity for both solvents and smaller intensities are detected 
between 10-50 nm and 200-1000 nm (Fig. 4A). Following incubation at 55 °C, the 
relative intensity of the monomer species for both H2O and D2O remains unchanged, 
however an increased intensity at ~ 100 nm is detected for BSA in H2O, suggesting 
the formation of larger intermediates (Fig. 4B). At 60 °C the size of these intermediates 
increases in H2O with the peak broadening to ~ 700 nm (Fig. 4C). The monomer 
intensity also decreases correspondingly. Meanwhile, the large aggregate intensity of 
D2O increases slightly, although the difference is not significant (Fig. 4C). At 65 °C 
there is a sharp decrease in monomer intensity for BSA in H2O and D2O, with 
corresponding increases in intermediates and large aggregates (Fig. 4D).  All species 
are roughly the same size between samples, however there is a narrower distribution 
of intermediates and large aggregates in D2O. Finally, at 70 °C, there is a further 
decrease in monomer intensity and an increase in intermediates (Fig. 4E). Large 
Figure 3. Relative mean monomer % of BSA samples in H2O or D2O measured at 
25 °C (“Untreated”) and following incubation at 55 °C (2 hours), 60 °C (1 hour), 65 °C 
(1 hour) and 70 °C (30 minutes). Incubated samples were adjusted to the control 
“Untreated”, where “Untreated” represents 100% monomer, or no monomer loss. Error 
bars represent the SD. 
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aggregate intensity also decreases, possibly due to rapid sedimentation of large 
aggregates formed at this temperature or reduced incubation time. Again, the size 
distribution of intermediates is narrower in D2O, suggesting that there is a less diverse 
population of intermediates in D2O at 70 °C (Fig. 4E). 
Figure 4. Mean intensity-based size distribution of BSA in H2O or D2O at (A) 25 °C 
and following incubation at (B) 55 °C (2 hours), (C) 60 °C (1 hour), (D) 65 °C (1 hour) 
and (E) 70 °C (30 minutes) using DLS. “Size” represents the measured hydrodynamic 
diameter in nm.  
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4. Discussion 
4.1. Stability of BSA monomers in D2O 
Our findings suggest that BSA dissolved in D2O compared with H2O, has higher 
stability against heat-induced degradation, particularly at denaturing conditions at, or 
above, the melting temperature of BSA (≥65 °C) [23], since the monomer % was 
significantly higher in D2O at these conditions (Fig. 2 and 3). There is also a slight 
blue-shift in the tryptophan max emission wavelength of all BSA samples in D2O at all 
conditions, most prominently at 70 °C, which suggests that the local environment 
surrounding the tryptophan residues is more compact and less exposed in D2O than 
in H2O (Fig. 1C). This is further supported by the higher tryptophan intensity in D2O 
following heat-treatment (Fig. 1B), although as demonstrated with NATA fluorescence 
(Fig. 1A), this may – at least partly - be due to enhanced emission of photons in D2O 
[24], rather than structural protein changes. Although the enhanced fluorescence of 
tryptophan in D2O is not apparent for BSA in D2O at room temperature, this is most 
likely due to the inaccessibility of the tryptophan residues at this temperature, as the 
enhanced tryptophan fluorescence becomes apparent at higher temperatures (Fig. 
1B), which expose the buried residues to D2O.   
Nonetheless, our findings are in accord with observations by Cioni and Strambini [19] 
who found that a number of proteins had a more rigid folded structure in D2O over H2O. 
They proposed that this is predominantly due to solvent effects, especially 
enhancement of hydrophobic interactions, with the exception of proteins such as LDH 
[19]. Therefore, the stabilizing effect of D2O is amplified at higher temperatures and 
conditions which destabilize the folded state [19], as shown in our results. D2O was 
first thought to enhance protein hydrophobic interactions based on previous 
observations with surfactant behaviour, where a lower critical micelle concentration 
was achieved in D2O compared with H2O [9]. This was explained by the increased 
cohesiveness of D2O molecules, since solvent-solvent deuterium bonds were found to 
be stronger in D2O than solvent-solvent hydrogen bonds in H2O [9]. The enhancement 
of hydrophobic interactions explains the observed improvements in native monomer 
stability.  
If we model BSA aggregation using a two-step model [25]:  
M ⇋ I ⟶ A 
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Scheme 1: A two-step model of protein aggregation 
Where the native monomer state is represented by M, reversible partially-unfolded 
species and/or small pre-cursor aggregates (referred to as intermediates) are I, and A 
represents large irreversible aggregates – we can acknowledge that large aggregates 
are formed via the formation of reversible intermediates, usually due to exposure of 
previously inaccessible hydrophobic patches which facilitate aggregation. From our 
findings, we conclude that D2O reduces the change from M to I, by strengthening the 
native structure and increasing its conformational stability. It is therefore, more 
thermodynamically favourable for the folded monomer structure to compact and 
minimise solvent exposure, resulting in stabilization of the monomer state. 
4.2. Formation of intermediates and large aggregates in D2O 
Our results reveal that D2O significantly increases the fluorescence of ANS dye by 2-
fold without BSA, and approximately 1.5-fold when bound to BSA (Fig. 1D). Thus, we 
cannot conclude that the higher fluorescence observed in the D2O samples is due to 
increased solvent-exposure, but rather due to the increased dye fluorescence in D2O 
compared with H2O, as was the case with tryptophan fluorescence (Fig. 1B).  
Interestingly though, ANS fluorescence in both BSA in D2O and H2O does not increase 
at 65 °C and is lowest at 70 °C, despite the expected high degree of denaturation at 
these temperatures (Fig. 1D). This may be due to the formation of aggregates that 
occupy newly exposed hydrophobic patches, reducing available ANS binding sites on 
BSA and resulting in a decrease in the fluorescence at these high temperatures. The 
larger decrease in fluorescence at 70 °C for BSA in D2O compared with the smaller 
decrease for BSA in H2O, suggests that D2O facilitates the formation of aggregates at 
high temperatures (Fig. 1D).  
This is confirmed by the higher ThT fluorescence of BSA samples dissolved in D2O 
compared with H2O (Fig. 1E). Unlike tryptophan and ANS fluorescence, ThT 
fluorescence does not seem to be affected by D2O itself, as the ThT fluorescence in 
both D2O and H2O is approximately the same even with BSA at room temperature (Fig. 
1E).  
It has been reported previously that BSA can form beta-sheet rich amyloid-like 
structures at high temperatures [23, 26] – the increasing ThT fluorescence when BSA 
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in H2O is incubated at higher temperatures may be due to the formation of these 
aggregates which are known to bind ThT. If this is the case, then D2O may accelerate 
the formation of these aggregates, resulting in the higher ThT fluorescence observed 
(Fig. 1E). However, ThT fluorescence is not quantitative and therefore it is not clear 
how significant this increase in aggregate formation is. Although DLS is not a 
quantitative technique either, it is well known that larger particles scatter light at much 
greater intensities, and therefore, if the quantity of large aggregates formed in D2O 
was significantly higher, we would expect a much higher aggregate intensity in D2O 
compared with in H2O using DLS. However, the intensity of large aggregates observed 
in H2O and D2O was quite comparable at each temperature (Fig. 4) - this suggests 
that the quantity of aggregates formed in D2O is not significantly higher. The difference 
in aggregate formation is likely due to the same monomer-stabilizing mechanism of 
D2O – increased strength of hydrophobic interactions. At melting point temperatures, 
BSA is forced into significant unfolding, and the resulting exposure of hydrophobic 
patches in D2O will therefore facilitate aggregation, as expected based on the two-step 
model (Scheme 1). In addition, since the hydrogen-deuterium rate is increased and 
higher solvent accessibility is expected at higher temperatures, the increased number 
and strength of deuterium bonds, results in stronger intra- and inter-molecular bonding 
which may have also contributed to the increased formation of these aggregates. 
Since the monomer % remains higher in D2O at the higher temperatures as seen with 
SE-HPLC (Fig. 2 and 3), and there is a minor increase in aggregates based on 
fluorescence measurements (Fig. 1D and E), then the total amount of intermediates 
in D2O must be lower. Furthermore, from the DLS results at higher temperatures, it is 
apparent that the variety of intermediates in D2O is also less (Fig. 4D and E). Based 
on the two-step model (Scheme 1), it is expected that the number of intermediates is 
lower in D2O, as the refolding/dissociation of intermediates back to the monomer state 
is favoured in D2O.  
5. Conclusion 
 
Our study reveals that D2O has two main effects on BSA stability: (1) enhancing its 
conformational stability, resulting in reduced monomer loss and reduced formation of 
intermediates; (2) increasing the formation of aggregates that bind ThT. Both effects 
are predominantly due to an enhancement of hydrophobic interactions with possible 
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contribution from an increase in the strength of intra- or inter-molecular bonds, due to 
hydrogen-deuterium exchange. Further studies need to be performed to assess the 
quantity of large aggregates formed with D2O and determine whether this is significant. 
Furthermore, long-term incubation may be useful to confirm if the reduction in 
intermediate formation will translate to even better overall stability. Nonetheless, it has 
been shown that a simple exchange of solvents increases the stability of a relatively 
stable protein such as BSA, thus there is great potential for D2O to improve the stability 
of biotherapeutics that are more susceptible to degradation during storage in solution 
and warrants further investigation. Furthermore, it may be important to consider these 
changes when performing NMR or neutron scattering experiments which utilize D2O.  
Acknowledgments 
The authors would like to acknowledge Professor Hak-Kim Chan for access to light 
scattering equipment and the School of Pharmacy for financial contribution. 
Declaration of interest 
The authors declare no conflicts of interest. 
References 
[1] A.R. Mazzer, X. Perraud, J. Halley, J. O’Hara, D.G. Bracewell, Protein A 
chromatography increases monoclonal antibody aggregation rate during subsequent 
low pH virus inactivation hold, Journal of Chromatography A, 1415 (2015) 83-90. 
[2] M.E.M. Cromwell, E. Hilario, F. Jacobson, Protein aggregation and bioprocessing, 
The AAPS Journal, 8 (2006) E572-E579. 
[3] F. Depreter, G. Pilcer, K. Amighi, Inhaled proteins: Challenges and perspectives, 
International Journal of Pharmaceutics, 447 (2013) 251-280. 
[4] C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, 
Nature Medicine, 10 Suppl (2004) S10-17. 
[5] S.J. Shire, Z. Shahrokh, J. Liu, Challenges in the development of high protein 
concentration formulations, Journal of Pharmaceutical Sciences, 93 (2004) 1390-1402. 
[6] M. Reslan, Y.K. Demir, B.L. Trout, H.-K. Chan, V. Kayser, Lack of a synergistic 
effect of arginine–glutamic acid on the physical stability of spray-dried bovine serum 
albumin, Pharmaceutical Development and Technology, (2016) 1-7. 
68 
 
[7] Z. Sahin, Y.K. Demir, V. Kayser, Global kinetic analysis of seeded BSA aggregation, 
European Journal of Pharmaceutical Sciences, 86 (2016) 115-124. 
[8] V. Kayser, N. Chennamsetty, V. Voynov, B. Helk, K. Forrer, B.L. Trout, Evaluation 
of a non-Arrhenius model for therapeutic monoclonal antibody aggregation, Journal of 
Pharmaceutical Sciences, 100 (2011) 2526-2542. 
[9] G.C. Kresheck, H. Schneider, H.A. Scheraga, The Effect of D2O on the Thermal 
Stability of Proteins. Thermodynamic Parameters for the Transfer of Model 
Compounds from H2O to D2O1,2, The Journal of Physical Chemistry, 69 (1965) 3132-
3144. 
[10] J.J. Lee, D.S. Berns, Protein aggregation. The effect of deuterium oxide on large 
protein aggregates of C-phycocyanin, The Biochemical journal, 110 (1968) 465-470. 
[11] R.F. Henderson, T.R. Henderson, B.M. Woodfin, Effects of D2O on the 
Association-Dissociation Equilibrium in Subunit Proteins, Journal of Biological 
Chemistry, 245 (1970) 3733-3737. 
[12] P.A. Baghurst, L.W. Nichol, W.H. Sawyer, The Effect of D2O on the Association 
of β-Lactoglobulin A, Journal of Biological Chemistry, 247 (1972) 3199-3204. 
[13] Y. Uratani, Polymerization of Salmonella Flagellin in Water and Deuterium Oxide 
Media, Journal of Biochemistry, 75 (1974) 1143-1151. 
[14] J.A.K. Harmony, R.H. Himes, R.L. Schowen, Monovalent cation-induced 
association of formyltetrahydrofolate synthetase subunits. Solvent isotope effect, 
Biochemistry, 14 (1975) 5379-5386. 
[15] F. Bonneté, D. Madern, G. Zaccai, Stability against Denaturation Mechanisms in 
Halophilic Malate Dehydrogenase "Adapt" to Solvent Conditions, Journal of Molecular 
Biology, 244 (1994) 436-447. 
[16] H. Omori, M. Kuroda, H. Naora, H. Takeda, Y. Nio, H. Otani, K. Tamura, 
Deuterium oxide (heavy water) accelerates actin assembly in vitro and changes 
microfilament distribution in cultured cells, European Journal of Cell Biology, 74 (1997) 
273-280. 
[17] M. Verheul, S.P.F.M. Roefs, K.G. de Kruif, Aggregation of β-lactoglobulin and 
influence of D2O, FEBS Letters, 421 (1998) 273-276. 
[18] G. Chakrabarti, S. Kim, M.L. Gupta, J.S. Barton, R.H. Himes, Stabilization of 
Tubulin by Deuterium Oxide, Biochemistry, 38 (1999) 3067-3072. 
[19] P. Cioni, G.B. Strambini, Effect of Heavy Water on Protein Flexibility, Biophysical 
Journal, 82 (2002) 3246-3253. 
69 
 
[20] P.K. Glasoe, F.A. Long, Use of glass electrodes to measure acidities in deuterium 
oxide1,2, The Journal of Physical Chemistry, 64 (1960) 188-190. 
[21] V. Kayser, N. Chennamsetty, V. Voynov, B. Helk, B.L. Trout, Tryptophan-
Tryptophan Energy Transfer and Classification of Tryptophan Residues in Proteins 
Using a Therapeutic Monoclonal Antibody as a Model, Journal of Fluorescence, 21 
(2011) 275-288. 
[22] V. Kayser, N. Chennamsetty, V. Voynov, B. Helk, B.L. Trout, Conformational 
stability and aggregation of therapeutic monoclonal antibodies studied with ANS and 
Thioflavin T binding, mAbs, 3 (2011) 408-411. 
[23] N.K. Holm, S.K. Jespersen, L.V. Thomassen, T.Y. Wolff, P. Sehgal, L.A. Thomsen, 
G. Christiansen, C.B. Andersen, A.D. Knudsen, D.E. Otzen, Aggregation and 
fibrillation of bovine serum albumin, Biochimica et Biophysica Acta (BBA) - Proteins 
and Proteomics, 1774 (2007) 1128-1138. 
[24] W.Q. Ong, Y.R. Citron, J. Schnitzbauer, D. Kamiyama, B. Huang, Heavy water: a 
simple solution to increasing the brightness of fluorescent proteins in super-resolution 
imaging, Chemical Communications, 51 (2015) 13451-13453. 
[25] R. Lumry, H. Eyring, Conformation Changes of Proteins, The Journal of Physical 
Chemistry, 58 (1954) 110-120. 
[26] M. Bhattacharya, N. Jain, S. Mukhopadhyay, Insights into the Mechanism of 
Aggregation and Fibril Formation from Bovine Serum Albumin, The Journal of Physical 
Chemistry B, 115 (2011) 4195-4205. 
 
 
 
 
 
 
 
  
70 
 
CHAPTER 4 
 
“Ionic Liquids as Biocompatible Stabilizers 
of Proteins” 
 
 
 
Chapter 4 was published in the Biophysical Reviews journal: 
Reslan, M., Kayser, V. (2018). Ionic liquids as biocompatible 
stabilizers of proteins. Biophysical Reviews. doi: 
10.1007/s12551-018-0407-6 
 
 
 
 
 
 
 
 
71 
 
Abstract 
Ionic liquids (ILs) have recently emerged as versatile solvents and additives in the field 
of biotechnology, particularly as stabilizers of proteins and enzymes. Of interest to the 
biotechnology industry is the formulation of stable biopharmaceuticals, therapeutic 
proteins and vaccines which have revolutionised the treatment of many diseases 
including debilitating conditions such as cancers and auto-immune diseases. The 
stabilization of therapeutic proteins is typically achieved using additives that prevent 
unfolding and aggregation of these proteins during manufacture, transport and long-
term storage. To determine if ILs could be used in the formulation of stable therapeutic 
proteins, a thorough understanding of the effects of ILs on protein stability is needed, 
as well as understanding the toxicity of ILs on humans, and other considerations for 
formulation development such as viscosity and osmolarity. In this review, we 
summarise recent developments on the stabilization of proteins and enzymes using 
ILs, with emphasis on identifying biocompatible ILs that may be suitable for the 
formulation of stable biopharmaceuticals in the future.  
1. Introduction  
Ionic liquids (ILs) are organic salts with low melting points, typically below 100 ºC. The 
interest in IL research began shortly after the synthesis of the first air- and moisture-
stable ILs in 1992 [1]. Initially developed as non-flammable alternatives to common 
organic solvents, ILs quickly found hundreds of applications spanning 
electrochemistry [2-4], energy [5-7], organic synthesis and catalysis [8, 9] to 
pharmaceutics [10-12], biotechnology [13-18] and more [19, 20]. It is estimated that 
there are over a million combinations of cations and anions that can form an IL [21]. 
Consequently, these versatile solvents which are often termed ‘designer solvents’ can 
access a wide range of physicochemical properties which can be tailored for almost 
any application; such properties include, low vapour pressure, high thermal stability, 
high conductivity, non-flammability, biocompatibility etc [22].  
The use of ILs in biotechnology has gained significant attention recently, particularly 
for the enhanced stabilization of proteins, enzymes [19, 23, 24] and viruses [16]. 
Proteins are highly sensitive to changes in their vicinity induced by temperature, pH, 
humidity and salt concentration, in addition to any shear stress applied during 
manufacturing [25]. As they are exposed to these ‘stresses’, they undergo gradual 
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changes in structure, or unfold, and form protein aggregates over time [26]. In addition, 
the poor stability of proteins and enzymes might result in loss of function and activity, 
significantly limiting their use in biological processes and as biopharmaceuticals.   
ILs have been utilized as ‘neat’ solvents or as solutes in an aqueous solution 
(“aqueous ILs”) to stabilize proteins [27, 28]. Although both approaches have led to 
improved protein stability, most neat ILs may not be suitable for biopharmaceutical 
applications due to the high viscosity of most ILs, and lack of solubility of proteins at 
high concentrations in neat ILs, which is particularly important for biologics. 
Consequently, dissolving ILs in an aqueous solution as an additive/co-solvent, has 
been a more favourable approach in this field and will be the focus of this review. 
The emergence of ILs as potential stabilizers of proteins is a significant finding that 
requires review, particularly for the development of stable biopharmaceuticals, an 
application of ILs which has not been addressed adequately in previous literature. 
Biologics have revolutionised management of cancers, auto-immune diseases, 
infections and other difficult conditions to treat since their introduction as therapeutic 
products more than 30 years ago [25]. The stabilization of biopharmaceuticals is more 
challenging because of additional considerations required to determine the suitability 
of a formulation additive, such as the toxicity of the additive, and particularly in the 
case of ILs, the influence on the viscosity of the final protein solution, especially if the 
product is to be injected intravenously, which is the case for many biopharmaceuticals.  
Our aim is to review the current literature on the application of ILs for the stabilization 
of proteins and assess the suitability of the promising IL candidates for the stabilization 
of biopharmaceuticals.  
2. Current literature on the stabilisation of proteins using ILs 
ILs are often classified as protic (PILs) or aprotic ILs (AILs). PILs act as hydrogen bond 
donors and often include ammonium or phosphonium derivatives as a cation, 
combined with a phosphate, sulfate or nitrate anion [24, 29, 30]. Examples of protic 
ILs include, ethylammonium nitrate (EAN) and choline dihydrogen phosphate 
([Chol][DHP]) (Fig. 1). AILs act as hydrogen bond acceptors and typically include a 
bulky cation such as pyrrolidinium, pyridinium or imidazolium or their derivatives, in 
combination with a halide anion, or hexafluorophosphate, tetrafluoroborate or other 
such anions [29, 30]. Examples of AILs include 1-butyl-3-methyilimidazolium chloride 
73 
 
([BMIM][Cl]) and 1-benzyl-3-methylimidazolium tetrafluoroborate ([BzMIM][BF4]) (Fig. 
1). Of both classes of ILs, we will review some of the findings on imidazolium- and 
choline-based ILs which have received the most attention in recent years [19, 23]. 
Research on the imidazolium class of ILs, has helped to gain insight into the 
mechanism behind the observed effects on protein stability, as well as develop better 
ILs. Additionally, choline ILs have emerged as one of the most suitable candidates for 
stabilization of biopharmaceuticals due to their biocompatibility and pronounced effect 
on protein stability and are therefore of primary relevance to this review.  For a quick 
summary of the literature findings see Table 1. 
2.1. Imidazolium-based ILs  
Imidazolium-based ILs are the most extensively researched family of ILs until date and 
are widely used in many of the applications mentioned previously [31-33]. Many 
studies which investigated the use of imidazolium-ILs on protein stability have found 
that they act as protein denaturants or chaotropes; however, they have been extremely 
useful in gaining mechanistic insight into the complex interactions of ILs with proteins 
and are worth investigation [18, 34].  
Kumar, et al. [35] studied the effect of three imidazolium-ILs - [BMIM][Cl], [BMIM][Br] 
and [BMIM][I] - on the conformational structure and thermal stability of stem bromelain. 
All three ILs were found to be denaturing above concentrations of 0.01 M, while having 
no stabilizing effect below that concentration. The order of thermal stability was: 
[BMIM][Cl] > [BMIM][Br] > [BMIM][I], with [BMIM][I] being the most denaturing.  
a b c d e f g 
Figure 1. Examples of protic and aprotic ILs. a) 1-benzyl-3-methylimidazolium 
tetrafluoroborate ([BzMIM][BF4]); b) 1-butyl-3-methyilimidazolium chloride 
([BMIM][Cl]); c) Triethylammonium acetate (TEAA); d) Choline dihydrogen phosphate 
([Chol][DHP]); e) Choline serinate ([Chol][Ser]); f) ethylammonium nitrate (EAN); g) 
tetrabutylphosphonium bromide (TBPBr) 
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Table 1. Summary of the literature on ILs and protein stability discussed in the 
review 
Ionic liquid Proteins tested Effect on 
protein stability 
References 
Imidazolium-based ILs 
[MMIM][I] Lysozyme crystals +  [36] 
[BMIM][Cl] Stem bromelain, 
lysozyme, lysozyme 
crystals 
-, -, + [35-37] 
[BMIM][Br] Lysozyme crystals + [36] 
[BMIM][I] Stem bromelain - [35] 
[BMIM][SCN] Lysozyme, cyt C -, - [38] 
[BMIM][BF4] Lysozyme crystals + [36] 
[EMIM][Ac] rPa^ ~ [39] 
[EMIM][Cl] rPa^, lysozyme^ +, - [37, 39] 
[EMIM][EtSO4] rPa^ + [39] 
 [EMIM][MDEGSO4] rPa^ + 
[EMIM][Et2PO4] rPa^ + 
[EMIM][Tos] rPa^ - 
[EMIM][HexSO4] rPa^ - 
[OH-EMIM][Cl] Lysozyme - [37] 
[OH-PMIM][Cl] Lysozyme - 
[HMIM][Cl] Lysozyme - 
[BzMIM][Cl] CT ~ [40] 
[BzMIM][BF4] CT ~ 
Ammonium-based ILs 
EAN Lysozyme, cyt C - [38] 
TEAA CT ++ [40] 
TEAP CT ++ 
[Chol][Ac] CT ++ [41] 
[Chol][DHP] CT, lysozyme, rHIL-2, cyt c ++, +, ++, +++  [41-46] 
[Chol][Cit] CT - [41] 
[Chol][OH] CT - [41] 
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[Chol][Cl] CT, lysozyme ++ [41] 
[Chol][TMA] Lysozyme + [43] 
[Chol][Lac] Lysozyme - 
[Chol][Prop] Lysozyme - 
[Chol][Hex] Lysozyme - 
[Chol][DMP] Lysozyme + 
[Chol][TFMS] Lysozyme - 
[Chol][TF2N] Lysozyme - 
[Chol][Glu] Cyt c ++ [44] 
[Chol][Thr] Collagen - [47] 
[Chol][Ser] Collagen - 
[Chol][Lys] Collagen - 
[Chol][Phe] Collagen - 
Others 
TBPBr CT ~ [40] 
[EOOEMIM][C12SO4] BSA - [17] 
[EOOEMPy][C12SO4] BSA - 
^Only refolding was measured 
Tertiary structure was also found to be disrupted at concentrations above 0.01 M and 
followed the same order; however, [BMIM][Cl] caused significantly less disruption of 
tertiary structure above 0.01 M than the other two ILs. The order of destabilization was 
found to follow the Hofmeister series; that is, the chaotropic (structure-breaking) anion 
- [I] - was the most destabilizing, while the kosmotropic (structure-making) [Cl] was the 
least destabilizing [35, 48]. 
Takekiyo, et al. [38] studied whether 1-butyl-3-methylimidazolium thiocyanate 
([BMIM][SCN]) and ethylammonium nitrate (EAN) could be used as cryoprotectants of 
cytochrome complex (cyt C) and lysozyme. Both ILs significantly decreased the 
activity of cyt C and lysozyme and induced unfolding. However, following the removal 
of the ILs by dialysis after cryo-storage and subsequent heating, the activities of both 
cyt C and lysozyme returned to > 90% and structural changes were recovered (i.e. 
refolded) at IL concentrations > 10% [38]. This study demonstrated that the denaturant 
effect of imidazolium-ILs (and EAN) is predominantly reversible. 
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Some imidazolium-ILs have been shown to act as protein refolding agents. For 
example, Yamaguchi, et al. [49] investigated numerous hydrophobic imidazolium 
cations coupled with a Cl anion, and found that refolding was best achieved with short 
N-alkyl chain cations, with [BMIM][Cl] achieving the highest refolding yield of 84%. 
Increasing the length of the alkyl side-chain and hydrophobicity of the cation moiety of 
the ILs, reduced the refolding yield. The authors suggested that the hydrophobic 
moieties of these ILs with long alkyl side-chains strongly interact with hydrophobic 
patches of the protein structure driving destabilization and preventing intra-molecular 
interactions required for refolding. This was shown to be the case for bovine serum 
albumin (BSA) [50]. 
Buchfink, et al. [39] looked at the influence of the anion on the ability of EMIM-ILs to 
induce refolding of recombinant plasminogen activator (rPa) and stability of lysozyme. 
A series of anions were tested including: 2(2-methoxyethoxy)-ethyl sulfate 
(MDEGSO4), ethyl sulfate (EtSO4), and hexyl sulfate (HexSO4), Cl, Ac, Tosylate (Tos) 
and diethyl phosphate (Et2PO4). The ability of the anion to promote refolding of rPa 
while coupled to EMIM followed the order of: [Cl] > [MDEGSO4] > [EtSO4]  > [Ac] > 
[Tos] > [Et2PO4] > ≈ [HexSO4]; [EMIM][Cl] was the only IL superior to ArgHCl as a 
refolding agent. Meanwhile the Tm of lysozyme in the same EMIM-ILs followed the 
order: [Cl] > [EtSO4] ≈ [MDEGSO4] > [Et2PO4] > [Ac] ≈ [Tos] > [HexSO4]. Interestingly, 
this finding did not obey the Hofmeister series, which predicts that [Ac] is more 
stabilizing than [Cl] [48]. To some degree, the ability of the anion to promote refolding 
was related to the hydrophobicity of the anion. More specifically, the authors found 
that ILs which had intermediate ability to solubilize tryptophan were most effective at 
promoting refolding of rPa.  
Interestingly, imidazolium-based ILs have been shown to act as denaturants, refolding 
enhancers and suppressors of insoluble aggregates at the same time. Lange, et al. 
[37] studied the effect of [BMIM][Cl], [OH-EMIM][Cl] and [OH-PMIM][Cl] on the stability 
of lysozyme and found that the melting temperature (Tm) of lysozyme decreased 
significantly with increasing alkyl chain length of the cation. The alkyl-ILs were found 
to be stronger denaturants than their OH-IL counterparts. They also tested the effects 
of [EMIM][Cl], [BMIM][Cl] and [HMIM][Cl], again confirming that increasing the alkyl 
chain length and hydrophobicity of the cation moiety, significantly decreases the 
conformational stability of lysozyme. However, insoluble aggregates were suppressed 
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in the presence of 2 M of each IL after denaturation of lysozyme and dilution into each 
IL, and at 0.5 M concentrations, [HMIM][Cl] was the most effective suppressor of 
insoluble aggregates, while less hydrophobic cations were not as effective. 
Additionally, [EMIM][Cl], [OH-EMIM][Cl], and [OH-PMIM][Cl] were found to be effective 
refolding enhancers, while [BMIM][Cl], [HMIM][Cl] and [OH-HMIM][Cl] were ineffective.  
While imidazolium-ILs appear to act as protein denaturants, refolding enhancers and 
suppressors of insoluble aggregation, other studies have found that some 
imidazolium-ILs improved the thermal stability of proteins tested under certain 
conditions.  
Wang, et al. [36] found that the Tm of lysozyme crystals produced in various 
imidazolium ILs as additives (1% w/v) increased from 65.6 to 71.4 °C ([BMIM][Cl]), 
78.2 ([MMIM][I]), 81.2 ([BMIM][BF4]) and 81.9 °C ([BMIM][Br]). Thus, the improved 
thermal stability obtained with the ILs followed the order of: [BMIM][Br] > [BMIM][BF4] 
> [MMIM][I] > [BMIM][Cl] [36]. The enhanced thermal stability of lysozyme crystals was 
attributed to enhanced crystal contacts, changes in conformational stability and 
intermolecular interactions between lysozyme molecules, and lysozyme and each IL, 
which influenced lysozyme nucleation, and crystal growth and morphology [36]. 
Attri, et al. [40] studied the thermal stability of -chymotrypsinogen (CT) in five ILs 
based on ammonium, phosphonium and imidazolium salts. Both imidazolium ILs 
tested (1-benzyl-3-methylimidazolium chloride ([BzMIM][Cl]), 1-benzyl-3-
methylimidazolium tetrafluoroborate ([BzMIM][BF4])) mildly improved the thermal 
stability of CT. On the other hand, triethyl ammonium acetate (TEAA) had the most 
stabilizing effect on CT increasing the Tm from 42 to 65 °C; followed by triethyl 
ammonium phosphate (TEAP) which increased its Tm to 62 °C. Tetra-butyl 
phosphonium bromide (TBPBr) only mildly improved thermal stability in comparison. 
However, all ILs reduced the activity of CT compared to buffer; TEAA retained the 
highest enzyme activity of all ILs. The stabilization of the native structure of CT was 
found to be due preferential expulsion of the ILs from the protein surface (the 
interaction between the ILs and disulfide bonds of CT is unfavourable) leading to the 
formation of a more compact CT structure which is more stable [40].  
IL concentration is another critical factor as it determines the nature of interactions and 
subsequent effects of ILs on proteins and protein stability. For instance, Takekiyo, et 
78 
 
al. [51] found that at 5 M concentrations of [BMIM][NO3] the tertiary structure of 
lysozyme was significantly disrupted, while at 6-10 M concentrations, partial refolding 
of the secondary structure was observed. At concentrations >10 M this partial refolding 
was maintained but the tertiary structure was significantly disrupted again. These 
observations were attributed to the changes in the spatial arrangement of water 
molecules around the protein structure, mediated by the concentration of IL in solution 
[51].  
Thus, we can conclude that the effects of ILs on protein stability are multi-faceted; 
whether imidazolium-ILs act as protein denaturants, stabilizers or refolding agents 
depends on the type of protein being investigated, the anion coupled to the 
imidazolium ion, the hydrophobicity and length of the alkyl side chain of the cation and 
the concentration of the IL used, and these factors are most likely relevant to all 
families of ILs.   
2.2. Choline-based ILs 
The ammonium family of ILs especially choline ILs and their derivatives, have gained 
significant attention in the last decade for their pronounced effect on protein stability 
and apparent biocompatibility [24, 52, 53]. 
One of the earliest reports of the effect of choline-based ILs on protein stability by 
Fujita, et al. [45], Fujita, et al. [46] showed that the long-term stability of cyt C was 
significantly improved when dissolved in a solution of 80% w/v [Chol][DHP]. Even at 
this saturated concentration of [Chol][DHP], up to 37 mg/mL of protein was soluble. 
However, it is not necessary to use the saturated concentration of [Chol][DHP] or other 
choline-based ILs to observe significant improvements in protein stability, thus 
allowing for significantly higher protein solubility.   
Bisht and Venkatesu [41] studied the effect of five choline-based ILs on the 
conformational stability, thermal stability and activity of CT. They tested 0.05-1.5 M 
concentrations of the following ILs: [Chol][Ac], [Chol][Cl], [Chol][Cit], [Chol][DHP] and 
[Chol][OH]. The conformational and thermal stability of CT in the different choline ILs 
followed the order: [Ac] > [Cl] > [DHP] || >> [Cit] >> [OH] with [Chol][Ac] having the 
most overall stabilizing effect on CT, increasing transition temperature from ~ 49 to 
63 °C; those to the right of “||” reduced the stability of CT. The activity of CT in the 
choline ILs also followed a similar order, except [Chol][Cit] reduced the proteolytic 
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activity of CT more than [Chol][OH], and a mild increase in activity was observed with 
[Chol][Ac]; such that the order was as follows: [Ac] > [Cl] > [DHP] || >> [OH] >> [Cit]. 
The destabilizing effect of the [Cit] and [OH] anions was attributed to direct strong H-
bonding with the CT structure, stripping off essential water molecules which normally 
stabilize the conformation of CT, while the stabilizing effect of anions such as [Ac], [Cl] 
and [DHP] was attributed to modification of water structuring around the protein, 
leading to its stabilization [41]. 
Weaver, et al. [42] studied the effect of [Chol][DHP] on the thermal and structural 
stability of lysozyme and recombinant human interleukin-2 (rHIL-2) at various 
[Chol][DHP] concentrations, and protein concentrations ≤ 1mg/mL. Increased 
concentrations of [Chol][DHP] (20 to 40% w/v) resulted in increased alpha-to-beta 
transition in the secondary structure of lysozyme at pH 4 and 7.2. On the other hand, 
increasing concentrations of [Chol][DHP] (0.5 to 12% w/v) improved the secondary 
order of rHIL-2 by decreasing the % of unordered content and increasing the % of 
alpha-helical content. The Tm of rHIL-2 was also found to be higher with increasing 
[Chol][DHP] concentrations, especially at the highest concentration tested (12% w/v 
or 680 mM), increasing from 61.7 to 74.2 °C. Lysozyme Tm was also increased with 
increasing concentrations of [Chol][DHP]; 40% w/v [Chol][DHP] at pH 7.2 shifted the 
Tm from 73.7 to 88.8 °C. At lower pH (e.g. 3.85), the increase in Tm was lower (76.5 
to 84 °C), alluding to the importance of surface charge for stabilization with 
[Chol][DHP].  The results illustrate that [Chol][DHP] inhibits denaturation of lysozyme 
and rHIL-2 via interactions with charged residues on the protein surface but modifies 
the secondary structural elements in a favourable or unfavourable way depending on 
the protein. Additionally, thermal denaturation of rHIL-2 and lysozyme formulated with 
[Chol][DHP] resulted in the formation of irreversible aggregates. 
Rodrigues, et al. [43] studied the stability of lysozyme in a series of choline-based ILs 
- choline trimethylacetate [Chol][TMA], choline lactate [Chol][Lac], choline propionate 
[Chol][Prop], choline hexanoate [Chol][Hex], choline dihydrogen phosphate 
[Chol][DHP], choline dimethyl phosphate [Chol][DMP], choline trifluoromethane 
sulfonate [Chol][TFMS], choline bis(trifluoromethylsulfonyl)amide [Chol][TF2N], and 
choline chloride [Chol][Cl]. Lysozyme was best stabilized in [Chol][DHP] and 
destabilized in [Chol][TF2N], following the order: [DHP] > [DMP] > [Lac] > [Cl] >> || 
[Prop] > [TFMS] ~ [TMA] > [Hex] > [TF2N]. The effect of choline ILs was also found to 
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be concentration-dependant; for example, [Chol][DHP] had a stabilizing effect above 
0.5 M and a destabilizing effect below this concentration [43]. 
Bisht, et al. [44] studied several choline ILs coupled to di/tri-carboxylate-based anions 
and dihydrogen phosphate as potential media for cyt C. Among the several ILs studied, 
>50-fold catalytic activity of cyt C was observed with choline glutarate ([Chol][Glu]) at 
50% w/v of the IL, compared to PBS; and > 25-fold compared to [Chol][DHP] ~33% 
w/v. Additionally, the catalytic activity of cyt C was maintained against chemical 
denaturants (H2O2 and GuHCl) and temperatures of up to 120 °C, as well as long term 
storage of up to 21 weeks. It is important to note however, that the activity of cyt C is 
increased with partial unfolding of the tertiary structure, unlike most other proteins. 
Thus, it is not clear if the increased activity in this case is due to increased structural 
stability, although some secondary structural elements were stabilized in the presence 
of [Chol][Glu]. The authors concluded from molecular docking studies that the 
enhanced activity is due to H-bonding and electrostatic interactions between the ILs 
and specific residues in the active site of cyt C, as ILs which did not significantly 
enhance activity, such as [Chol][DHP], did not interact with the active site.  
Mazid, et al. [54] published a short study characterizing the fragmentation of an 
Epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in the presence 
of buffered [Chol][DHP]. 20 and 50% w/v concentrations of buffered [Chol][DHP], 
prolonged the biological activity of the EGFR mAb and stabilized it against 
fragmentation in the presence of proteinase K. Higher stability was observed with 50% 
w/v buffered [Chol][DHP]. These effects were attributed to stabilization of the EGFR 
mAb alpha-helices in the presence of buffered [Chol][DHP]. This structural ordering is 
likely due to the [DHP] anion inducing water restructuring around the protein. 
Interestingly, the aggregation index of the formulations containing buffered 
[Chol][DHP] was found to be higher than control PBS by 20-30%, suggesting a modest 
increase in aggregation propensity.   
Amino acid-based ILs are another promising class of biocompatible ILs that have 
received some interest in recent years [47, 55-57]. Amino acids have been mostly 
incorporated as anions, especially with imidazolium or choline cations to produce a 
biocompatible or ‘green’ IL. Guncheva, et al. [57] tested a series of choline-amino acid 
ILs on a hemocyanin and found that the thermal stability was lower in all ILs tested 
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than in the control. Tarannum, et al. [47] recently studied the effect of four choline-
based amino acid ILs (choline serinate, threoninate, lysinate, and phenylalaninate) on 
the structural stability of collagen and had similar findings; they determined that 
competing hydrogen bonds between the ILs and OH groups on the collagen may be 
responsible for the destabilisation observed.  
Unfortunately, research into the stabilization of proteins in amino acid-ILs is still in its 
early stages. Additionally, research is lacking on the formulation of ILs with 
therapeutically-relevant proteins such as mAbs, and other novel formats of antibodies 
such as antibody-drug conjugates and bi-specifics (antibody products that bind to two 
different epitopes), which are receiving considerable attention and undergoing intense 
research. Investigating the effect of ILs on such antibody formulations is important, as 
they are more complex multi-domain proteins with high therapeutic value and will 
certainly increase our understanding of the mechanisms behind protein stabilization 
with ILs.   
3. Simulation studies of ILs: mechanisms of protein stabilization or 
destabilization   
To determine the mechanism of stabilization or destabilization of ILs on proteins, an 
understanding of the interactions of ILs with water [58, 59] and ILs with proteins is 
necessary. Molecular dynamics (MD) simulations have been important in reaching 
some understanding of these interactions [58-60]. A comprehensive review of the 
findings of MD simulations is beyond the scope of this review; Schröder [61] and 
Smiatek [29] recently summarised important aspects. In brief, several important 
mechanisms of interaction and stabilization or destabilization of proteins have been 
identified with the help of MD simulations which will be discussed below.  
As a solute, ILs share properties with inorganic salts and other stabilizing solutes, 
especially in how they interact with water and the protein surface [29, 58]. However, 
unlike simple inorganic salts which cannot typically form hydrogen bonds, IL 
interactions with water or proteins are in fact dominated by extensive hydrogen-
bonding. Thus, the influence of ILs on protein stability is two-fold: the effect of the ions 
on water structure and direct hydrogen bonding to the protein surface residues.  
IL interactions with water are based to some degree on the nature of the individual 
ions comprising the IL – i.e., if they are kosmotropic (structure-making/stabilizing) or 
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chaotropic (structure-breaking/destabilizing). In turn, the effects of IL ions on water 
structure affect protein solvation and stability. Although the Hofmeister series - which 
ranks anions based on their ability to precipitate proteins - is not always followed [62], 
understanding the effects of IL ions on water structure gives some insight into the 
complex mechanisms involved in protein stabilization or destabilization.  
In most cases ILs are composed of a chaotropic cation such as imidazolium and a 
kosmotropic anion such as chloride or acetate. Interactions between ions and water 
are typically limited to their direct environment; i.e. they only influence the first 
hydration shell [63], however, these interactions may still impact protein stability. If 
there is strong involvement of the anions in the hydrogen bond network of water, the 
cations are often expelled from the water network, and then either accumulate at the 
surface of the protein (Fig. 2) [64, 65] or cluster together and form small aggregates 
Figure 2. Ionic liquid (IL) interactions with water and the protein surface. Purple = 
protein; Red = IL cation; Green = IL anion; Blue = water. (a) Anions interact with water 
network and with positively charged regions on the protein surface electrostatically 
and via hydrogen bonding; (b) Cations interact electrostatically with negatively 
charged regions on the protein surface; (c) cations and anions interact with polar 
regions on the surface of the protein electrostatically; (d) IL cations expelled from water 
network cluster around non-polar or hydrophobic regions on the protein surface IL. 
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or micelles [66]; it is not clear if or how these micelles affect protein stability, but they 
do not disrupt the water network as significantly as individual ions dispersed 
throughout [61, 66].  
Secondly, the observed effects on protein stability exhibited by ILs is significantly 
influenced by the type of interactions with the protein surface. IL cations which are 
expelled from the anion-water network, may directly interact with protein residues 
resulting in water removal from the surface, and increased or decreased stability (Fig. 
2) [61, 67]. These cations may interact with polar, non-polar (through alkyl side chains) 
or negatively charged residues, while anions interact with positively charged and polar 
residues only (Fig. 2) [61]. MD simulations have shown that hydrophobic IL cations 
are inserted into phospholipid membranes through their alkyl side chains [68]. Micaêlo 
and Soares [67] performed molecular simulations on the interaction of two [BMIM] ILs 
formulated with low water content, with a serine protease cutinase enzyme. They 
found that the two ILs directly interacted with the enzyme surface, stripping off most 
of the water from the surface of the enzyme, and that the remaining water molecules 
formed many small clusters. Furthermore, molecular docking studies of BSA in various 
BMIM ILs revealed that the imidazolium cations of these ILs interact with hydrophobic 
residues in the subdomains of BSA via hydrophobic interactions causing protein 
unfolding [50]. Long alkyl chains would likely promote these hydrophobic interactions, 
contributing further to water removal from the surface, promoting further denaturation, 
as evident by the experimental results discussed in the previous section. 
In cases where poorly soluble hydrophobic ILs have exhibited stabilizing effects, this 
stabilization has been attributed to the formation of two-phase systems, which results 
in less water depletion from the surface of the protein, enhancing its solubility and its 
overall stability [21].  
MD simulations also show that the influence of the IL anion on protein stability, is 
stronger at higher concentrations of ILs. At higher concentrations, anions interact with 
positively charged residues of the protein, promoting refolding [69]. Additionally, 
because of the strong interaction of an anion with many positively charged residues, 
these residues are forced into a more compact conformation, facilitating the formation 
of H-bonds and restructuring of secondary structural elements, resulting in increased 
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thermal stability of the protein [69]; this is likely the case with choline ILs such as 
[Chol][DHP] which are better stabilizers at higher concentrations.  
Recent computer simulations have suggested that the nucleophilicity and hydrogen 
bond basicity of the ions of an IL are the primary contributors to protein stability in ILs 
rather than their hydrophobicity, as postulated by numerous experimental studies, 
especially for enzymes. [29, 61]. The body of work on modelling IL interactions with 
proteins is in its early stages – as more computational studies are performed, a deeper 
understanding of the specific interactions of ILs on protein stability will be possible.   
4. Considerations for IL use in formulations of biologics and vaccines 
4.1. Toxicity of ILs 
The widespread interest in the use of ILs, particularly as industrial solvents, 
necessitated studies into the toxicity of these compounds on environmental systems 
and various organisms, including humans. While the ecotoxicity of ‘green’ ILs has 
been studied extensively and summarised elsewhere [70], of significant interest in 
biological applications of ILs, is understanding their toxicity to humans, particularly 
their cytotoxicity [71]. Numerous cytotoxicity assays have been performed on animal 
cell lines, particularly mouse leukaemia cells (IPC-81) [72, 73] and various human cell 
lines [74, 75]. The high toxicity of some ILs is even being exploited for the development 
of IL-based cytotoxic drugs and anti-bacterial agents [76]. Given that ILs can exhibit a 
range of toxicities, it is important to identify which class of ILs may be considered 
biocompatible or ‘safe’ to use in formulations of biopharmaceuticals (Fig. 3).  
The toxicity of ILs is a product of both the cation and anion [70, 71, 76], despite earlier 
claims that the cation moiety was a more significant determinant of toxicity. Both cation 
and anion toxicity is influenced by several factors; most significantly is the length of 
the alkyl side chain and branching, and the hydrophobicity of the ion. Several studies 
have shown that increasing the alkyl chain length of the cation significantly increases 
the toxicity of the IL [70, 74, 77, 78]. For example, Wang, et al. [74], found that the half 
maximal effective concentration (EC50) of 1-ethyl-3-methylimidazolium bromide in a 
human cervical cancer cell line (HeLa), decreased from 8.4 mM to 2.8 mM when the 
ethyl was substituted for a butyl group, and further to 0.3 mM when substituted for an 
octyl group.  
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It has also been shown that introducing hydrophilic functional groups such as 
hydroxyls, nitriles and polar ethers to the side chains of ILs reduces the toxicity of the 
IL cation when compared with a non-functionalised alkyl side chain [78-80]. This is 
attributed to a reduction in hydrophobicity and ability to interact with and disrupt the 
lipid bilayer of cell membranes [81]. Additionally, some perfluorinated anions may be 
cytotoxic if they decompose and release fluoride ions [82]; however this is dependent 
on the organism tested and whether the anion is hydrolysable or not. Nonetheless, 
most AILs without modification, would not be an ideal choice of biocompatible ILs 
especially at high concentrations due to toxicity issues.  
In most cases, PILs have been shown to exhibit less cytotoxicity than commonly-used 
AILs, as they typically lack the bulky hydrophobic cations and perfluorinated anions 
[77, 83].  Choline-based ILs are a promising class of biocompatible PILs for the 
stabilization of biopharmaceuticals. At least, the choline cation is significantly less toxic 
IL-Protein 
formulations
Protein
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•Solubility
Cytotoxicity
Viscosity*
Osmolarity* 
Figure 3. Important considerations for the use of ILs in protein formulations for 
therapeutic use. *considerations for injectable formulations 
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than an imidazolium or pyridinium-based cation as shown by [83]. The authors found 
that the EC50 of choline IL in HeLa cells were at least 10-fold lower than imidazolium 
and pyridinium ILs tested. Additionally, choline is an FDA approved molecule.  
As the choline cation is typically considered a ‘non-toxic’ essential micronutrient, the 
overall cytotoxicity of choline ILs is mostly dependent on the anion it is coupled with.  
Weaver, et al. [84] studied the cytotoxicity of choline cation paired with five phosphate-
based anions; DHP, dibutyl phosphate (DBP), bis(2-ethylhexyl) phosphate (BEH), 
bis(2,4,4-trimethylpentyl) phosphinate (TMP), and O,O′-diethyl dithiophosphate (DEP). 
The cytotoxicity of the choline ILs was assessed on a J774 murine macrophage cell 
line. Of all the choline ILs tested, [Chol][DHP] exhibited the lowest cytotoxicity to J774; 
the EC50 values (mM) of the ILs were 0.25 [Chol][TMP], 0.3 [Chol][BEH], 8.2 
[Chol][DEP], 9.1 [Chol][DBP], 20 [Chol][DHP] compared with values of 63 for NaCl and 
34 for [Chol][Cl] [84]. Increased anion size and the presence of moderately long and/or 
branched alkyl chains increased the cytotoxicity of the IL, as previously shown with 
cations of AILs.  
Following on from work by Weaver, et al. [42], Foureau, et al. [85] investigated the 
potential of [Chol][DHP] as a biocompatible additive for the stabilization and 
formulation of recombinant human interleukin-2 (rHIL-2). [Chol][DHP] in vitro 
concentrations < 80 mM were found to have no cytotoxic activity towards primary 
splenocytes nor mouse melanoma cells (B16-F10), suggesting that [Chol][DHP] is 
biocompatible at these physiological concentrations in an in vitro mouse model. Thus, 
it appears that the choline family of ILs is one of the most promising candidates for 
biocompatible ILs that exhibit a strong protein stabilizing effect.  
4.2. Viscosity of ILs 
ILs are typically quite viscous and range in viscosities from 10s to 1000s in cP (Table 
2); thus, it is integral to assess the viscosity of typical IL solutions, to ensure they are 
below the acceptable viscosity for injectables (< ~20 cP), which is still one the most 
common methods of formulating and administering biopharmaceuticals (Fig. 3). Since 
these ILs are often used in concentrations ≤ 50% w/v their viscosity would be expected 
to be significantly lower than in their ‘neat’ form. Using [Chol][DHP] as an example, we 
observe that the viscosity of the 80% w/v as measured by Fujita, et al. [86] was 440 
cP; however, at 65% w/v IL concentration, the viscosity decreases significantly to 25 
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cP (Table 2). Thus, it is expected that the viscosity of [Chol][DHP] solutions ≤ 50% w/v 
to be below 20 cP - the generally acceptable viscosity of IV formulations. However, it 
is important to consider the contribution of the high protein concentrations often 
formulated in these injectables to the total viscosity of the solution; the final formulation 
viscosity would need to be measured in a case-by-case basis to determine the 
suitability of the IL used.  
Table 2. Viscosities of some common ILs 
Ionic Liquid Viscosity (cP) @25 °C Reference  
[BMIM][I] 1110 [87] 
[BMIM][TF2N] 69 
[BMIM][BF4] 219 
[HMIM][Cl] 716 
[EMIM][TF2N] 28 [88] 
[Chol][DHP] 80% w/w 440 [86] 
[Chol][DHP] 65% w/w 25 
 
4.3. Osmolarity of IL solutions for injection 
When choosing ILs for use in IV formulations of biologics, the final solution osmolarity 
must be measured (Fig. 3). If ILs are used in large concentrations (for e.g. > 50% w/v), 
they would undoubtedly result in hypertonic formulations that may not be suitable for 
IV injection. For example, Foureau, et al. [85] measured the osmolarity of rHIL-2 
formulations containing 680 mM (12% w/v) [Chol][DHP], and found that the solutions 
were hypertonic with an osmolarity of 1520 mOsm/L, approximately 2.5-5-fold higher 
than near-isotonic levels suitable for IV injection (~300-600 mOsm/L) [89]. Since ILs 
have concentration-dependant effects on protein stability, and are often stabilizing in 
higher concentrations, issues with osmolarity are inevitable. One approach to address 
the hypertonicity of the solutions is to introduce an intermediate dilution step prior to 
injection. Alternatively, if lower concentrations of IL are used as with Foureau, et al. 
[85], the product may be formulated in other types of injectables or infused; for 
example, Nony, et al. [90] reported that intramuscular injections comfortably 
administered 0.5 ml of up to 1100 mOsm/L hypertonic vaccine-like solutions. Such 
88 
 
considerations are becoming less significant as we head towards the development of 
non-invasive formulation routes for the administration of biopharmaceuticals.  
5. Conclusion  
 
ILs have demonstrated potential as novel versatile protein-stabilizing additives albeit 
with complex mechanisms of action. However, most studies up to date have focused 
on the thermal or chemical denaturation of proteins in IL solutions. While partial protein 
unfolding may lead to protein aggregation and influence overall protein stability, it is 
not sufficient to describe protein aggregation mechanism, as the aggregation process 
is distinct and is driven by protein-protein interactions. It is possible for an additive to 
inhibit unfolding while also promote aggregation, resulting in a limited overall benefit. 
Additionally, few of the studies on protein stability with ILs were performed on 
therapeutically-important and multi-domain proteins such as mAbs, which are 
extremely valuable, and few at high protein concentrations. With the development of 
biocompatible ILs, toxicity issues are becoming less of a concern for their use in 
therapeutic formulations. Additionally, the viscosity and osmolarity of protein-IL 
formulations is not an issue for long-term storage of biotherapeutics as long as the 
product is diluted prior to administration and only if the product is injected. ILs are 
exciting versatile liquids – with high potential yet to be exploited fully for rationally 
developed formulations of biologics and vaccines – certainly with more research in this 
field, as well as computational MD simulations for deeper mechanistic insights, we 
may see the incorporation of ILs in biotherapeutic formulations within the next decade. 
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Abstract 
Monoclonal antibodies (mAbs) have dominated the pharmaceutical market in the last 
decade, with thousands more in the development pipeline. Despite rapid growth in the 
mAb industry, protein aggregation continues to plague the development of novel 
antibody therapies due to the immunogenicity of antibody aggregates, thus limiting the 
product’s shelf-life. To combat protein aggregation more effectively, a mechanistic 
understanding of the aggregation process is needed; studying the aggregation kinetics 
of therapeutic antibodies provides mechanistic insight into the intricate processes that 
precede aggregation, with the possibility of developing predictive models to determine 
parameters such as shelf-life and establish a connection between accelerated studies 
with long-term storage conditions. Hereby, we thoroughly characterised the 
aggregation kinetics of Herceptin® (trastuzumab) using spectroscopic methods 
including fluorescence, dynamic and static light scattering (DLS, SLS), and size-
exclusion chromatography (SE-HPLC) and at various temperatures to gain insight into 
the process of mAb aggregation. We have developed a simple model summarising the 
aggregation process of Herceptin® with mechanistic insight into the predominant 
steps in the aggregation process. 
1. Introduction 
 
Therapeutic monoclonal antibodies (mAbs) and antibody-based products have 
consistently led the biopharmaceutical market in the last ten years. Over 70 
therapeutic antibody products have been approved by the FDA and EMA, and 
hundreds more are in clinical trials [1-4]. One of the most challenging facets of 
developing novel antibody biologics is protein aggregation [5]; a common physical 
degradation process that often causes adverse effects and leads to undesired 
immunogenicity and loss of antibody function [1, 6, 7]. The success of these novel 
therapeutic antibodies is heavily dependent on the aggregation propensity of the 
antibody and how effectively aggregation can be suppressed at high protein 
concentrations over the shelf-life of the product. 
To combat aggregation more effectively, mechanistic insight into the pathways of 
antibody aggregation and molecular level protein-protein interaction is necessary. 
Studying the aggregation kinetics of antibodies allows us to expand our understanding 
of the aggregation process and more accurately determine important parameters such 
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as shelf-life [8-12]. Numerous kinetic models of different protein aggregation pathways 
have been described in the last fifty years [13-19]. We have previously summarised 
and discussed these elsewhere [15, 20]. Briefly, aggregation proceeds through a 
number of sequential processes as follows and shown in Scheme 1: (1) reversible 
transition from native (M) to partially unfolded monomers (assumed to be reactive 
monomers (Mu)); (2) addition of Mu to other reactive species such as other Mu and (3) 
aggregates (A); and (4) aggregate-aggregate association/clustering. It is worth nothing 
that these processes may be reversible or irreversible depending on the protein, 
excipients and experimental conditions. For example, the native monomer can unfold 
to an extent that it becomes irreversible. Additionally, precipitation of large aggregates 
can occur especially at high concentrations; however, therapeutic mAbs are relatively 
stable under standard long-term storage conditions and rarely unfold completely or 
precipitate at low temperatures.  For simplicity, the model can be summarised as 
follows: 
(1) 𝑀 
𝑘𝑢
↔𝑀𝑢 
(2) 𝑀𝑢 +𝑀𝑢  
𝑘𝑑𝑖
↔ 𝐴2 
(3) 𝑀𝑢 + 𝐴2  
𝑘𝑚1,1
↔  𝐴3 
         ⋮ 
𝑀𝑢 + 𝐴𝑛−1  
𝑘𝑚1,𝑛−2
↔    𝐴𝑛 
(4) 𝐴2 + 𝐴2  
𝑘𝑚2,1
↔  𝐴4 
𝐴2 + 𝐴3  
𝑘𝑚2,2
↔  𝐴5 
⋮ 
𝐴𝑥 + 𝐴𝑦  
𝑘𝑚2,𝑥
↔  𝐴𝑥+𝑦 
         Note: (x+y) < n 
Scheme 1. Model for protein aggregation  
Such models are often reduced down further and analysed with 1-3 unknown 
parameters, often relying solely on monomer loss kinetic data to model aggregation 
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[15]. The above reaction rate constants that define each step are often obtained 
experimentally by analyzing protein folding/unfolding kinetics at either elevated 
temperatures or using chaotropic agents such as urea or guandine HCl (GuHCl), and 
performing accelerated-protein-aggregation studies. Kinetic data such as monomer 
loss and/or aggregate formation is determined using separation methods such as size 
exclusion-HPLC (SE-HPLC) and spectroscopic methods such as light scattering and 
fluorescence [16, 21, 22]. In general, kinetic data are analysed with (pseudo)first-order 
or second order functions although sometimes more complicated models are required 
to explain the data [13, 18, 21, 23]. Obtaining these rate constants can also be useful 
for predicting parameters such as shelf-life from accelerated data at elevated 
temperatures [21]. However, while some protein aggregation kinetics display the 
Arrhenius tendency, the aggregation of complex multi-domain proteins such as mAbs 
has been shown to be non-Arrhenius over a wide range of temperatures [21]. Thus, 
mathematical prediction of therapeutic antibody shelf-life remains a challenge [6, 21].  
To our knowledge, limited kinetic analyses have been performed on the marketed mAb 
product Herceptin® in its original formulation. Hereby, we thoroughly investigated the 
conformational and colloidal stability of trastuzumab in its marketed formulation 
conditions (Herceptin®) as a model for IgG1 therapeutic antibodies using SE-HPLC, 
fluorescence spectroscopy, static (SLS) and dynamic light scattering (DLS) to develop 
a deeper understanding of the aggregation phenomenon of therapeutic mAbs. Our 
results provide mechanistic insight into the aggregation kinetics under accelerated and 
long-term storage conditions. 
2. Materials and Methods 
 
Herceptin® was generously donated by Genentech (San Francisco, US) and was used 
in its formulation buffer for all experiments at the reconstituted concentration of 21 
mg/mL (except where otherwise mentioned). Millex-GV syringe filter units (0.22 µm, 
PVDF, 33 mm, gamma sterilized, SLGV033RS), di-potassium hydrogen phosphate 
(EMPROVE® Ph Eur, BP, E 340 grade, 105101) and potassium dihydrogen 
phosphate (EMSURE® ISO grade, 104873) were purchased from Merck Millipore (MA, 
USA). 8-anilino-1-naphthalenesulfonic acid (ANS; >97% HPLC) grade, A1028), 
thioflavin T (ThT; T3516), guanidium hydrochloride (GuHCl) and all other reagents 
were purchased from Sigma Aldrich (Castle Hill, Australia). 
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2.1. Accelerated stability studies at elevated temperatures 
 
Accelerated studies at elevated temperatures were conducted as previously described 
[21]. 30 or 100 μL aliquots of Herceptin® (hereafter referred to as trastuzumab) at 
concentrations of 21 mg/mL (aggregation kinetics) or 0.2 mg/mL (for ANS unfolding 
kinetics) were incubated in a Thermal Cycler 2720 (Applied Biosystems, CA, USA) at 
temperatures between 65-75 °C for various durations based on incubation 
temperature. A thermal cycler was used to prevent sample evaporation during 
incubation (with heated lid cover). Heated samples were immediately stored on ice 
following incubation to halt further aggregation and characterized with or without 
dilution in either formulation buffer or 150 mM potassium phosphate buffer, pH 6.5.  
2.2. SE-HPLC 
 
Size exclusion-high performance liquid chromatography (SE-HPLC) was used to 
quantify monomer loss and aggregation of trastuzumab following accelerated stability 
studies. Analysis was performed using an Agilent 1200 Liquid Chromatography 
system (Agilent Technologies, California, USA) with a single or double column set-up 
of TSKgel Super SW3000 columns (Tosoh Bioscience, Tokyo, Japan) at 22 °C, using 
a 150 mM potassium phosphate mobile phase, at pH 6.5, and a flow rate of 1 mL/min. 
5 μL of each Herceptin® sample at a concentration of 21 mg/mL was injected.  
Monomer and aggregate peaks were detected using an in-line UV signal detector set 
at 280 nm. The area under the curve (AUC) of the monomer and the aggregate peaks 
was averaged over three runs and the mean % of each species was calculated for 
each sample. The standard deviation (SD) was plotted as error bars in the figures. For 
fractionation of chromatogram peaks, 100 μL of Herceptin® at a concentration of 21 
mg/mL was injected, and monomer and aggregate peaks were evenly fractionated into 
4 aggregate samples (from 11 to 15 minutes), and 7 monomer samples (from 10 to 20 
minutes).  
 
2.3. Fluorescence spectroscopy 
 
Fluorescence measurements were performed using the Fluorolog 3 FL3-22 
Spectrophotometer (HORIBA scientific, New Jersey, USA). Herceptin® samples were 
diluted to 0.2 or 0.15 mg/mL (GuHCl unfolding) in formulation buffer (excluding 
polysorbate 20 for ANS measurements due to its fluorescence contribution) while SE-
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HPLC fractions were kept in the mobile phase buffer (potassium phosphate 150 mM) 
and diluted if necessary to approximately 0.02 mg/mL, pH 6.5. All samples were 
measured in a Hellma® ultra-micro fluorescence quartz cuvette (Hellma® Analytics, 
Müllheim, Germany) at right-angled detection mode.  Data was analyzed using Igor 
Pro 6 software.  
2.4. Tryptophan fluorescence 
 
Tryptophan fluorescence of trastuzumab was used to characterize conformational 
changes between monomer fractions and different-sized aggregate species separated 
by SE-HPLC, by comparing differences in maximum fluorescence intensity and the 
maximum emission wavelength, which provide information on the environment 
surrounding the tryptophan residues. A change in tryptophan fluorescence and an 
increase in maximum emission wavelength (termed red-shift) usually suggests that 
there is increased solvent exposure near the tryptophan residue(s), which may be due 
to unfolding. On the other hand, a decrease in the maximum emission wavelength 
(termed blue-shift) is due to the formation of a more hydrophobic local environment 
near the tryptophan residue(s) which may occur because of protein aggregation [22]. 
For unfolding studies, a stock of 8 M GuHCl was used to dilute trastuzumab samples 
to required concentrations of antibody and GuHCl (1-6 M). Trastuzumab samples were 
incubated overnight at room temperature with GuHCl prior to measurement.  ΔG’ at 
0M GuHCl was calculated from the normalised maximum trp wavelength using the 
following equation:  
ΔG =  −RT ln 𝐾𝑒𝑞 
and Keq: 
𝐾𝑒𝑞 = 
𝑊𝐹𝑜𝑙𝑑𝑒𝑑 −𝑊
𝑊 −𝑊𝑈𝑛𝑓𝑜𝑙𝑑𝑒𝑑
 
where W is maximum trp wavelength at different concentrations of GuHCl (folded = 0 
M; unfolded = 6 M) and Keq is the equilibrium constant of the unfolding process.  
Tryptophan fluorescence of trastuzumab was detected in the emission wavelength 
range of 300-500 nm with an excitation wavelength of 295 nm. Both excitation and 
emission slit sizes were set at 3 nm. Samples were corrected by blank subtraction of 
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150 mM potassium phosphate, pH 6.5 or formulation buffer. All measurements were 
performed in triplicates and averaged, and the standard deviation (SD) was calculated.  
2.5. ANS and ThT fluorescence 
 
ANS fluorescence was used to characterize the unfolding behaviour of trastuzumab 
following incubation at elevated temperatures. A significant increase in maximum ANS 
fluorescence is usually indicative of protein unfolding [24]. This is often accompanied 
by a blue-shift, as unfolding allows ANS to bind to hydrophobic pockets of the protein, 
away from the polar solvent environment. ANS fluorescence was detected in the 
emission wavelength range of 400-650 nm with an excitation wavelength of 385 nm. 
Both excitation and emission slit sizes were set at 3 nm. ANS kinetic data was fit using 
the IGOR 6 in-built single exponential function.  
ThT fluorescence was used to characterize different-sized trastuzumab aggregates 
following incubation at elevated temperatures. A significant increase in maximum ThT 
fluorescence is usually associated with the formation of protein aggregates [24], and 
the degree of increase is also dependent on the hydrophobicity of the environment 
and the aggregate structure. A change in the maximum emission wavelength may also 
be observed, based on the aggregate environment. ThT emission was detected in the 
emission wavelength range of 425-600 nm with an excitation wavelength of 415 nm. 
Both excitation and emission slit sizes were set at 3 nm.  
For both dyes, 5 µL of dye from a working stock was added to 95 µL of each 
trastuzumab sample to a final concentration of 20 µM ANS for unfolding kinetics 
studies, 3.5 µM ANS for monomer fractions, and 3 µM ThT for aggregate fractions. All 
samples were then incubated while in ice for exactly 20 minutes before analysis to 
allow for dye binding. Samples were corrected by blank subtraction of H2O (for dye-
only samples) or a trastuzumab sample dissolved in the respective solvent with no dye 
(for samples containing dye and trastuzumab). All dye fluorescence measurements 
were performed in triplicates and averaged, and the SD was calculated.  
2.6. Dynamic light scattering (DLS) 
 
The hydrodynamic diameter of trastuzumab monomer and aggregate fractions were 
measured by DLS using the Malvern Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). The size range cut-off was adjusted to 1nm–0.5 µm as no 
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antibody particles were detected outside that range, minimising unwanted scatter. The 
refractive index was set at 1.33 and the absorption value was 0.1. The viscosity was 
set at 0.8879 mPa/s. Samples were diluted to 0.5 mg/mL in their respective solvents 
and measured in triplicates. 
2.7. UV-Vis spectroscopy 
 
UV-Vis absorbance was used to measure the concentration of soluble Herceptin® 
following accelerated stability studies. Absorbance was measured at 280 nm over a 
wavelength range of 220-350 nm using a Shimadzu UV-2600 spectrophotometer 
(Shimadzu, Japan). Samples were corrected by blank subtraction of the respective 
solvent. Data was not included as the absorbance of all samples remained unchanged 
following incubation, and therefore no change in soluble antibody concentration was 
observed.  
3. Results and discussion 
 
3.1. Conformation of monomeric antibody and aggregates 
 
The unfolding of trastuzumab was characterised by thermal and GuHCl-induced stress, 
using ANS and trp fluorescence, respectively (Fig. 1 and 2). The melting temperatures 
(Tm) of each trastuzumab domain are 68-70 °C for the CH2 and 81-83 °C for both the 
Fab and CH3 domains  [25, 26]. This was confirmed for our samples using trp 
fluorescence (data not shown). Thermal unfolding kinetics of trastuzumab was 
achieved by incubating very low concentrations of antibody in order to minimise 
aggregation, and probing external dye-binding kinetics using ANS fluorescence as 
previously described [24]. As expected, at 65 °C (below the melting temperature (Tm) 
of CH2 of trastuzumab) minor changes in the native structure occur, illustrated by the 
changes in ANS fluorescence (Fig. 1). At higher temperatures 70 and 75 °C, however, 
the max fluorescence intensity of ANS increases 3-fold, with a blue-shift of ~40 nm as 
the ANS dye buries itself within the exposed hydrophobic domains of trastuzumab. 
The rate of unfolding is very rapid at 70 and 75 °C, with an exponential rate of 
fluorescence change and near maximum occurring within an hour at 70 °C and 6 
minutes at 75 °C (Fig. 1). Unfolding rate is significantly slower at 65 °C, but an 
exponential rate of change is still observed. The unfolding rate constants at 65, 70 and 
75 °C based on a single exponential fit, are 0.0192, 0.0235 and 0.325 min-1 (Fig. 1A; 
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max fluorescence) and 0.0112, 0.0905 and 0.890 min-1 (Fig. 1B; max wavelength), 
respectively.  
Chemical unfolding of trastuzumab with increasing concentrations of GuHCl allows us 
to determine the sensitivity of the trp max emission wavelength of trastuzumab to 
Figure 1. Trastuzumab unfolding kinetics measured with ANS fluorescence 
spectroscopy A) ANS max fluorescence plot with heat-stressed trastuzumab 
samples; B) ANS max emission wavelength shift with heat-stressed trastuzumab 
samples. Error bars represent the SD.  
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changes in its conformational structure and calculate ΔG’ which was determined to be 
14.7 kJ/mol at 0 M GuHCl. As can be seen, complete unfolding of trastuzumab 
domains is associated with a ~16 nm red-shift in the trp maximum emission 
Figure 2. Characterisation of trastuzumab monomer and aggregate fractions from 
SE-HPLC by fluorescence spectroscopy; A) trp max emission wavelength shift of 
trastuzumab with increasing concentrations of GuHCl; B)  trp max emission 
wavelength of monomer fractions from different sections of the chromatogram peak 
stressed at elevated temperatures; C) trp max emission wavelength of monomer and 
aggregate fractions stressed at 70 °C compared with 4 °C; D) max emission 
wavelength of ANS bound to monomer fractions stressed at 70 °C compared with 
fractions at 4 °C; E) max emission wavelength of ThT bound to aggregate fractions 
stressed at 70 °C; F) max fluorescence of ThT bound to aggregate fractions stressed 
at 70 °C. Error bars represent the SD.  
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wavelength, obtained with 6 M GuHCl (Fig. 2A). To determine whether there is any 
heterogeneity of eluted monomer species on SE-HPLC, we measured the trp max 
emission wavelength of 7 monomer fractions obtained from different sections of the 
eluted monomer peak, and from monomeric species incubated at different 
temperatures. We observed no difference in the trp max emission wavelength between 
monomer fractions taken at earlier or later sections of the elution peak, nor between 
these fractions and the corresponding fractions of monomer peaks from samples 
incubated at different temperatures (Fig. 2B). 
Figure 3. Aggregation kinetics of trastuzumab formulation at elevated temperatures 
(65, 68, 70 and 75C) A) monomer loss kinetics at elevated temperatures fit with a 
double exponential function; B) same as A) fit with a single exponential function; C) 
dimer formation kinetics at elevated temperatures fit with a double exponential 
function; D) same as C) fit with a single exponential function; E) large aggregate 
formation kinetics fit with a double exponential function;  F) same as E) fit with a 
single exponential function. Aggregate concentration is determined based on 
monomeric concentration. Error bars represent the SD.  
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This suggests that the eluted monomer peak is at least predominantly made up of a 
single monomer species, that is native, and that the monomer species of incubated 
samples are similar in conformational structure with regards to their degree of 
unfolding.  This allows us to confirm that the monomer concentration obtained from 
SE-HPLC at different temperatures is reflective of the native monomer concentration. 
However, since this is an ex situ analysis, it does not rule out the formation of other 
species during the reaction which are involved in aggregation; these species are either 
‘used’ up to form aggregates or refold immediately upon cooling and dilution into the 
mobile phase, resulting in one native conformation that is eluted. Our results are 
consistent with observations in our previous study with BSA [15]. 
Surprisingly though, fractions 1-4 from the aggregate peak, also display no change in 
trp max emission wavelength (Fig. 2C). Aggregates are expected to bury trp residues 
in hydrophobic pockets, resulting in a blue-shift. The lack of any shift illustrates that 
trp environments are almost identical to that of trps in monomers. Furthermore, it 
suggests that the formation of the eluted aggregates is preceded by minimal changes 
in antibody conformation. That is, the formation of both dimers and large aggregate 
species proceeds with minimal structural rearrangement due to unfolding or otherwise. 
A similar observation with another mAb was reported by us using time-resolved trp 
fluorescence lifetime analysis [21], where individual antibody structures were 
somewhat different in very small and very large protein aggregates but were similar to 
each other if aggregate fractions were close to each other in size. However, these 
results are contrary to what we have previously found with BSA – whereby dimer and 
aggregate fractions from different incubation temperatures were found to have 
different conformations measured by trp fluorescence [15].  
The lack of changes in conformational structure of monomer and aggregate species 
is further confirmed by ANS and ThT dye binding studies (Fig. 2D, E and F). Fractions 
2-7 for both 4 and 70 °C samples are slightly red-shifted, compared to fraction 1 and 
ANS-dye only. However, when comparing the 4 °C fractions to the 70 °C fractions, no 
significant difference is observed. This illustrates that the monomeric species of heat-
stressed samples have the same or very similar conformation to those samples which 
are not stressed. The apparent red-shift in fractions 2-7 compared to fraction 1 is likely 
due to the presence of a small amount of aggregate species in fraction 1, due to 
overlap between peaks.  
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Interestingly, no significant difference is observed when assessing the differences 
between aggregate fractions 1-4 with ThT (Fig. 2E and F), further demonstrating that 
the different-sized aggregates formed are conformationally similar in structure. This 
implies that beyond dimer formation, aggregates form via mechanisms which do not 
require further unfolding, such as aggregate-aggregate clustering/association. Based 
on DLS measurements of aggregate fractions, we can deduce that these findings 
apply up to the largest aggregate species detected which is approximately 8-10 times 
larger than the monomer – i.e. a decamer (Fig. 4B). 
3.2. Accelerated trastuzumab aggregation studies and kinetics of aggregation 
 
We further performed protein aggregation studies and measured the monomer, dimer 
and large aggregate concentration of trastuzumab to study its aggregation kinetics. 
Due to the large size of an antibody monomer (~148 kD) - and therefore the large size 
of its aggregates - it is difficult to resolve the different sized-aggregate species present 
in the elution. With a double column SE-HPLC set-up to assist separation, we 
achieved reasonable separation between dimer and larger aggregate species, which 
were fractionated and quantified (Fig. 2 and 3). Size-determination of the SE-HPLC 
fractions with DLS shows that the dimer peak fraction is predominantly dimer, with 
minimal heterogeneity (Fig. 4B). When trastuzumab is incubated at elevated 
temperature, we initially observe rapid dimer formation (Fig. 3C and D); the rate of 
formation of dimer species then begins to plateau reaching an equilibrium, as large 
aggregates ‘consume’ dimers and form more rapidly with increasing incubation time 
(Fig. 3E and F). Eventually, the rate of large aggregate formation also beings to 
decrease and the rate of formation of all aggregates (i.e. monomer loss) reaches a 
‘plateau’ (Fig. 3A and B). As expected, little to no fragmentation was observed at 
elevated temperatures as fragmentation typically occurs slowly due to hydrolysis, or 
enzymatic digestion. The change in concentration of different-sized aggregates with 
incubation time confirms that large aggregates form by aggregate-aggregate 
association, utilizing dimers formed by monomer addition. Additionally, an equilibrium 
must exist between monomer and aggregate concentration, leading to the ‘plateau’ of 
monomer consumption. Altogether, a complex equilibrium between reversible and 
non-reversible species forms, leading to the steady rate of monomer loss observed 
after the rapid initial aggregation process at all temperatures.   
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3.3. Trastuzumab kinetic fits and aggregation mechanism 
 
Several models of antibody aggregation have been previously proposed [6, 11, 13, 14, 
16, 21, 27]. However, till-date most monomer loss kinetic data is fit with simple 
equations such as an exponential fit or a first/second order kinetic equation to derive 
a rate constant of aggregation. We compared the degree of ‘fit’ using in-built IGOR 6 
single and double exponential functions and derived rate constants (k, and k1 and k2, 
respectively) of reactions contributing to monomer loss, dimer formation and large 
aggregate formation (Table 1). Since we did not obtain an ideal fit for monomer loss 
and dimer formation with a single exponential function, we used a double exponential 
function, while no significant difference was observed when fitting large aggregate 
formation kinetics (Fig. 3E and F). Analysis with a double exponential function 
suggests that monomer loss is involved in at least two different ‘reactions’ - a faster 
and slower reaction - defined by k1 and k2, respectively. Typically, the rate of small 
aggregate formation (e.g. dimer and trimer) is faster than the rate of monomer addition 
to larger aggregates as there is more accessibility to aggregation-prone regions, and 
therefore more possible combinations for association.  
 
Table 1. Rate constants of trastuzumab unfolding (ku), monomer loss and aggregation 
from single (k) and double exponential equation fits (k1 and k2). N.D. denotes not 
determined. 
T 
(°C) 
Unfold
ing 
(min-1) 
Monomer loss (min-1) Dimer formation (min-
1) 
Large agg. formation 
(min-1) 
ku k1 (km1)  
n ≤ 3 
k2 (km1)  
n > 3 
k (km1)  k1 (kdi) k2  k k1 
(km2) 
k2  k 
65 0.019 0.201 0.006 0.024 0.287 0.002 0.084 0.115 0.008 0.014 
68 N.D. 0.202 0.011 0.019 0.201 0.011 0.05 0.017 0.004 0.009 
70 0.024 10.53 0.022 0.038 71.71 0.019 0.175 0.023 0.166 0.023 
75 0.325 0.365 0.089 0.246 2.443 0.147 0.711 0.138 0.184 0.155 
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Figure 4. A) Representative SE-HPLC chromatogram of trastuzumab aggregation 
with inset showing the dimer and large aggregate peaks that were fractionated. B) 
DLS hydrodynamic diameter measurements of fractioned monomer, dimer and 
large aggregate species including monomer fractions from unstressed samples 
(4 °C).  
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The proportionally high concentration of dimers with respect to each other aggregate 
size, and the rapid formation of dimers initially (Fig. 3C and D) supports this idea. Thus, 
the first rate constant k1 reflects the rapid initial rate of monomer loss due to dimer and 
possibly trimer formation (km1, n ≤ 3), while k2 reflects the slower rate of monomer loss 
due to addition of monomers to larger aggregates (km1, n > 3). Interestingly, although 
dimer formation is expected to proceed via monomer addition only, we did not obtain 
an ideal fit with a single exponential equation (Fig. 3C). It is not unusual to expect the 
formation of dimers to proceed via different pathways, or that conformationally-
different dimer species are formed, as previously reported [21, 28]. Additionally, there 
may be small quantities of larger aggregates in the fraction that are unavoidable during 
fractionation. We can assume that k1 derived from the dimer double exponential fit is 
kdi, while k2 may be the average rate of formation of other dimer species and/or non-
dimeric species present in the fraction. This is supported by the rate constants 
obtained from the monomer fits; i.e. km1 for n ≤ 3 is smaller than kdi, which supports 
our hypothesis, as it is expected that dimers form faster than trimers. The kinetics of 
large aggregate formation were fit well with both single and double exponential fits 
(Fig. 3E and F). Thus, we can assume that k1 represents the average rate constant 
km2 for all aggregate clustering steps in our model. Alternatively, the two mechanisms 
may proceed at a similar rate and are therefore indistinguishable from each other.  
3.4. Arrhenius behaviour of trastuzumab aggregation and linearization of non-
Arrhenius plot using VFT function 
 
The Arrhenius equation is an empirical temperature-dependant function used to 
describe kinetic data of many processes including decomposition [29], oxidation rate 
[27] and chemical degradation [30, 31]. Arrhenius plots of reaction rate constants at 
accelerated conditions are often used to predict shelf-life of small molecule drugs at 
lower storage temperatures [30, 32-34]. Using rate constants of aggregation obtained 
with single and double-exponential fits, we extrapolated the accelerated conditions at 
elevated temperature to predict experimental rate constants for 45 °C (obtained from 
[26]) and 4 °C (Fig. 5A). ln(k2) and ln(k) inverse temperature plots, appear linear up to 
45 °C. Non-Arrhenius behaviour becomes apparent at temperatures below 45 °C as 
demonstrated by the data point for 4 °C. Because of the linearity of the aggregation 
kinetics at elevated temperatures, no adjustments were needed to extrapolate the data 
to lower temperatures such as 4 °C. However, as expected, the extrapolation of  
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Figure 5. Arrhenius plots and extrapolations of accelerated monomer loss data to 
lower temperatures. A) Monomer loss kinetics at 4 °C; B) Arrhenius plot of the 
logarithm of k1 vs. the inverse temperature in kelvins (rate constant derived from 
double exponential fit) extrapolated to 45 and 4 °C long-term data; C) Same as B) 
but excluding the k1 data point for 70 °C; D) same as B) except plotting the 
logarithm of k2 vs. inverse temperature in kelvins; E) Arrhenius plot of the 
logarithm of k vs. the inverse temperature in kelvins (rate constant derived from 
single exponential fit) extrapolated to 45 and 4 °C long-term data; F) VFT plot 
using a T0 of 200 °C to linearize the non-Arrhenius data from E) at high and low 
temperatures (excluding rate constant at 45 °C); G) VFT plot using a T0 of 110 °C 
to linearize data from E) including rate constant at 45 °C; H) VFT plot at 110 °C to 
linearize data from D)  
114 
 
accelerated data at elevated temperatures, did not accurately predict the rate 
constants at 4 °C using Arrhenius equation. Antibody aggregation is known to display 
non-Arrhenius behaviour [21]; in this case, the non-Arrhenius behaviour only became 
apparent when incorporating the data at 4 °C, making it difficult to use elevated 
temperatures as predictors of shelf-life. Several methods have been described in the 
literature to linearize non-Arrhenius data. Previously, the Vogel-Fulcher-Tammann 
(VFT) equation showed the most success in predicting mAb shelf-life at lower 
temperatures, when a T0 larger than the melting temperature of the mAb was used 
[24]. The VFT equation is described by the following equation when used to derive 
Arrhenius parameters:  
𝑘 = 𝐴𝑉𝐹𝑇𝑒
(
𝐵
𝑇−𝑇0
)
 
Whereby AVFT is the pre-exponential factor, B is the activation energy and T0 is the 
reference temperature. Although in this case we could not use VFT for prediction, we 
were able to derive a T0 that fit the entire range of data from 75 to 4 °C. As predicted, 
this T0 was greater than the Tm of trastuzumab (T0 = 110 °C). We also obtained a 
better linear fit of the rate constants using k2 values. In our case, more data points with 
a wider range of elevated temperatures were needed to observe the non-Arrhenius 
behaviour of trastuzumab aggregation more clearly and perform the prediction of the 
aggregation rate at lower temperatures. Nonetheless, we obtained an accurate 
reference temperature that allows prediction of shelf-life between a wide range of 
temperatures for this antibody formulation. With additional aggregation kinetic data 
from a large set of IgG1 antibodies, it may be possible to derive a relationship between 
the VFT reference temperature (T0) and the Tm of the antibody, which can be used to 
link accelerated data with long-term storage conditions and predict long-term stability. 
4. Conclusion 
 
Protein aggregation continues to be the main complication for the development of 
novel biologics such as mAbs; a stronger mechanistic understanding of this process 
is required to elucidate important parameters such as shelf-life, and drive 
manufacturing decisions to ensure the most aggregation-resistant candidates are 
developed. We thoroughly analysed the aggregation kinetics of trastuzumab in its 
original formulation to gain insight into the process of aggregation for therapeutic 
antibodies. Our findings strengthen our mechanistic understanding of this complex 
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process by connecting the different steps in the aggregation process through a simple 
protein aggregation model with insight into utilising the VFT function to determine 
important parameters such as shelf-life and connection of experimental results from 
accelerated studies to the long-term storage behaviour.  
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CHAPTER 6 
 
“Choline Ionic Liquid Enhances the Stability of 
Herceptin® (Trastuzumab)” 
Graphical abstract 
 
 
Chapter 6 was published as a communication article at Chemical 
Communications: 
Reslan, M., Vijayaraghavan R., Macfarlane D. R., Kayser, V. (2018). 
Choline ionic liquid enhances the stability of Herceptin® (trastuzumab). 
Chemical Communications, 54:10622-10625.  
Supplementary information was combined with the manuscript for the 
thesis chapter with other minor changes. 
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Short Abstract 
We investigated the effect of an emerging biocompatible ionic liquid, choline 
dihydrogen phosphate (CDHP), on the stability of high-concentration formulations of 
Herceptin® (trastuzumab). Our results show that CDHP significantly suppresses 
unfolding and aggregation of trastuzumab, demonstrating great promise as an additive 
in the development of stable therapeutic antibody formulations.   
1. Introduction 
 
Therapeutic monoclonal antibodies (mAbs) are an ever-growing class of biologics 
widely used in diagnostics and in the treatment of a variety of ailments including cancer 
and auto-immune diseases. Antibodies have been used in various formats including, 
as whole antibodies and fragments, linked to other drugs as an antibody-drug 
conjugate [1], or modified to form a bispecific antibody which binds to two targets [2, 
3].  Various novel antibody-based formulations are also in development, including 
nanobodies [4], nanoparticle formulations and more [2]. mAbs have dominated the list 
of top 10 best-selling drugs worldwide in the last decade, with more than 70 mAb 
products currently on the market and hundreds in the development pipeline [2, 5, 6]. 
Undoubtedly, mAbs are an extremely useful class of therapeutics; however, like other 
proteins, they pose several challenges for manufacturers during production, transport 
and storage, and patients who are administered these products.  
One of the most significant challenges with the development of antibody products is 
protein aggregation, which not only results in the loss of activity and therapeutic 
efficiency but can also cause undesired immunogenic reactions to patients 
administered these products [7, 8]. Generally, protein aggregation is addressed either 
via mutational studies [9-11] or using stabilizing excipients which are added to the 
formulation [12-14]. If the protein stability and aggregation still pose a problem, then 
the final product can be freeze-dried to further extend the shelf-life of the product [15, 
16]. Even though some antibody products have been developed as subcutaneous 
injections at high concentrations, there is still an urgent need for novel choices of 
stabilizing excipients to pave the way for the development of non-invasive drug 
delivery options, which are more convenient for patients and prolong the shelf-life of 
these products.  
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Ionic liquids (ILs) are a versatile class of compounds utilised in applications including 
electrochemistry [17], fuel production [18], bio-catalysis [19], analytics and 
biotechnology [20]. Put simply, ILs are ‘molten’ salts, typically having melting points 
below 100 °C, and possess several useful physicochemical properties determined by 
the combination of organic cation and anion [21]. These properties include, negligible 
vapor pressures, high thermal stabilities, high conductivities and non-flammability. ILs 
have been shown to influence the stability and activity of certain enzymes when added 
into the storage buffers or used as a solvent [22]. In particular, the choline family of 
ILs have exhibited protein-stabilizing effects in some cases. Some of the proteins that 
have been investigated using choline-ILs include cytochrome complex (cyt C) [23-25], 
-chymotrypsinogen (CT) [26], lysozyme [27-29] and more [30, 31]. Mondal et al., [32] 
showed that aqueous biphasic systems based on choline ILs were excellent platforms 
for purification of antibodies, partly due to keeping antibodies stable during extraction.  
Of several choline-ILs studied, choline dihydrogen phosphate (CDHP) appears to be 
the most suitable candidate for the stabilization of therapeutically important proteins 
such as mAbs, owing to its overall stabilizing potential and biocompatibility [33-35]. 
For instance, Foureau, et al. [36] found that recombinant human interleukin-2 (rHIL-2) 
had increased thermal stability with 12% CDHP and had no cytotoxicity in mouse 
melanoma and primary splenocytes at physiological concentrations of up to 80 mM. 
Additionally, Jagannath et al.[37] found that CDHP appears to reduce aggregation of 
capture probe antibodies.  
 We previously [38], showed that CDHP inhibits the fragmentation of an EGFR mAb 
and does not reduce antigen binding efficiency. Besides these few studies, research 
is lacking on the potential use of CDHP or other ILs for the stabilization of therapeutic 
mAbs and prevention of mAb aggregation. Hereby, we have studied the effect of 
CDHP on the stability of trastuzumab, a marketed therapeutic mAb used for the 
treatment of HER2+ breast cancer, as a model for IgG1 therapeutic mAbs and other 
antibody products. We are the first to assess the potential of CDHP to be used as an 
excipient for the stabilization of trastuzumab with and without other stabilizing 
excipients and determine its usefulness as a solvent or excipient for high concentration 
antibody formulations.  
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2. Materials and Methods 
 
2.1. Materials 
 
Herceptin® was obtained from Genentech (San Francisco, US) as freeze-dried 
powder containing (858.1 mg): 51.4% trastuzumab, 0.74% L-histidine, 1.15% L-
histidine hydrochloride monohydrate, 46.7% trehalose dihydrate and 0.01% 
polysorbate 20. Millex-GV syringe filter units (0.22 µm, PVDF, 33 mm, gamma 
sterilized, SLGV033RS), Amicon® centrifugal filters (Ultracell® 50,000 NMWL), di-
potassium hydrogen phosphate (EMPROVE® Ph Eur, BP, E 340 grade, 105101) and 
potassium dihydrogen phosphate (EMSURE® ISO grade, 104873) were purchased 
from Merck Millipore (MA, USA). All other reagents were obtained from Sigma Aldrich 
and used without further purification.  
2.2. Synthesis and characterization of choline dihydrogen phosphate (CDHP)  
 
CDHP was made by neutralization reaction involving 1 mole of choline hydroxide with 
1 mole of phosphoric acid as given in the literature[35]. Typically, 10 g of CDHP was 
made by slow addition of an aqueous solution (85%) of phosphoric acid (5.7g, 58 
mmoles) to 20% aqueous choline hydroxide solution (30.1g, 248 mmoles) in an ice 
bath. The contents were stirred for about 1 hour at room temperature and the mixture 
was roto-evaporated at reduced pressures to obtain crude CDHP. To the crude 
compound activated charcoal (approx. 1 g) was added, stirred with water and filtered. 
The filtrate was again evaporated to get pure white solid in 98% yield. The sample was 
characterized by Electrospray Mass spectrometry to reveal the presence of the cation 
and anion.   
Electrospray Mass spectroscopy analysis, (cone ±35V): CDHP, m/z (relative 
intensity, %): ES+, 103.9 (Me3N+CH2CH2OH, 100); ES–, 96.9 (H2PO4-, 100). The acid 
base stoichiometry was confirmed by determining the pH of a 0.1 M aqueous solution 
of the material. This was found to be in satisfactory agreement with a control aqueous 
sample (pH= 5.6). 
13C NMR (600 MHz, D2O) δ: 67.3 (CH2), 55.5 (CH2), 53.8 (3 x CH3) 
1H NMR (300.13 MHz in D20, δ, ppm relative to TMS): 3.16(s,9H), 3.49-3.46(m,2H), 
4.04-4.06(m, 2H). The choline OH proton and OH protons from dihydrogen phosphate 
appear to be exchanged with the solvent D2O peak at 4.67 ppm. 
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The purity of the synthesised CDHP was determined to be 99.5% (based on 1H NMR 
spectrum) and observed only tiny impurities at around 2.7ppm (to an extent of ~0.5 %). 
The peak integral shows 9 protons (for 3 methyl groups of choline cation), 2 protons 
for methylene groups (attached to Nitrogen atom) and another 2 protons for methylene 
groups (attached to oxygen atom).  
Elemental analysis (%), calculated: C 29.85, N 6.96, H 7.96; found: C 28.10, N 6.87, 
H 8.09. 
2.3. Formulation preparation 
 
Two sets of Herceptin® formulations were prepared: (1) 20 mg/mL antibody 
formulations containing no other excipients besides any added CDHP; and (2) 60 
mg/mL antibody formulations containing the excipients present in the Herceptin® 
formulation as provided by the manufacturer in the same antibody:excipient ratio, in 
addition to any added CDHP (Table 1). The formulations prepared were designed to 
test: 
1) The effect of CDHP alone on antibody stability, in addition to its effect in 
combination with excipients commonly used in marketed antibody products. 
This way, its compatibility and potential synergy with other stabilizing excipients 
can be tested.  
2) The effect of CDHP on antibody stability in formulations containing high 
antibody concentrations 
3) Whether the influence of CDHP on protein stability is related to the protein:ionic 
liquid ratio or the ionic liquid:solvent ratio, which would determine its practicality 
in more highly concentrated protein formulations. 
Buffer exchange and concentration of Herceptin® solutions was performed using 50 
kDa centrifugal filters to achieve the desired formulation. Due to the high viscosity of 
CDHP stock solutions concentrated Herceptin® solutions were diluted in CDHP to the 
desired antibody (20 mg/mL) and IL concentration to minimize unwanted aggregation.  
For 60 mg/mL formulations, the Herceptin® powder provided (containing the 
excipients listed in Materials section) was dissolved in water (control), a solution of 
53% w/v CDHP or 30% w/v CDHP such that the final concentration of trastuzumab 
was 60 mg/mL in each formulation and the antibody:excipient ratio was maintained. 
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Dissolution was achieved by keeping each formulation at 4 °C overnight with gentle 
pipetting to assist dissolution of all the powder. When necessary, sodium hydroxide 
and phosphoric acid were used to adjust solution pH to 6 for all formulations. Solutions 
were filtered using 0.22 µm syringe filter units then the UV absorbance at 280 nm was 
checked to confirm the concentration of trastuzumab in each formulation was 60 
mg/mL. All formulations were stored at 4 °C until needed.  
2.4. Accelerated aggregation studies at elevated temperature 
 
5 µL of each antibody formulation was pipetted into a 0.2 mL PCR vial and incubated 
at 68 °C in a Thermal Cycler (Applied Biosystems, CA, USA) for various durations to 
induce aggregation as previously described[39]. A thermal cycler was used to: 1) 
minimize sample amount; 2) prevent evaporation of the sample and consequent 
changes in antibody concentration during incubation (lid/cover of thermal cycler is 
heated above incubation temperature). Following incubation, incubated samples were 
removed and immediately stored on ice to halt aggregation and then characterized by 
size exclusion-high performance liquid chromatography (SE-HPLC). To investigate 
the nature of aggregates formed in the 60 mg/mL formulations, each of the 60 mg/ml 
formulations that were incubated at 68 °C were also kept for 20 hours at 4 °C after 
dilution, then monomer content was re-measured using SE-HPLC.  
2.5. SE-HPLC 
 
Table 1. Trastuzumab (TmAb) formulations prepared for this study 
Formulation [TmAb] mg/mL [CDHP] % 
w/v 
Buffer 
Control 20 0 15 mM potassium phosphate 
53% CDHP 20 53 
Water 
 
40% CDHP 20 40 
25% CDHP 20 25 
Control H 60 0 5.5 mM L-histidine, 6.4 mM L-
histidine HCL monohydrate, 
144 mM trehalose dihydrate 
and 0.001% w/v polysorbate 20 
53% CDHP H 60 53 
30% CDHP H 60 30 
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Size exclusion-high performance liquid chromatography (SE-HPLC) was used to 
quantify antibody monomer loss following incubation at 68 °C. Analysis was performed 
using an Agilent 1200 Liquid Chromatography system (Agilent Technologies, 
California, USA) with a Zorbax GF-250 column coupled to a guard column at 22 °C, 
using a 150 mM potassium phosphate mobile phase, at pH 6.5, and a flow rate of 0.5 
mL/min. The incubated 5 μL samples of each trastuzumab formulation were diluted to 
50 μL with mobile phase buffer prior to injection to prevent blockage of column with 
high amounts of protein. 10 μL of the diluted samples were then immediately injected 
and each injection was repeated three times. Stressed 60 mg/mL samples were re-
injected after 20 hours at 4 °C.  Monomer peaks were detected using an in-line UV 
signal detector set at 280 nm. The area under the curve (AUC) of the monomer peak 
was averaged over the three runs and the mean relative monomer % was calculated 
for each sample, by setting the monomer AUC of the unincubated samples as 100% 
and calculating the change in monomer AUC accordingly. The standard deviations 
(SD) were plotted as error bars in the figures.  
2.6. Trastuzumab melting temperature (Tm) and onset temperature of 
aggregation (Tagg) 
 
Intrinsic tryptophan fluorescence and static light scattering (SLS) techniques were 
used to calculate the Tm and Tagg respectively, of each formulation. A linear 
temperature ramp from 15 to 95 °C at 1 °C/min scan rate was performed whilst 
measuring tryptophan fluorescence and SLS simultaneously through laser excitation 
at 473 nm using UNcle (Unchained Labs, CA, USA). 8.5 µL of each formulation was 
pipetted undiluted into the UNcle UNI (a sample holding unit containing 16 quartz cells) 
in triplicates. A holding time was not used to maximise the frequency of measurements. 
Tm and Tagg were determined by the UNcle Analysis software, and in some cases 
manually, by using the first derivative (for Tm determination). The barycentric mean 
(BCM) was used to plot the Tm curves, which is defined by the following equation: 
𝜆𝐵𝐶𝑀 =
∑ 𝜆𝐼(𝜆)𝜆
∑ 𝐼(𝜆)𝜆
  
The equation is defined over the range 300-450 nm, whereby each wavelength value 
(λ) is multiplied by the tryptophan fluorescence intensity (I) at that wavelength, and the 
sum of that value for all wavelengths between 300 to 450 is divided by the sum of the 
intensities at those wavelengths. This results in an ‘averaged’ peak wavelength (λBCM) 
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for a given spectrum which eliminates noise and accommodates for changes in the 
shape of the spectrum. Since antibodies are multi-domain proteins, up to three Tms 
can be measured, corresponding to the CH2, Fab and CH3 domains. For trastuzumab 
only two Tms are usually distinguishable as the Fab and CH3 domain have 
approximately the same Tm, leading to overlap.  
2.7. UV-Vis spectroscopy  
 
UV-Vis spectroscopy was used to measure the concentration of soluble antibody after 
dissolution of powder to ensure complete dissolution and following incubation at 
elevated temperatures to confirm the lack of insoluble aggregates. Absorbance was 
measured at 280 nm over a wavelength range of 220-350 nm using a Shimadzu UV-
2600 spectrophotometer (Shimadzu, Japan). Samples were corrected by blank 
subtraction of the respective solvent. Data was not included as the absorbance of all 
samples remained unchanged following incubation, and therefore no change in 
soluble antibody concentration was observed.  
3. Results and discussion 
 
Our results demonstrated for the first time, that CDHP significantly suppresses the 
unfolding of trastuzumab by stabilizing the CH2, Fab and CH3 domains as 
demonstrated by the significant improvements in all Tms measured. The improvements 
in Tms are seen in both formulations of trastuzumab (20 and 60 mg/mL) with and 
without other stabilizing-excipients, suggesting that the effect is additive. The Tms of 
excipient-free trastuzumab measured in our study corresponds with literature values; 
DSC studies with separate Fab and Fc fragments of trastuzumab identified that the 
first transition corresponds to the unfolding of the CH2 domain, and the second 
transition is an overlap of the Fab and CH3 domain [40, 41]. In most excipient-free 
formulations containing CDHP, three distinct Tms are identified, whereas only two are 
determined in the control (Fig. 1A and B; table 2). This suggests that CDHP improves 
the stability of all regions of trastuzumab but either the Fab or the CH3 domain is 
stabilized more strongly than the other, leading to the separation of those two Tms. 
Interestingly, the stabilizing effect is proportional to the concentration of CDHP in the 
formulation, with higher concentrations (53% w/v) increasing the Tms the most. A 
similar trend is shown by [42] who found that CDHP had a destabilizing effect on 
lysozyme below 0.5 M and a stabilizing effect above this concentration. This protein 
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stabilizing effect has been attributed to the DHP anion inducing water restructuring 
around the protein [26]. Additionally, at higher concentrations each DHP anion may 
form strong interactions with many positively charged residues on the antibody surface 
forcing it into a more compact conformation and enhancing the antibody’s thermal 
stability [43].  
It is commonly believed that unfolding is a precursor to protein aggregation, and many 
models of protein aggregation kinetics incorporate unfolding as a crucial step in the 
protein aggregation pathway (see supplementary table by Kayser, et al. [39] for a 
summary of commonly used kinetic models) Accordingly, it is expected that CDHP 
would also inhibit protein aggregation, as it significantly suppresses trastuzumab 
unfolding. Indeed, we observed that in the presence of CDHP the Tagg of trastuzumab 
was also significantly increased in a concentration-dependant trend, demonstrating a 
strong inhibition of aggregation in formulations containing CDHP; however, Tagg is 
based on light scattering signals and therefore may only detect the formation of 
Figure 1. Representative Tm and Tagg curves of trastuzumab formulations (20 
mg/mL) with and without CDHP. (A) The change in Trp BCM wavelength throughout 
the temperature ramp; (B) the 1st derivative of data in (A) showing the Tms of each 
formulation at the peaks; (C) Changes in SLS counts at 473 nm throughout the 
temperature ramp showing the Tagg of each formulation 
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insoluble aggregates (precipitates) which form in the late stages of antibody 
aggregation.  
To reach a more complete understanding of the entire aggregation process, we 
measured the formation of soluble aggregates that typically form during storage or 
manufacturing through accelerated studies at 68 °C. This was achieved through short 
incubation times to limit the degree of aggregation. From these results, we identified 
that there is a strong initial suppression of aggregation (first ~10% of monomer loss) 
in formulations containing 53% CDHP at both concentrations of trastuzumab (Fig. 2 
and 3). Interestingly however, monomer loss proceeds faster in CDHP formulations 
after this initial stage of antibody aggregation. The reversibility data of these 
aggregates provides valuable insight into the protein aggregation process in CDHP. 
After storing the stressed/incubated samples at 4 °C for 20 hours, we observed a 
significant recovery of monomeric species for formulations containing 53% CDHP, 
especially for the 90-minute-stressed samples which had significantly lower monomer 
content than the control (Fig. 3). The recovery is so significant that the final monomer 
content of these formulations is higher than the control after incubation at 4 °C. 
 
Figure 2. Mean relative monomer loss % of the 20 mg/mL trastuzumab formulations 
following incubation at 68 °C for 5, 10 and 30 minutes. Time point ‘zero’ is 100% 
monomer. The error bars represent the SD. 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
This demonstrates that the significant monomer loss observed in CDHP formulations 
after the initial ~10% aggregation which occurs at 90 minutes of incubation is 
predominantly due to the formation of reversible species, which revert to monomers 
over time.  We propose the following simplified model of trastuzumab aggregation:  
𝑀 ↔  𝑈 ↔ 𝑟𝐴 → 𝑝𝐴 
               ↓ 
𝑖𝐴 → 𝑝𝐴 
Whereby M = monomer; U = partially unfolded monomer; rA = reversible small 
aggregates; iA = irreversible soluble aggregates; pA = irreversible insoluble 
aggregates (precipitates). Thus, in summary CDHP: 
1) Suppresses trastuzumab unfolding (suppresses MU reaction) 
especially at 53% CDHP 
2) At 53% w/v: promotes reversible aggregation (promotes UrA) and 
suppresses irreversible soluble aggregation (suppresses UiA)  
At 30% w/v: promotes both reversible and irreversible soluble 
aggregation (UrA and iA) 
Table 2. The Tm and Tagg values of the 20 mg/mL trastuzumab formulations 
Formulation Tm1 Tm2 Tm3 Tagg @473 nm 
Control 70.5 ± 0.4 - 82.2 ± 0.3 79 ± 0.5 
53% CDHP 76.1 ± 0.4 86.6 ± 1.4 92 ± 0.3 89.4 ± 0.3 
40% CDHP 73.7 ± 0.6 85.1 ± 0.4 89.9 ± 0.4 86.9 ± 0.5 
25% CDHP 70.6 ± 0.4 - 85.8 ± 0.3 81.3 ± 0.2 
 
Table 3. The Tm and Tagg values of the 60 mg/mL trastuzumab formulations 
Formulation 
(60 mg/mL) 
Tm1 Tm2 Tm3 Tagg @473 nm 
Control H 72.9 ± 0.2 - 88.2 ± 0.9 81.2 ± 1.5 
53% CDHP H - - 94.0± 0.5 90.3 ± 0.1 
30% CDHP H 77.8 ± 1.4 - 89.7 ± 0.2 83.5 ± 0.1 
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3) Inhibits formation of insoluble aggregates (suppresses rA/iApA) 
especially at 53% CDHP 
 
At low [CDHP] unfolding is not as strongly suppressed, and irreversible 
aggregation dominates, thus, we observe significant monomer loss and minimal 
reversibility. While at 53% CDHP, both unfolding and irreversible aggregation 
are significantly suppressed, resulting in reduced monomer loss. Reversible 
aggregation dominates at later stages of aggregation. 
It is generally accepted that therapeutic antibody formulations must not exceed >5% 
aggregates to minimize the risk of immunogenicity [44, 45]. At 53% w/v, CDHP acts 
as a strong stabilizer against aggregation in the initial stages of monomer loss up to 
~90% relative monomer %. Even if the formation of reversible aggregates after this 
stage is undesirable, the strong suppression of aggregation up to ~10% is extremely 
useful in the context of developing safe therapeutic antibody formulations. 
Figure 3. Mean relative monomer loss of the 60 mg/mL trastuzumab formulations 
following incubation at 68 °C for 10, 30 and 90 minutes. Time point ‘zero’ is 100% 
monomer. ‘post-20h’ are the stressed samples re-measured after 20 hours at 
4 °C. The error bars represent the SD. 
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The fact that the trends observed are consistent in both the 20 mg/mL (excipient-free) 
and 60 mg/mL formulations illustrates that: 
1) Stability is based on ionic liquid:solvent ratio rather than protein:ionic liquid ratio  
2) The effects observed are due to CDHP and not other excipients only  
3) The stabilizing effect of CDHP is maintained when combined with other 
stabilizing excipients and may be strategically incorporated in a formulation to 
enhance formulation stability further, even for relatively stable antibodies such 
as trastuzumab 
4) CDHP can be used to stabilize antibodies against aggregation at high antibody 
concentrations 
 
4. Conclusion 
 
Ionic liquids have emerged as versatile solvents and additives in a wide range of 
applications and industries spanning organic chemistry and biotechnology. Amongst 
the many applications within the biotechnology industry, is the use of ILs for protein 
stabilization, whereby CDHP has emerged as one of the most promising biocompatible 
ILs for the stabilization of biopharmaceuticals. We have demonstrated for the first time 
that CDHP can be used to stabilize trastuzumab in high concentrations and in 
combination with other excipients, against unfolding and irreversible aggregation. Our 
results pave the way for utilising ILs such as CDHP as stabilizing additives in much 
needed rationally engineered formulations of therapeutic mAbs.  
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Abstract 
Ensuring the successful production of a therapeutic antibody begins early on in the 
development process. The first stage is vector expression of the antibody genes 
followed by stable transfection into a suitable cell line. The stable clones are subjected 
to screening in order to select those clones with desired production and growth 
characteristics. This is a critical albeit time-consuming step in the process. This 
protocol considers vector selection and sourcing of antibody sequences for the 
expression of a therapeutic antibody. The methods describe preparation of vector DNA 
for stable transfection of a suspension variant of human embryonic kidney 293 (HEK-
293) cell line, using polyethylenimine (PEI). The cells are transfected as adherent cells 
in serum-containing media to maximize transfection efficiency, and afterwards 
adapted to serum-free conditions. Large scale production, setup as batch overgrow 
cultures is used to yield antibody protein that is purified by affinity chromatography 
using an automated fast protein liquid chromatography (FPLC) instrument. The 
antibody yields produced by this method can provide sufficient protein to begin initial 
characterization of the antibody. This may include in vitro assay development or 
physicochemical characterization to aid in the time-consuming task of clonal screening 
for lead candidates. This method can be transferable to the development of an 
expression system for the production of biosimilar antibodies.  
I. Introduction 
 
The success of therapeutic antibodies continues to drive substantial investment into 
antibody development as a wave of next generation therapeutics begins. The antibody 
market is expected to be reshaped by antibody fragments [1], antibody-drug 
conjugates [2], bispecific antibodies [3] and engineered antibodies with favorable 
properties [4]. Another class gaining pharmaceutical interest are biosimilars. Biosimilar 
antibodies are ‘highly similar’ replicate products of a therapeutic antibody that has 
already received regulatory approval. A proposed biosimilar must be comparable with 
the originator antibody with respect to its structure, function, animal toxicity, clinical 
safety and effectiveness, human pharmacokinetics (PK), pharmacodynamics (PD) 
and immunogenicity [5, 6].  
The approval rates of biosimilar antibodies have been slow due to the strict constraints 
on the final quality of the product. The exact manufacturing processes such as specific 
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cell lines and culturing conditions through to the final processing steps can remain 
proprietary. What is more, the manufacturing of antibodies inherently involves a 
degree of variability which can add to the challenge of producing a highly similar 
product. A comprehensive physiochemical and biophysical characterization and 
comparison is quite difficult, yet a number of studies demonstrating the characteristics 
of biosimilar antibodies are emerging in the literature [7-9].  
Generating a therapeutic antibody begins with transfection of mammalian host cells 
with a vector carrying the genes for the respective antibody. Vector design, cell line 
and culture conditions are key considerations for setting up the expression system.  
The DNA sequences of antibodies can be sourced from Drug Bank 
(www.drugbank.ca), IMGT (www.igmt.org) or research publications including patents. 
For example, the sequence of trastuzumab is available through Drug Bank (DB ID: 
DB00072). The amino acid sequence of the variable regions can undergo gene design 
and optimization for synthesis in the desired host species. It is important for a 
biosimilar antibody that no modification is made to the amino acid sequence. Once 
synthesized, antibody genes can be subcloned into the appropriate vector of choice.  
Human IgG antibodies consist of two identical heavy chains and two identical light 
chains. Tightly regulated expression of both chains is essential for optimal production 
of heterologous IgG protein in mammalian cells [10]. Intra- as well as inter-chain 
disulfide bonds have to be formed and a number of post-translational modifications 
have to be introduced during protein biosynthesis. A number of vectors are available 
that have been designed specifically to express antibody genes (refer to Table S1 in 
supplementary information). These antibody-specific vectors usually express the 
constant regions for both heavy and light chains so only the variable regions of each 
chain require cloning.  
Transfection of cells with two independent constructs (co-transfection) is the most 
common approach for delivering heavy and light chain-encoding genes. That is, each 
gene is driven by its own promoter and transcribed as separate antibody chains before 
being assembled in the endoplasmic reticulum. On the other hand, multi-cistronic 
vectors have internal ribosome entry site (IRES) elements incorporated that allow 
expression of multiple genes as a single mRNA transcript with translation permitted 
from internal regions of the mRNA [11]. In this instance, the heavy and light chain-
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encoding genes are coupled in an arrangement to achieve co-expression of both 
antibody chains [10, 12]. 
While transiently transfected cells yield sufficient protein to perform a limited number 
of experiments, stably transfected cell lines that have undergone selection for genome 
integration can deliver higher yields. Higher protein amounts allow for assay 
development relating to in vitro characterization and can provide an indication of 
antibody quality in consideration for downstream applications such as clonal cell line 
and lead candidate selection. 
The goal of this article is to describe the stable expression and purification of a 
therapeutic antibody produced in a mammalian expression system. Indeed, this 
method can be applied to the expression of a biosimilar antibody. The method can be 
used for the initial characterization of antibodies before proceeding on to the critical, 
albeit time-consuming steps of identifying a desirable clone for larger scale 
manufacturing. Moreover, this method can be used to express other proteins and not 
just antibodies. 
The following detailed protocol describes the expression of therapeutic antibody 
trastuzumab. This consists of preparation of vector DNA followed by stable 
transfection in HEK-293 cell line and purification of antibody protein by an automated 
chromatographic method.  
II. Protocol 
 
Note: A suitable mammalian expression vector must be used for this protocol. Here, a 
single construct containing two expression cassettes is used (i.e. heavy and light chain 
expression is driven by separate promoters). Trastuzumab heavy and light chains 
were previously cloned into the vector. This vector was a gift from Andrew Beavil, 
obtained through a not-for-profit plasmid repository [13].  
1. Recovery and Scale-up of Vector DNA 
 
Note: Vector DNA was received as a soft agar stab culture in Escherichia coli XL-1 
Blue strain; vector carries hygromycin resistance. 
1.1. Insert a sterile inoculation stab or loop into the soft agar of the stab culture then 
streak a Luria Bertani (LB) agar plate prepared with 75 µg/ml hygromycin for isolated 
colonies. Incubate the plate at 37 °C for 18-24 h. 
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1.2. Inoculate a single colony into 5 ml Terrific broth (TB) containing 75 µg/ml 
hygromycin. Incubate the culture at 37 °C for 18-24 h with 225 rpm shaking. 
1.3. Use the overnight culture to prepare a glycerol stock of vector DNA by gently 
mixing 800 µl of culture with 200 µl 80% glycerol in a cryovial and freeze at -80 °C.  
1.3.1. Add 100 μl of the overnight culture to 100 ml TB containing 75 µg/ml hygromycin 
in a baffled shaker flask (i.e. 1/1000 dilution). Incubate the culture at 37 °C for 18-24 
h with 225 rpm shaking.  
1.4. After overnight culture, extract and purify the DNA according to manufacturer’s 
instructions of midi/maxi preparation kit with the following exception; during the final 
step, elute or resuspend DNA with water (pH 7.0-8.5). 
1.5. Check concentration and purity of DNA by absorbance readings at 260 and 280 
nm then store DNA at -20 °C. 
Note: Optional (highly recommended): Sequence DNA using vector-specific primers 
to confirm identity. 
2. Stable Transfection of HEK-293 Cells 
 
a) PEI Transfection and clone selection 
 
2.1 Grow and maintain HEK-293 cells (suspension cells) according to standard 
protocols in serum-free media supplemented with 0.1% non-ionic surfactant in baffled 
flasks. Maintain at 2x105 cells/ml and subculture every fourth day. Culture cells at 
37 °C with 5% CO2 and 120 rpm rotation.  
Note: Cells should have been in culture for no less than 4 days and no more than 4 
weeks prior to transfection. HEK-293 cells grown as monolayers in serum-containing 
media can also be used for this procedure.  
2.2. On the day prior to transfection, seed HEK-293 cells at 3x105 cells/ml in wells of 
a 12-well plate in 2 ml of Dulbecco's Modified Eagle Media (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS). On the day of transfection, check 
that cells have reached 80-90% confluency 
2.3. Dilute DNA and polyethylenimine (PEI) separately in transfection media then mix 
together.  
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2.3.1. Dilute 1.25 µg vector DNA per well (15 µg for 12 wells) in 300 µl transfection 
media. Incubate at room temperature for 5 min. 
2.3.2. Dilute 2.5 µl of 1 mg/ml PEI solution (30 µl for 12 wells; i.e. 1:2 ratio of DNA to 
PEI) in 300 µl transfection media. Incubate at room temperature for 5 min.  
2.3.3. Add diluted DNA to diluted PEI, gently mix and incubate at room temperature 
for 15 min. 
2.4. Add 50 µl of DNA/PEI mixture dropwise to each well of the plate. Rock the plate 
gently to distribute the transfection mixture then place the plate at 37 °C, 5% CO2 for 
24 h. 
2.5. Add 50 µg/ml hygromycin B per well and return plate to 37 °C, 5% CO2 for 10 
days. 
Note: By Day 10, un-transfected cells will have died and detached from the surface of 
the plate, whereas stably-transfected cells will be viable and attached to the plate. 
b) Adaptation of stable clones to serum-free media  
 
2.6. Replace the media in wells with 1/4 volume serum-free media and 3/4 volume 
DMEM supplemented with 10% FBS (i.e. 0.5 ml serum-free media + 1.5 ml DMEM = 
7.5% final serum concentration) and incubate for 4 days. 
2.7. Replace the media in wells with 1/2 volume serum-free media and 1/2 volume 
DMEM supplemented with 10% FBS (i.e. 1 ml serum-free media + 1 ml DMEM = 5% 
final serum concentration) and incubate for 4 days. 
2.8. Replace the media in wells with 3/4 volume serum-free media and 1/4 volume 
DMEM supplemented with 10% FBS (i.e. 1.5 ml serum-free media + 0.5 ml DMEM = 
2.5% final serum concentration) and incubate for 4 days. 
2.9. Replace the media in wells with 2 ml of serum-free media supplemented with 0.1% 
non-ionic surfactant (i.e. 0% final serum concentration) and incubate for 4 days. 
Note: Maintain 50 µg/ml hygromycin B selective pressure on cells during serum-free 
adaptation. Cells adapted to serum-free media detach from the surface of wells and 
may cluster in suspension. Refer to step 2.1 for culture conditions with the additional 
supplement of 50 µg/ml hygromycin B. 
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2.10. Using a pipette, gently mix the suspension cultures in the 12-well plate and pool 
cells into a separate tube.  
2.10.1. Using a hemocytometer, enumerate pooled cells and seed in 30 ml serum-free 
media in a baffled flask at 2x105 cells/ml. Culture cells at 37 °C with 5% CO2 and 120 
rpm rotation. Subculture and expand every fourth day. 
2.11. Continue to expand culture size to required cell density to obtain 10 vials at 1x107 
cells/vial for cryopreservation in liquid nitrogen. Freeze the cells in serum-free media 
containing 10% dimethylsulfoxide (DMSO). 
Note: Conditioned media containing antibody can be harvested at each subculture to 
confirm protein production or used to optimize purification conditions. To harvest 
conditioned media and maintain cells for subculture, centrifuge the culture at 300 x g 
for 5 min then filter-sterilize supernatant through a 0.22 µm filter. Filtered supernatant 
may be kept at 4 oC for 1-2 weeks or -20 oC for longer term storage. 
3.  Large Scale Antibody Production from Batch Overgrow Culture 
 
Note: Antibody production can be followed on from step 2.11 where existing cells are 
expanded to the required cell density based on the batch overgrow culture volume to 
be setup. Otherwise, cells that have been thawed from cryopreservation begin at this 
stage once expanded to an appropriate cell density and volume. Various culture 
supplements may be used to optimize antibody production; the use of tryptone to 
increase antibody yield is demonstrated in this protocol.  
3.1. Seed cells at 2x105 cells/ml in 100 ml serum-free media in two baffled flasks (to 
compare antibody yields from un-supplemented and nutrient-supplemented cultures). 
Culture at 37 oC, 5% CO2 and 120 rpm. 
3.2. After 24 h, add tryptone to a final concentration of 0.5% to nutrient-supplemented 
culture. Equalize volume of un-supplemented culture with serum-free media.  
3.3. From day 8, perform cell counts of the cultures daily using a hemocytometer to 
monitor cell viability. Harvest the culture supernatants once cell viability is less than 
80%. 
143 
 
3.3.1. Harvest supernatant by centrifugation of the cultures at 3000 x g for 15 min then 
filter-sterilize the supernatant (containing antibody) through a 0.22 µm filter. Store the 
supernatants at 4 oC (short-term) or freeze at -20 oC (long-term).  
4. Antibody Purification by Affinity Chromatography Using an Automated Fast 
Protein Liquid Chromatography (FPLC) System  
 
Note: The following procedure can generally be applied to most automated systems. 
Purification can be performed at room temperature or at 4 °C (if FPLC system is kept 
in a cool room). A series of scouting tests can be performed to identify the optimal 
purification conditions including appropriate column matrix, binding buffer, elution 
buffer and pH to ensure maximum recovery of purified antibody from conditioned 
media (refer to Results section). The optimal conditions are dependent on the antibody 
or protein being purified. Purifications were performed on an automated FPLC system. 
Purifications were performed at room temperature using a 5 ml Protein A column. 
4.1. Prepare the following buffers using ultrapure water and adjust to the 
recommended pH then filter through a 0.22 µm filter. 
4.1.1. Prepare 1 L of phosphate buffered saline (PBS) pH 7.4 (binding buffer) by mixing 
the following: 0.14 M NaCl, 0.0027 M KCl, 0.01 M Na2HPO4 and 0.001 M KH2PO4. 
Adjust pH if necessary before filtering the buffer. 
4.1.2. Prepare 500 ml of 0.1 M glycine-HCl pH 2.7 (elution buffer). Adjust pH before 
filtering the buffer. 
4.1.3. Prepare 50 ml of 1 M Tris pH 9.0 (neutralization buffer).  
4.2. Ensure all system power and communication connections with computer are 
made. Devices should be visible in the software ‘System Control’ module. Ensure UV 
cell is set at 280 nm wavelength. Optional: Calibrate pH meter if connected and to be 
used. 
4.3. Immerse inlet tubes of A, B and sample pump in ultrapure water to wash the 
system. Purge the pumps with a syringe if there is air in the tubing or a suspicion of 
air in the system. Wash the system with water by manual operation via the system 
controller or via an automated method. Observe that pressure, conductivity, UV280 
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tracing and pH remain consistent and that the pressure limit for the column is not 
exceeded as per manufacturer’s specification.   
Note: Abnormalities may indicate air or blockage in the system that should be 
addressed before proceeding. 
4.4. In the system controller module, start the flowrate at 1 ml/min manually via pump 
A in either load (bypassing sample loop) or inject (through the sample loop) position 
to begin connecting the column. Disconnect system tubing at the column position inlet 
and remove the stopper connected to the column inlet.  
4.4.1. Allow water to flow from the system tubing dropwise on top of the column then 
attach the system tubing to the column. Having the column inlet and inlet fitting 
overflowing with drops of water ensures a connection free of air bubbles. 
4.5. Attach the column outlet at the downstream outlet and verify all fittings are tightly 
fastened. With the column now attached to the system, do not exceed limits for 
maximum pressure limit and flowrate as outlined in column specifications. 
4.6. Wash column with 5 column volumes (CV) of water. If necessary, continue column 
wash until UV280 tracing has stabilized. 
4.7. Immerse inlet tubes of A in Binding buffer, B in Elution buffer and sample pump in 
Binding buffer to equilibrate the system in correct buffers. Fill the inlet tubes with buffer 
using PumpWash by manual operation.  
4.8. In the ‘Method Editor’ module of the software, use the method wizard to setup an 
affinity chromatography method for the column that is intended to be used.  
Note: Automated FPLC systems come with methods pre-filled with the recommended 
settings (i.e. flowrate and pressure limit) and run steps based on the column 
(manufacturer, matrix and size) selected for purification.  
4.8.1. Use the following run steps for Protein A affinity chromatography: 
4.8.1.1 Equilibrate system with 5 CV of Binding buffer and collect flowthrough into 
waste container. 
4.8.1.2. Load sample onto the column (volume to be loaded is specified manually in 
the method) and collect flowthrough into a separate container. 
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4.8.1.3. Wash system with 5 CV of Binding buffer and collect flowthrough into a 
separate container.  
4.8.1.4. Elute column with 5 CV isocratic fractionation using Elution buffer and collect 
purified antibody sample as fractions by fraction collector. 
4.8.1.5. Equilibrate system with 5 CV of Binding buffer and collect flowthrough into 
waste container. 
4.9. Once the method has been setup, specify the volume of conditioned media to be 
applied to the column and save the method.  
Note: The specified volume in the method should be 5-10 ml less than the actual 
volume to avoid introduction of air during the sample run. The specified volume used 
in this protocol is 90-120 ml. 
4.10. Submerge the sample pump tubing into the vessel containing the conditioned 
media.  
4.11. Prepare a separate container to collect sample flowthrough via the specified 
outlet tubing.  
Note: It is important to collect the flowthrough in the case an error occurs during the 
run or the binding capacity of the column is exceeded requiring the flowthrough to be 
reapplied to the column or the purification repeated. 
4.12. Prepare collection tubes in the fraction collector. Add 100 µl of neutralization 
buffer per 1 ml fraction volume. The FPLC system will automatically elute the fractions 
into the collection tubes. 
4.13. In the ‘System Control’ module of the software, open the method to be run. 
Note: The method run is initiated in a series of pages that include checking the 
variables of the method, fraction collector setup and defining result file name and 
storage location.  
4.14. Click START to initiate the run. The run can be monitored in the ‘System Control’ 
module.  
4.15. At the completion of the purification run, check the resulting chromatogram in the 
‘Evaluation’ module in the system software. 
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4.16. Combine all protein-containing fractions into a separate tube, buffer exchange 
and concentrate in PBS using a centrifugal filter device with 30 kDa molecular weight 
cut off. Perform centrifugation steps according to manufacturer’s instructions. 
4.17. Measure antibody concentration using bicinchoninic acid assay (BCA) according 
to manufacturer’s instructions.  
4.18. If another purification run is to be performed, prime the sample pump tubing in 
Binding buffer and repeat steps 4.9-4.14. 
4.19. At the completion of purification runs, immerse inlet tubes of A, B and sample 
pump in ultrapure water and wash the system and column as performed in step 3. 
4.20. Submerge A, B and sample pump tubing in 20% ethanol and repeat wash 
procedure for storage of the system and column. 
4.21. Disconnect the column from the downstream outlet and replace column stopper, 
then disconnect column at the inlet and replace stopper, reconnect tubing to the 
system. Store the column at 4 °C. 
III. Representative results 
 
Stable production of trastuzumab by transfected HEK-293 cells was confirmed using 
bio-layer interferometry (BLI) as presented in Figure 1. An IgG standard curve was 
generated by measuring the binding rate between an IgG antibody standard and 
protein A biosensor (Fig. 1A). The crude supernatant sample was similarly measured, 
then its concentration interpolated from the standard curve (Fig. 1B). The supernatant 
concentration was measured to be approximately 25 µg/ml (sampled from 50 ml 
collected at subculture) two weeks after serum-free adaptation and prior to setting up 
cells for overgrow batch cultures. Supernatant collected at each subculture after 
serum-free adaptation was pooled and used to optimize purification conditions; 
scouting of binding and elution buffers was performed as shown in Figure 2. The steps 
of purification are depicted in Figure 2A based on UV280 signal. Once the Protein A 
column equilibrates, an increase in UV280 signal represents sample loading; this 
increase is due to supernatant flowthrough passing through the column (containing 
unbound proteins which absorb UV light at this wavelength), while antibodies have 
been captured by the column. Once the sample has finished loading, the UV280 signal 
returns to baseline as any remaining unbound proteins are washed away. Elution 
147 
 
occurs as pH decreases to the optimal pH to release the antibodies captured by the 
column, depicted by an increase in UV280 signal with eluted antibodies fractionated 
and collected by the fraction collector. Throughout the sample run, conductivity 
changes based on the salt concentration in the buffers whereas system pressure 
should remain relatively constant.  
Figure 1. Confirmation of protein production by stably transfected HEK-293 cells using 
bio-layer interferometry (BLI). (A) Standard curve was generated by measuring 
binding rate of IgG antibody standard to protein A biosensor over 120 seconds (grey) 
followed by crude supernatant sample of PEI-transfected trastuzumab (PEI-Tmab; 
black). (B) Concentration of antibody protein in crude supernatant (open black circle) 
was interpolated from standard curve (closed black circles) by plotting IgG antibody 
standard concentration versus binding rate. 
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Optimal elution, pH and buffer were scouted first (Fig. 2B); it was observed that 
antibody eluted more efficiently off the column at lower pH using either 0.1 M glycine 
HCl or citric acid. However, below pH 2.7 there was no further improvement in the 
elution profile. In addition, elution peaks with 0.1 M glycine HCl appeared less 
broadened when compared with 0.1 M citric acid at similar pH (Fig. 2B). Subsequently, 
0.1 M glycine-HCl pH 2.7 buffer was used to optimize binding buffer conditions (Fig. 
2A).  The effect of different binding buffers on elution was also compared (Fig. 2A). It 
was observed that PBS pH 7.4 and 20 mM sodium phosphate pH 7 had comparable 
elution profiles, while the addition of 3 M NaCl to sodium phosphate buffer (to enhance 
antibody binding to the column) was not favorable. Due to the ease of PBS buffer 
preparation, PBS pH 7.4 was selected as the binding buffer for future purifications.  
The purification chromatograms of batch overgrow cultures are shown in Figure 3; 
tryptone-supplemented culture is compared to un-supplemented culture. It was noted 
that the addition of tryptone to the supplemented culture resulted in an increased 
UV280 signal during the sample loading step, compared to the un-supplemented 
culture. The tryptone-supplemented culture yielded 3.8 mg and the un-supplemented 
culture 1.7 mg of trastuzumab, based on protein recovered after buffer exchange and 
concentration. Quality control of the purified antibody was confirmed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 4). 
Trastuzumab grown in un-supplemented and tryptone-supplemented conditions 
results in similar antibody profiles under non-reducing and reducing conditions. As 
expected, a prominent band at approximately 150 kDa confirms correctly folded 
antibody; other bands represent fragmented forms of the antibody, a result of disulfide 
bond breakage and a method-induced artefact. Likewise, two bands at 50 and 
approximately 25 kDa confirm the presence of antibody heavy and light chains, 
respectively. 
IV. Discussion 
 
This protocol details the transfection, stable expression and purification of a 
therapeutic antibody in HEK-293 cells. Stable expression of antibody genes is the first 
step in generating an antibody-producing cell line for the development and 
manufacture of a therapeutic antibody. While Chinese hamster ovary (CHO) cells 
remain the expression platform of choice for therapeutic proteins, the HEK-293 cell 
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Figure 2. Purification chromatograms of elution and binding buffer scouting 
experiments. (A) The steps of purification are depicted according to UV280 signal 
(blue, green or black lines); sample loading onto the column followed by column 
wash to wash away unbound proteins then elution of bound protein from the column. 
Measurement of pH (red line), conductivity (brown line) and system pressure (grey 
line) is monitored throughout the run. Three buffers were tested for optimal binding of 
trastuzumab to the column and washing away of unbound protein to maximize 
elution yield. (B) 0.1 M glycine-HCl (pH 2.5-3.3) and 0.1 M citric acid (pH 2.5-3.5) 
buffers were tested for optimal elution of trastuzumab from protein A column. 
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line is gaining prominence with the realization that proteins produced in these cells are 
a closer match to naturally occurring human proteins, in terms of post-translational 
modifications and function [14, 15].  
Mammalian cell lines including CHO (e.g., CHO-DG44 and CHO-K1) as well as non-
immunoglobulin secreting murine B cell lines NS0 and SP2/0 are predominantly used 
in biopharmaceutical production.  Expression systems based on these cell lines are 
based on selection processes whereby high producing clones are induced and 
selected through incremental addition of a specific selective drug [16, 17].  The 
selection process for a stable clone can therefore be arduous and time-consuming.  In 
comparison to these existing methods, the HEK-293 cell line robustly transfects with 
high efficiency. The selection process is simplified and very easily adapts to serum-
free suspension culture, making it an ideal expression system for laboratory scale 
production of proteins [18]. 
Figure 3. Purification chromatograms of trastuzumab (TmAb) batch overgrow cultures 
grown with no supplement or supplemented with tryptone. Stably transfected HEK-
293 cells were setup at 2x105 cells/ml and cultured for 8 days either un-supplemented 
(120 ml; black line) or supplemented with 0.4% tryptone (90 ml; green line). After 
harvesting, supernatants were purified using PBS pH 7.4 (binding buffer) and 0.1 M 
glycine-HCl pH 2.7 (elution buffer). 
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A limitation of stable transfection is time in which a practical amount of protein can be 
produced and utilized in experiments.  To try and overcome this, the current protocol 
describes a culturing step that can achieve substantial amounts of protein within 3-6 
weeks of transfection.  The batch overgrow cultures (large scale production) provide 
the opportunity to produce substantial amounts of antibody for the setup of in vitro 
characterization experiments in the lead up to selection of a clonal cell line and lead 
candidates. This has clear advantages over transient transfection, which can require 
higher amounts of DNA and reagents. In addition, the protein yield is not reproducible 
from batch to batch since expression is only temporary and determined by transfection 
efficiency.  
The addition of tryptone in this protocol provided an increased yield in protein 
expression. Addition of tryptone to transfection cultures has previously been shown to 
improve protein synthesis [19, 20]. The tryptone supplemented culture resulted in 
improved trastuzumab antibody yields of 40 mg/L versus the un-supplemented culture 
Figure 4. Analysis of purified trastuzumab by SDS-PAGE. Approximately 2 µg of 
trastuzumab purified from un-supplemented (-) or tryptone-supplemented (+) cultures 
was sampled by 10% SDS-PAGE under non-reduced or reduced conditions. The gel 
is stained with coomassie R-250.    
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of 14 mg/L (Fig. 3). SDS-PAGE verified that: (1) the antibody was being produced 
correctly; and (2) the addition of tryptone did not alter structure based on comparison 
of the antibody bands under non-reducing and reducing conditions (Fig. 4). The 
addition of tryptone to the cultures is optional and is particularly used to achieve higher 
protein yields. Other supplements have been considered to enhance protein 
expression such as sodium butyrate and valproic acid [21-23]. 
The first checkpoint of the protocol is the confirmation that protein is being produced 
by the transfected cell line. This step may be performed any time after the two-week 
period of selective pressure used to select stable transformants. A number of methods 
may be used to confirm protein production including bio-layer interferometry (Fig. 1) 
or the similar approach of an IgG ELISA. Alternatively, a western blot may be 
performed using an anti-IgG detection antibody to identify antibody protein in the crude 
supernatant or purified sample.  
Other researchers have shown that higher transfection efficiency is achieved using 
adherent cells in serum-containing media [24]. The presence of supplements from 
animal origin is undesirable for biopharmaceutical production. Therefore, the 
sequential adaptation to serum-free media is a critical step in the protocol requiring 
patience and careful monitoring of cell viability. The 4-day turnover period suggested 
in this protocol is a guide and so if problems are encountered at a certain serum 
concentration, it is recommended that the cells be subcultured 2-3 times in the 
previous ratio of serum-containing to serum-free media before continuing with the next 
ratio. Prior to setting up batch cultures and cryopreservation of cells, consider that 
most cell lines are deemed fully adapted after three subcultures in 100% serum-free 
media.  
One of the most crucial steps at the purification stage is the scouting for optimal 
conditions and buffers to ensure efficient binding of the antibody to the column and 
then complete elution off the column (Fig. 2). The conditioned media collected at each 
subculture is useful for this purpose. In this case, the elution buffer of citric acid pH 3.5 
generally recommended for protein A affinity chromatography was unsuitable for 
elution of trastuzumab from the column. The scouting experiment using two different 
elution buffers at various pH clearly showed that even within the narrow range of pH 
tested, the degree of elution was affected (Fig. 2B). 
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In terms of downstream processing of the antibody fractions after purification, the 
antibody can be buffer-exchanged using a desalting column either by manual or 
automated operation. Alternatively, dialysis membrane can also be used. Final protein 
concentration can be determined by other protein quantification methods including 
measurement of the absorbance signal at 280 nm with concentration deduced from 
Beer Lambert’s Law based on the extinction coefficient of the antibody.  
This protocol has successfully produced the antibody protein of trastuzumab by stable 
transfection of HEK-293 cells. The antibody was purified and characterized to confirm 
integrity. The steps in this protocol detailing DNA preparation, stable transfection 
followed by serum-free adaptation, large scale production and automated purification 
can be transferred to producing other proteins. 
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Abstract 
Monoclonal antibodies (mAbs) are of high value in the diagnostic and treatment of 
many debilitating diseases such as cancers, auto-immune disorders and infections. 
Unfortunately, protein aggregation is one of the ongoing challenges, limiting the 
development and application of mAbs as therapeutic products by decreasing half-life, 
increasing immunogenicity and reducing activity. We engineered an aggregation-
prone region of adalimumab, the top selling mAb product worldwide - with additional 
glycosylations to enhance its resistance to aggregation by steric hindrance as a next 
generation biologic. We found that the addition of N-glycans in the Fab domain 
significantly enhanced its conformational stability, with some variants increasing the 
melting temperature of the Fab domain by more than 6 °C. The mutations tested had 
minimal impact on antigen binding affinity, or affinity to Fcγ receptors responsible for 
effector function. Our findings highlight the significant utility of this rational engineering 
approach for enhancing the conformational stability of therapeutic mAbs and other 
next-generation antibody formats.  
1. Introduction 
 
Monoclonal antibodies (mAbs) are amongst the top-selling therapeutic prescription 
products worldwide. In 2017, Humira® (adalimumab) alone, generated over 18 billion 
US dollars, maintaining its position as the top-selling drug worldwide [1, 2]. mAbs are 
revolutionary biopharmaceuticals used to treat cancers, auto-immune and 
inflammatory conditions, and even some types of asthma. Approximately 80 antibody 
products have been approved and marketed by the FDA and EMA with hundreds more 
in early and advanced clinical trials [3]. Advances in antibody engineering technology 
have led to the development of a multitude of novel, next-generation antibody-derived 
products often termed biobetters, which include bispecifics, nanobodies, antibody-
drug conjugates, and nanoparticles functionalised with antibodies [3, 4].  
Despite the four-decade-long progress and ever-growing interest in antibody research, 
one of the major challenges in the development of antibody therapeutics remains 
unsolved: protein aggregation [4-7]. Protein aggregation is one of the most common 
form of antibody degradation, having significant implications for a therapeutic product 
under development; aggregation can result in reduced therapeutic efficacy, and may 
trigger severe immunogenic side effects when administered [8, 9]. Formulations of 
158 
 
biologics including mAbs and other protein products are stabilized with the use of 
additives such as salts, sugars, amino acids and surfactants [10-12]. Some novel 
formulation additives have also been investigated to inhibit protein aggregation, 
including deuterated solvents [13], hydrogels [14, 15], peptide dendrons [16] and ionic 
liquids [17]. However, the type and amount of additives allowed in any given 
formulation is limited, especially in parenteral formulations – which are often used to 
administer mAbs. Thus, other approaches to enhance the aggregation-resistance of 
mAbs are needed.  
Another approach to significantly enhance the stability of a mAb is to modify the 
antibody structure itself. A single amino acid mutation in an aggregation-prone region 
(APR) can be sufficient to significantly improve the stability of an antibody against 
aggregation and/or increase its melting temperature. Predictions of aggregation-prone 
regions are often aided by computational tools – these include TANGO, 
AGGRESCAN3D, SAP [18-20], docking studies and/or molecular dynamics 
simulations [21]. For instance, the spatial aggregation propensity (SAP) tool has 
previously been used to guide mutations of aggregation-prone motifs of rituximab. 
These motifs predicted by SAP were ‘neutralised’ by single-point mutations, and 
multiple mutations were then combined to increase the overall antibody stability [22].  
A variation of this approach, involves engineering an additional N-glycosylation site in 
a spatially proximate region to an APR, to sterically hinder aggregation in that APR 
[23, 24]. Naturally occurring N-linked glycans in the Fc domain are known to 
significantly influence antibody stability and effector function and to increase half-life 
in patient serum. The introduction of extra N-linked glycosylation sites in the Fab 
domain may not only improve resistance to aggregation, but also enhance solubility 
and conformational stability of the antibody, offering additional benefits to a single-
point mutation in a hydrophobic region.  
Courtois, et al. [23] recently tested a series of Fab-glycosylated bevacizumab variants 
and reported significant improvements in overall stability. Nakamura, et al. [24] also 
tested a glycan-introducing mutation in the Fab of adalimumab expressed in Pichia 
pastoris and found that it inhibited protease digestion and precipitation under pH stress. 
However, its impact on soluble aggregation of the full antibody is not clear. 
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In this study, we report on and discuss the stability of Fab-glycosylated adalimumab 
variants that have spatial proximity to a previously determined APR in the IgG1 CH1 
region of rituximab [22] and bevacizumab [23]. Specifically, the amino acid of the APR 
transposed to the adalimumab IgG1 peptide sequence is leucine 178. The substitution 
of this hydrophobic amino acid to lysine in bevacizumab [23], or to serine in rituximab 
[22] in the equivalent position, had experimentally demonstrated increased stability. 
This amino acid can also be substituted with asparagine (e.g. L178N) to introduce an 
N-linked glycosylation site. For this study, surface exposed amino acids were identified 
that can be substituted to asparagine to introduce N-linked glycosylation sites i.e. Asn-
X-Ser/Thr, where X is any amino acid except proline (Fig. 1). All substitutions except 
T199N, were previously identified to have 10 Angstrom spatial proximity to the APR of  
 
 
Table 1. Surface exposed amino acid (AA) residues identified in adalimumab Fab 
region for substitution 
AA 
Residue 
Position Region Mutation Proposed Function 
L 178 CH1 
K 
Remove APR by introducing polar 
amino acid [23] 
N 
Remove APR and introduce 
glycosylation site [23] 
Q 160 Ckappa 
Sterically hinder APR by introducing 
glycosylation site [23] 
L 116 
Cjoin 
T 118 
A 122 
CH1 
Improve solubility by introducing 
glycosylation site [25] 
Q 179 Sterically hinder APR by introducing 
glycosylation site [23, 25] L 183 
T 199 
Improve solubility and sterically hinder 
self-association by introducing 
glycosylation site [25, 26] 
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interest [22, 23]. T199N was specifically chosen as it had been reported to dramatically 
increase the solubility of a poorly soluble antibody [25], however it does not have 
spatial proximity to the APR. This particular substitution also has the potential to 
sterically hinder reversible self-association [26] which warranted further investigation 
through this study. The substitutions that were identified and pursued for this study are 
listed in Table 1.  
. 
In addition to studying the effect of these Fab N-linked glycosylations on the 
aggregation propensity of adalimumab, we also investigated the conformational 
stability of the variants, and characterised their binding affinity to TNF-, and Fcγ 
receptors (FcγRs) responsible for effector function, to understand the broader impact 
of these additional glycans.  
Figure 1. Crystal structure 3wd5 of adalimumab Fab fragment complexed to partial 
TNF- fragment. Adalimumab VH/CH1 (green), VL/CL (aqua), TNF- fragment 
(orange), APR site (purple) and surface exposed amino acids identified for 
substitution to an N-linked glycosylation site (pink). 
T199 
L178 L116 
T118 
A122 
Q179 
Q160 
L183 
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2. Materials and methods 
 
2.1. Materials 
 
Humira® subcutaneous injections (40 mg/0.8 mL) were purchased from Symbion (VIC, 
Australia) and used as a reference. Adalimumab (AdmAb) wild-type (WT) and mutant 
variants were expressed transiently in FreeStyle™ human embryonic kidney cells 
adapted for serum-free media (HEK293F). The expression vector gWiz (blank) was 
obtained from Genlantis (CA, USA) and vector pVITRO1-trastuzumab-IgG1/κ was a 
gift from Andrew Beavil (Addgene plasmid # 61883). Primers and synthetic AdmAb 
variable region gene constructs were purchased from Integrated DNA Technologies 
(Singapore). In-Fusion cloning kit was obtained from Scientifix (Australia). FreeStyle™ 
293 Expression Medium, OptiPRO™ Serum Free Medium (SFM) and HIS-tagged 
FcRγ1A receptor were purchased from Life Technologies Pty Ltd (VIC, Australia). 
Polyethylenimine (PEI), Linear, MW 25 kDa was purchased from BioScientific 
(Australia).  0.22 µm PVDF filters), 50 kDa centrifugal filters, trypsin and chymotrypsin 
were purchased from Sigma Aldrich (Australia). PCR kits and all other enzymes were 
purchased from GeneSearch (Australia). Phosphate Buffered Saline (PBS) was 
purchased from Astral Scientific Pty Ltd (NSW, Australia). HiTrap MabSelect SuRe 
column, Biacore CM5 and ProA chips, amine coupling kit and HIS capture kit were 
purchased from GE Healthcare (Australia). All other receptors, chemicals, 
consumables and reagents were obtained from Sigma Aldrich (Australia). 
2.2. Cloning and mutation of AdmAb WT and variants 
 
The blank gWiz expression vector was used to construct separate AdmAb IgG1 and 
kappa chain expression vectors. The secretion signalling genes, IgG1 and kappa 
chain genes were sourced from genes contained in pVITRO1_trastuzumab_IgG1/κ 
vector; they were cloned separately into the empty gWiz vector through conventional 
restriction cloning techniques. The variable regions of AdmAb genes were designed 
and synthetically produced; they were exchanged with the trastuzumab variable 
regions in the gWiz vectors through In-Fusion cloning to produce gWiz AdmAb IgG1 
and gWiz AdmAb kappa vectors.         
Mutations were then introduced to the gWiz AdmAb IgG1 and kappa vectors through 
high fidelity inverse PCR to produce a library of AdmAb mutant expression vectors. 
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AdmAb WT and mutant variants were confirmed through sequencing and expressed 
through transfection of vector pair combinations. 
2.3. Expression and Purification of AdmAb WT and variants  
AdmAb WT and mutants were transiently expressed in suspension HEK293F culture. 
HEK293F culture was maintained and transfected in Freestyle 293F media, 120 rpm, 
37 °C, 5% CO2, humidified incubation conditions. 24 hours prior to transfection, 
HEK293F culture was seeded to 6 - 7 x 105 cells/mL in a 60 mL culture and the culture 
was adjusted to 1 x 106 cells/mL on the day of transfection.  
The complexing DNA for transfection was prepared as 1 µg total DNA per 1 x 106 cells. 
The gWiz AdmAb IgG1 and kappa vectors were combined in a w/w ratio of 1:1, and 
the complexing w/w ratio of PEI to total DNA was 2:1. The vector DNA and PEI were 
separately diluted in OptiPRO SFM. The dilutions were combined and left to complex 
for 15 minutes before adding dropwise to the transfection culture.  
After 24-hour incubation of the transfection culture, the culture was scaled up to 
120 mL with Freestyle 293F media and supplemented to a total concentration of 0.5% 
Tryptone w/v. After a further 24 hours of incubation, the culture was scaled up to 
240 mL with Freestyle 293F media and supplemented to a total concentration of 0.5% 
Tryptone w/v. The transfection culture remained in incubation for a total of 8 days 
before the media containing secreted antibody was harvested by centrifugation, and 
the culture supernatant was clarified by filtration. 
AdmAb WT and variants were purified from the culture supernatants using protein A 
affinity with a 1mL HiTrap MabSelect SuRe column. PBS pH 7.4 was used as the 
binding and wash buffer, and glycine HCL pH 3 was used to elute bound antibody. 
Eluted antibody samples were neutralised in 1 M Tris-HCl pH 8 and concentrated to 
<1 mL using 50 kDa centrifugal filters. To purify the samples from any aggregates and 
obtain pure monomer samples, concentrated samples were fractioned using size-
exclusion chromatography (as per 2.6) and the monomer fractions were collected and 
concentrated in 150 mM potassium phosphate buffer, pH 6.5, for analysis.  
2.4. LC-MS/MS analysis of AdmAb variants 
Successful mutation and introduction of glycosylation motifs of the AdmAb variants 
was confirmed through site-specific liquid chromatography tandem mass spectrometry 
(LC-MS/MS). Briefly, AdmAb variants were separated on reducing SDS-PAGE and 
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digested with trypsin and chymotrypsin. A fraction of the digestions was further treated 
with PNGase F for glycan release. The digestion products were analysed by LC-
MS/MS using higher-energy collisional dissociation (HCD), collision induced 
dissociation (CID) and electron transfer dissociation (ETD) methods. 
The AdmAb variants (10 μg) were run on a reducing SDS-PAGE, in-gel trypsin 
digestion was performed on the heavy chain band (50 - 60 kDa) of variants L116N, 
T118N, A122N, L178K, L178N, Q179N, L183N, T199N and the light chain band (25 - 
30 kDa) of Q160N. The bands were excised, diced and washed with 50% (v/v) 
acetonitrile (MeCN) in 100 mM NH4HCO3. The gel pieces were then reduced with 10 
mM DTT at 56 °C for 45 min, followed by alkylation by addition of 55 mM 
iodoacetamide (IAA) in 100 mM NH4HCO3, and incubation at 25 °C for 30 minutes. 
The samples were subsequently washed with 50% (v/v) MeCN in 100 mM NH4HCO3. 
The alkylated polypeptides were incubated with trypsin (T6567) (1 μg trypsin per 50 μg 
antibody) in 50 mM NH4HCO3, pH 6.8 at 37 °C overnight. The resulting tryptic peptides 
were further digested with chymotrypsin (11418467001) in 100 mM Tris-HCl, 10 mM 
CaCl2, pH 7.8 at room temperature overnight.  
Glycan release was performed to confirm amino acid substitution; a fraction of the 
chymotryptic peptides (excluding L178K) was incubated with recombinant PNGase F 
(P0708S) (400 units per 1 μg of peptide) in 50 mM sodium phosphate buffer pH 7.5 at 
37 °C overnight. The chymotryptic peptides and the de-glycosylated fractions were 
desalted with C18 ZipTips (Millipore), eluted in 80% (v/v) MeCN, dried by vacuum 
centrifugation then redissolved in 0.1% formic acid (FA) for LC-MS/MS analysis. 
Glycopeptides and de-glycosylated peptides were separated on an in-house packed 
20 cm × 75 μm Reprosil-Pur C18AQ (3 μm, 120 A; Dr. Maisch GmbH) column using 
a Dionex 3500RS HPLC over a 90-minute 0-40% solvent B gradient at a flow rate of 
300 nL/min, at 60°C (solvent A was 0.1% (v/v) formic acid; solvent B was 80% (v/v) 
acetonitrile and 0.1% formic acid). MS analysis was performed on an Orbitrap Fusion 
MS (Thermo Scientific) in positive mode. Instrument parameters were set up as 
follows: source voltage = 2.3 kV, S-lens RF level = 68%, and capillary temperature = 
275 °C. The initial MS scan was acquired in the Orbitrap mass analyzer (350–2000 
m/z; MS AGC = 6 × 105) with a resolution of 60,000 at 400 m/z. MS1 was followed by 
data-dependent HCD using top speed, where as many dependant scans as possible 
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are acquired in a specified time. HCD fragmentation was followed by re-isolation of 
the top two most intense precursors, and fragmentation with CID and ETD MS/MS. 
HCD parameters were as follows: activation time = 0.1 ms, resolution = 30,000, 
maximum injection time = 200 ms, dynamic exclusion = enabled with repeat count 1, 
normalized energy = 40, exclusion duration = 20 s, default charge state = 2, and MSn 
AGC 2.0e5. CID parameters were as follows: 30,000 resolution in orbitrap, activation 
time = 10 ms, max injection time = 300 ms, dynamic exclusion = enabled with repeat 
count 1, normalized energy = 35, exclusion duration = 20 s, default charge state = 2, 
and MSn AGC 5.0e4. ETD parameters were as follows: 30,000 resolution in orbitrap, 
5.0e4 AGC, ETD reaction time = 50 ms, Max injection time = 300 ms. 
The peptide spectrum matches (PSM) were generated through a search against the 
corresponding fasta file (wild-type or variant Adalimumab amino acid sequence) 
utilising the search engine Byonic (Protein Metrics Inc.). Annotation of the HCD and 
ETD spectra were automated through Byonic and the PSM assignments were 
validated by manually annotating the aforementioned spectra and the complementary 
CID spectrum. Further confirmation of the identity assignment was achieved through 
analysis of the de-glycosylated chymotryptic peptides utilising the same LC-MS/MS 
approach as for the glycosylated fraction. 
2.5. Accelerated stability at elevated temperatures 
We performed accelerated studies at an elevated temperature as previously described 
[7]. Briefly, 20 µL of each AdmAb variant (1 mg/mL) was pipetted into a 0.2 mL PCR 
vial and incubated at 65 °C for 1, 2 or 3 hours in a Thermal Cycler (Applied Biosystems, 
CA, USA) to induce aggregation. Each experiment was repeated three times. A 
thermal cycler was used to minimize sample amount and prevent evaporation of the 
sample and consequent changes in antibody concentration during incubation 
(lid/cover of thermal cycler is heated above incubation temperature). Following 
incubation, incubated samples were removed and immediately stored on ice to halt 
aggregation and then characterized by size exclusion-high performance liquid 
chromatography (SE-HPLC).  
2.6. SE-HPLC analysis of monomer loss 
Size exclusion-high performance liquid chromatography (SE-HPLC) was used to 
quantify AdmAb monomer loss following incubation at elevated temperature as 
165 
 
previously described [7]. Analysis was performed using an Agilent 1200 Liquid 
Chromatography system (Agilent Technologies, California, USA) with a Zorbax GF-
250 column coupled to a guard column at 22 °C, using a 150 mM potassium phosphate 
pH 6.5 mobile phase, and a flow rate of 0.5 mL/min. 5 μL of each incubated sample 
was then immediately injected and each injection was repeated three times. Monomer 
peaks were detected using an in-line UV signal detector set at 280 nm. The area under 
the curve (AUC) of the monomer peak was averaged over the three runs and the mean 
relative monomer % was calculated for each sample, by setting the monomer AUC of 
the non-incubated samples as 100% and calculating the change in monomer AUC 
accordingly. The standard deviations (SD) were plotted as error bars in the figures. 
2.7. AdmAb melting temperature (Tm) and onset temperature of aggregation 
(Tagg) 
The Tm and Tagg of Humira®, AdmAb WT, and variants were simultaneously measured 
using intrinsic tryptophan fluorescence and static light scattering (SLS), respectively, 
on the UNcle system (Unchained Labs, CA, USA). A linear temperature ramp from 15 
to 95 °C at a 1 °C/min scan rate was performed whilst measuring tryptophan 
fluorescence and SLS simultaneously through laser excitation at 266 nm. 8.5 µL of 
each AdmAb sample (1 mg/mL) was pipetted undiluted into the UNcle UNI (a sample 
holding unit containing 16 quartz cells) in triplicates. A holding time was not used to 
maximise the frequency of measurements. Tm and Tagg were determined by the UNcle 
Analysis software. The barycentric mean (BCM) was used to plot the Tm curves, which 
is defined by the following equation: 
𝜆𝐵𝐶𝑀 =
∑ 𝜆𝐼(𝜆)𝜆
∑ 𝐼(𝜆)𝜆
 
The equation is defined over the range 300-450 nm; each wavelength value (λ) is 
multiplied by the tryptophan fluorescence intensity (I) at that wavelength, and the sum 
of that value for all wavelengths between 300-450 is divided by the sum of the 
intensities at those wavelengths. This results in an ‘averaged’ peak wavelength (λBCM) 
for a given spectrum.  
2.8. Binding kinetics (KD) to TNFα and Fcγ receptors (FcγRs) 
The binding kinetics of Humira®, AdmAb WT and variants were assessed to TNF- 
and FcγR1A, 2B and 3A through surface plasmon resonance (SPR) to confirm that the 
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mutations did not contribute to a loss of biological function. Briefly, a Biacore T200 
system (GE Healthcare, Australia) was used, running single cycle kinetic assays. 
Monomeric AdmAb samples were captured on a ProA chip and increasing dilutions of 
TNF- were injected, with a 60-minute dissociation. HIS-tagged FcγR1A, 2B and 3A 
were captured on an anti-HIS chip and increasing dilutions of monomeric AdmAb 
samples were injected, with a 30-minute dissociation. The sensograms were analysed 
to determine association (Ka), dissociation (Kd) and equilibrium binding constants (KD). 
All runs were performed at 25 °C with running buffer HBS-T (10 mM HEPES, 150 mM 
NaCl, 0.05% v/v Tween 20, pH adjusted to 7.4).  
Soluble homotrimeric TNF- (H8916) was assayed against monomeric AdmAb 
samples on a ProA chip under continuous flow rate of 20 µL/min. Monomeric AdmAb 
samples were prepared to 10 nM and captured on the sensor chip surface with a 
contact time of 10 seconds. TNF- was injected in 2-fold increasing concentrations 
(2.5 – 40 nM) with a contact time of 120 seconds at each concentration, then a 
dissociation time of 60 minutes. The chip surface was regenerated with 50 mM NaOH 
for 30 seconds at a flow rate of 30 µL / min.  
Monomeric AdmAb samples were assayed against HIS tagged FcRγ receptors. Anti-
HIS antibody was covalently attached to a CM5 biosensor chip using an amine 
coupling kit and HIS capture kit. HIS tagged FcγR1A (10256H08H), FcγR2B 
(SRP6396) and FcγR3A (SRP6436) were prepared to 4 nM and captured to the sensor 
chip surface with a contact time of 300 seconds at 5 µL/min flow rate. AdmAb samples 
were injected on FcγR1A coated surface in 2-fold increasing concentrations (2.5 – 40 
nM) at a flow rate of 20 µL/min with a contact time of 120 seconds at each 
concentration, followed by 30-minute dissociation time. AdmAb samples were injected 
on FcγR2B and FcγR3A-coated surfaces in 2-fold increasing concentrations (25 – 400 
nM unless otherwise stated) at a flow rate of 10 µL/min with a contact time of 120 
seconds at each concentration, followed by 1800 second dissociation time. The chip 
surface was regenerated with 10 mM Glycine HCl, pH 1.5 for 60 seconds at a flow rate 
of 30 µL/min.  
The sensograms were analysed globally using a Langmuir 1:1 binding model to 
determine Ka, Kd and KD. All samples were conducted in duplicate to obtain average 
values and standard deviation. Kinetic rate and binding constants determined from 
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sensograms were accepted if the goodness of fit value (χ2) was within 5% of the 
maximum response level (Rmax) of the sensograms and KD was calculated as Kd/Ka. 
3. Results 
3.1. Confirmation of mutation and glycan attachment through LC-MS/MS 
Detailed analysis of LC-MSMS data confirmed that all AdmAb variants had successful 
amino acid substitution. Incorporation of HCD, ETD and CID fragmentation techniques 
further provided compositional glycan information of the new N-glycosylation sites. 
Except for Q160N mutant, all other AdmAb glycosylation-site variants were found to 
contain an N-glycan (data not shown). 
Here, we show the characterization of glycan site-engineered AdmAb variant T199N 
as a representation of the analysis performed for all AdmAb variants.  
Figure 2. (A) HCD, (B) ETD and (C) CID spectra of chymotryptic T199N glycopeptide 
observed at m/z 909.65 (4+). Peptide sequence SLSSVVTVPSSSLGNQTY and 
attached complex type N-glycan HexNAc5Hex4Fuc1 are shown. Blue square; N-
acetylglucosamine, red triangle; fucose, green circle; mannose, yellow circle; 
galactose, Hex; hexose, HexNAc; N-acetylhexosamine, M; precursor ion. 
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HCD spectrum of SLSSVVTVPSSSLGNQTY peptide observed at m/z 909.65(4+) 
showed b- and y-ion series confirming amino acid sequence and the asparagine 
substitution was shown specifically by y4-y11 fragment ions (Fig. 2A). HCD of T199N 
mutant also contained diagnostic HexNAc (m/z 204.09) and HexNAcHex (m/z 366.14) 
oxonium ions, strongly indicating glycosylation on the mutant peptide (Fig. 2FigureA). 
ETD further confirmed the structure of T199N glycopeptide by multiple fragment ions 
corresponding to dissociated peptide backbone with intact glycan (Figure 2B, c-15, c-
16, c-17 and z-16 ions). Theoretical monosaccharide composition of the N-glycan was 
derived using Byonic (Protein Metrics) search results and GlycoMod 
(https://web.expasy.org). CID data in Figure 2C shows sequential loss of 
monosaccharides from glycopeptide fragments of T199N mutant and contains 
complementary oxonium ions m/z 366.14, m/z 528.19, and m/z 569.22 of the observed 
glycan in the low mass region. Extensive glycosidic bond cleavages (Fig. 2C, y-ions, 
m/z 1616.2(2+), m/z 1535.19(2+), m/z 1461.67(2+)) observed in CID confirmed that 
SLSSVVTVPSSSLGNQTY peptide is occupied by a complex type N-glycan with 
HexNAc5Hex4Fuc1 composition.  CID spectra of deglycosylated T199N peptide m/z 
609.64(3+) showed enhanced peptide backbone fragmentation and provided 
additional information for the expected mass shift from threonine to asparagine (y4-
y18 ions and b17 ion, Fig. 3). Same ion series also displayed deamidation (+1Da) of 
the new asparagine residue which is a characteristic result of PNGaseF treatment of 
a formerly N-glycosylated peptide. 
3.2. Monomer loss following accelerated studies at elevated temperature 
 
Incubation at 65 °C revealed modest differences in aggregation propensity between 
the reference Humira®, WT and single-mutant variants (Fig. 4). Variants L116N and 
T118N were completely degraded after an hour of incubation and were therefore not 
Figure 3. CID spectrum of de-glycosylated chymotryptic T199N mutant peptide 
SLSSVVTVPSSSLGNQTY observed at m/z 609.64(3+). b- and y- ions show CID 
fragments of the peptide. 
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included in the figure (Fig. 4). Variant Q160N had very similar monomer loss data at 
all incubation temperatures to the WT, while L183N had a noticeably higher monomer 
loss. Variants A122N, Q179N and T199N retained higher monomer content than the 
control at most incubation conditions, with A122N having the least monomer loss (Fig. 
4). While Q179N had comparable monomer loss after 1 hour, monomer loss was lower 
at 2 and 3 hours, when compared to the WT. Interestingly, variants L178N and L178K 
had comparable monomer loss profiles which were not significantly different to the WT 
(Fig. 4). Humira® reference had slightly lower monomer loss than the WT.  
3.3.  Tm and Tagg  
The WT AdmAb had a very similar Tm1 and Tm2 to the Humira® reference product; a 
slightly lower Tm1 was measured at 69.6 °C (WT) compared with 70.8 °C (Table 2). 
The Tm2 was comparable at 82 °C compared with 82.5 °C for Humira®. Variant Q160N 
had a similar melting profile to the WT, with an identical Tm1 and comparable Tm2 of 
69.6 and 82 °C, respectively. Variants T118N and L116N had a significantly lower Tm1 
at 59.7 and 63.6 °C, respectively; the Tm2 was also lower at 68 and 78.6 °C, 
respectively. Interestingly, a third Tm was recorded for variants T118N and L116N at 
87.8 and 88.3 °C, respectively. Variants L178K, A122N and Q179N had similar Tms 
Figure 4. Monomer loss of Humira®, AdmAb wild-type (WT) and variants following 
incubation at 65 °C for 1, 2 and 3 hours. Error bars represent the SD.  
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and were comparable to the WT. Variants T199N and L178N had similar Tm1 values 
to the WT (70.6 and 69.9 °C, respectively), but significantly higher Tm2 values (88.2 
and 89.3 °C, respectively). Variant L183N had a similar Tm1 to the WT, but had a 
consistent minor unfolding event at ~65 °C (not shown); Tm2 was higher than the WT 
(88.3 °C, Table 2). The Tagg of the WT and variants ranged from 70.6 to 72.5 °C, except 
for variants T118N and L116N, which had significantly lower Tagg values (61.7 and 
64.7 °C, respectively; Table 2). Most variants had a slightly higher Tagg than the WT 
(70.7 °C) by approximately 1-2 °C, while the Tagg of Q160N and L178K were 
unchanged. Compared with L178K, the Tagg of glycosylated variant L178N was 1.7 °C 
higher.  
 
3.4. Binding kinetics of AdmAb to TNF- and FcγRs 
The binding kinetics of reference Humira®, monomeric AdmAb WT and variants to 
TNF- and FcγR1A, 2B and 3A were assessed using SPR single cycle kinetic analysis. 
Samples were run in duplicate and sensograms were fitted to a Langmuir 1:1 binding 
model to obtain Ka, Kd and KD values for comparison as per previous studies [27, 28]. 
It was determined that in general, the majority of AdmAb variants did not experience 
a significant loss of biological activity.  
Table 2. The melting (Tm) and onset of aggregation temperatures (Tagg) of the 
AdmAb variants compared with the wild-type (WT) and reference Humira® product. 
^see discussion 
AdmAb Tm1 (°C) ± SD Tm2 (°C) Tm3 (°C) Tagg @266 nm 
Humira® 70.8 ± 0.2 82.5 ± 0.8 - 71.3 ± 0.4 
WT 69.6 ± 0.5 82 ± 1.4 - 70.7 ± 0.1 
Q160N 69.6 ± 0.3 81.1 ± 1.4 - 71 ± 0.4 
T199N 70.6 ± 0.2 88.2 ± 2.2 - 71.7 ± 0.1 
T118N 59.7 ± 0.5 68 ± 0.7 87.8 ± 2.5 61.7 ± 0.6 
L178K 68.4 ± 0.6 83.5 ± 0.5 - 70.6 ± 0.3 
L178N 69.9 ± 0.5 89.3 ± 0.2 - 72.3 ± 0.3 
A122N 69.7 ± 0.5 83.4 ± 0.7 - 71.8 ± 0.4 
Q179N 69.4 ± 0.2 82.7 ± 0.9 - 71.7 ± 0.5 
L118N 63.6 ± 0.5 78.6 ± 0.5 88.3 ± 1.2 64.7 ± 0.3 
L183N 70^ ± 0.5 88.3 ± 1.1 - 72.5  ± 0.7 
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The KD range determined for monomeric AdmAb variants binding to soluble 
homotrimeric TNF- spanned 36.69 – 110.27 pM, while Humira® had a mean KD of 
30.77 pM (Table 3). Monomeric AdmAb WT had a KD of 66.43 ± 2.37 pM which lies 
within the range, with no significant outlier (Table 3). Of all variants tested, T199N had 
the strongest KD to TNF- (36.69 pM) - approximately 1.8-fold stronger than the WT - 
while Q179N had the weakest KD (110.27 pM).  
The KD range determined for FcγR1A binding to monomeric AdmAb variants spanned 
2.1 – 6.81 nM, while Humira® had a mean KD of 1.84 nM (Table 4). Monomeric AdmAb 
WT had a KD of 4.4 ± 0.01 nM which lies within the range with no significant outlier 
(Table 4). Of all variants tested, the strongest KD was recorded for mutant T118N (2.1 
nM), while the weakest KD was recorded for L178N (6.81 nM).  
Due to sample limitations, monomeric AdmAb Q160N was not tested for the cycle 
assays against FcγR2B (Table 4).  
The KD range determined for FcγR2B binding to monomeric AdmAb variants spanned 
1.81 – 9.61 nM, while Humira® had a mean KD of 2.55 nM. Monomeric AdmAb WT 
had a KD of 4.47 ± 0.1 nM which lies within the range with no significant outlier (Table 
4). T199N had the strongest KD to FcγR2B (1.81 nM), while T118N had the weakest 
KD (9.61 nM). However, due to the large variation in KD values for the WT and several 
mutants, most differences were not deemed significant.  
The KD range determined for FcγR3A binding to monomeric AdmAb variants spanned 
1.48 – 18.01 nM, while Humira® had a mean KD of 1.84 nM. Monomeric AdmAb WT 
had a KD of 5.96 ± 1.62 nM which lies within the range with no significant outlier (Table 
4). The strongest KD was recorded for L183N (1.48 nM), while the weakest KD was 
recorded for A122N (18.01 nM) with large ranges. Overall, all differences in KD 
recorded compared to the WT, were no larger or smaller than 3-fold for TNF- and all 
receptors tested.  
4. Discussion 
 
We rationally designed and produced a library of glycan-engineered AdmAb variants 
to enhance stability through steric hindrance of an APR. Successful mutation and 
glycan addition was confirmed for all mutants aside from Q160N, through LC-MS/MS. 
Consequently, the stability and binding kinetics results for the Q160N variant are 
172 
 
directly related to the amino acid substitution alone. Since Q160N had similar stability 
and antigen binding affinity to the WT, it was concluded that the amino acid substitution 
did not have any significant impact on the antibody properties tested. The KD values 
for the AdmAb WT produced in our study (Table 3 and 4) are comparable to Humira® 
KD values observed, and as reported in the literature; TNF- (30-110 pM), FcγR1A 
(15-23 nM), FcγR2B (4.3-14.2 nM) and FcγR3A (5.8-7.9 nM) [29, 30]. 
 
Likewise, most measured KD values for the mutants tested lay within a close range 
to reported literature values for the reference AdmAb, showing that these mutations 
had minimal impact on binding properties.  
The highest improvement in resistance to aggregation was observed in mutant A122N 
with a slight increase in Tagg and reduction in monomer loss (Table 2 and Fig. 4). The 
A122N mutation resulted in 1.5-fold increased binding affinity to TNF- with slightly 
reduced binding to FcγRs tested and with no impact on conformational stability. 
Pepinsky, et al [25] reported that a mutation equivalent in position to AdmAb variant. 
A122N significantly improved the solubility of an anti-LINGO antibody, with no impact 
Table 3. Kinetics and binding affinity of reference (Humira®) and monomeric 
AdmAb mutants to soluble homotrimeric TNF-  (± SD). 
AdmAb 
TNF- 
Ka (x 105) M-1.s-1 Kd (x 10-5) s-1 KD (pM) 
Humira® 11.7 ± 0.01 3.59 ± 0.80 30.77 ± 6.83 
WT 6.08 ± 0.07 4.04 ± 0.10 66.43 ± 2.37 
L178K 4.84 ± 0.01 4.61 ± 0.64 95.33 ± 13.3 
L178N 5.33 ± 0.03 5.42 ± 0.67 101.7 ± 12.1 
Q160N 6.2 ± 0.07 2.86 ± 0.05 46.05 ± 1.31 
L116N 5.19 ± 0.09 2.84 ± 0.1 54.77 ± 2.87 
T118N 5.04 ± 0.02 3.59 ± 0.21 71.19 ± 4.50 
A122N 6.47 ± 0.03 2.87 ± 0.05 44.32 ± 0.57 
Q179N 5.02 ± 0.40 5.53 ± 0.1 110.3 ± 6.56      
L183N 5.58 ± 0.14 3.05 ± 0.03 55.37 ± 0.86 
T199N 7.15 ± 0.69 2.62 ± 0.01 36.69 ± 3.54 
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on binding affinity or conformational stability. Improvements in solubility often correlate 
with reduced precipitation and insoluble aggregate formation. 
This may explain the minor improvement in Tagg we observed with mutant A122N 
which reflects a higher resistance to precipitation at higher temperatures. Although 
only a minor improvement in monomer loss, the improvement is consistent at higher 
concentrations tested (15 mg/mL, data not shown) and is significant in a clinical setting, 
where typically no more than 5% of aggregates are considered acceptable by 
regulatory standards.  
 
No significant improvements in monomer loss were observed with other mutants (e.g. 
T199N and Q179N). Courtois, et al [22] hypothesised that a mutant equivalent in 
position to Q179N in bevacizumab could not be glycosylated as it was inaccessible to 
glycosylases. However, we confirmed that Q179N was glycosylated; likewise,  
Pepinsky, et al. [25] were able to express a glycosylated variant with a mutation in an 
equivalent position to Q179N which mildly improved antibody solubility. Accessibility 
to glycosylases does not determine whether the initial glycan is added or not, as this 
addition occurs in the endoplasmic reticulum prior to the folding of the protein. Thus, 
Table 4. Binding affinity of reference Humira® and monomeric AdmAb mutants 
to FcγR1A, FcγR2B and FcγR3A. 
AdmAb 
KD (nM) 
FcγR1A  FcγR2B  FcγR3A  
Humira® 1.84 ± 0.18 2.55 ± 1.67 1.84 ± 0.68 
WT* 4.4 ± 0.01 4.47 ± 1.00 5.96 ± 1.62 
L178K 4.14 ± 0.06 9.16 ± 6.86 2.37 ± 1.19 
L178N 6.81 ± 0.45 3.67 ± 0.93 2.15 ± 0.73 
Q160N 5.3 ± 0.01 N.D. 16.2 ± 3.05 
L116N 3.87 ± 0.14 6.15 ± 1.10 6.71 ± 1.91 
T118N 2.1 ± 0.01 9.61 ± 1.38 13.3 ± 0.45 
A122N 5.58 ± 0.18 7.53 ± 2.74 18.01 ± 7.4 
Q179N 2.74 ± 0.01 5.27 ± 0.11 2.92 ± 0.16 
L183N 2.6 ± 0.04 2.52 ± 2.05 1.48 ± 0.84 
T199N 6.49 ± 0.06 1.81 ± 1.25 11.80 ± 0.2 
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it may have been possible to introduce a glycan in this position with bevacizumab as 
well. Nevertheless, with the additional N-glycan, Q179N was expected to sterically 
hinder Fab-mediated aggregation in the targeted APR; while T199N was reported to 
significantly improve solubility [25] and sterically hinder self-association [26], however 
this was not observed for AdmAb. The Q179N mutation also mildly reduced antigen 
binding affinity by ~1.6-fold. Interestingly, Pepinsky, et al. [25] reported no change in 
the Tm of the mutation equivalent in position to AdmAb variant T199N, while we 
observed a significant improvement in Fab Tm with variant T199N (~6 degrees higher). 
Additionally, T199N had 1.8-fold improved KD to TNF- with minimal differences in KD 
to FcγRs. The lack of improvement in resistance to aggregation, despite the 
improvement in Fab stability, may be related to the mechanism of aggregation in 
AdmAb. Since the CH2 has the lowest Tm in most IgG1s, it is expected that most 
aggregation steps are at least initiated with unfolding of the CH2; thus, an improvement 
in Fab stability may not significantly impact overall resistance to soluble aggregation.  
Similarly, we observed an improvement in Fab Tm for mutants L178N and L183N. 
L178N is an interesting example, because when compared to the non-glycosylated 
variant L178K, there is an improvement in Tagg and Fab Tm through glycosylation. This 
emphasises the impact of the N-glycans added via mutation on the conformational 
stability of the Fab and its resistance to precipitation, and highlights that these changes 
are not due to the amino acid substitution. The mutation significantly improved the 
conformational stability of the Fab domain. Furthermore, despite suppressing pH-
induced precipitation when tested on the Fab alone [24], the L178N mutation had 
minimal impact on soluble aggregation when tested on the full AdmAb. Surprisingly, 
the non-glycosylated variant L178K which was reported to significantly suppress 
aggregation in bevacizumab [23], but enhance aggregation in rituximab [22], also had 
minimal impact on the stability of AdmAb. This finding highlights that framework 
regions differ significantly between IgG1 antibodies despite having identical 
sequences.  
Variants L116N and T118N had multiple Tms, with a lower Tm1, higher Tm3 and a 
significantly reduced Tagg; additionally, they were completely degraded at 65 °C. The 
Tms of these mutants are harder to interpret, and do not necessarily represent the CH2, 
Fab and CH3 in that order. As previously reported [31], disturbances in the joining 
region between the Fab domains can create additional Tms for each separate domain. 
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Thus, we expect that the Tm1 value of these mutants is representative of only part of 
the Fab (for e.g. the CH1 or VL); since the Tm of this part of the Fab is now less stable 
than the CH2, aggregation proceeded more rapidly at 65 °C. Again, our results do not 
correspond with findings reported for the mutation equivalent to AdmAb L116N in 
bevacizumab, which showed improved resistance to aggregation with no 
destabilization of the Fab [23]. Some perturbation in Fab stability was also observed 
with mutant L183N, resulting in increased monomer loss. The perturbation was minor 
and hard to detect; however consistently appeared in temperature ramps for Tm 
measurement. It is likely that the amino acid substation in this position impaired the 
conformational stability of part of the Fab domain as observed with mutants L116N 
and T118N.  
5. Conclusion 
 
Protein aggregation is a complex challenge hindering the development and long-term 
stability of therapeutic mAbs. Using advanced computational tools, we identified 
aggregation prone regions and engineered adalimumab, a marketed therapeutic mAb, 
with additional N-glycans in the Fab domain, with the aim to sterically hinder 
aggregation and increase long-term stability. Our glycan-engineered variants 
displayed a range of different stabilities, with some mutations increasing susceptibility 
to aggregation, others enhancing the conformational stability of the Fab domain, and 
one showing minor improvements in resistance to aggregation.  This approach has 
potential application for other antibodies where the Fab domain has poor stability or is 
a pre-cursor to aggregation.  We demonstrated that the conformational stability of 
blockbuster therapeutic antibodies such as AdmAb can still be improved with glycan-
engineering without compromising its antigen and Fc receptor binding affinity; these 
findings highlight the significant value of this engineering approach in the quest for 
developing more stable therapeutic mAbs with improved half-lives and therapeutic 
outcomes.  
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Antibodies have dominated the therapeutic market for the last decade as treatments 
for cancers, auto-immune disorders, inflammatory conditions and infections. The 
antibody landscape continues to evolve beyond the use of mAbs and fragments, with 
novel formats being developed including bispecifics, antibody-drug conjugates and 
nanobodies. Each of these formats also benefits from antibody engineering, whereby 
rational structural changes are made to enhance the biophysical properties of the 
antibody product, including antigen binding, cytotoxicity and stability.  Some Fc-
engineered antibodies have already entered the market as therapeutic products such 
as benralizumab in 2017. 
Antibodies, like all proteins, undergo chemical and physical degradation, often leading 
to protein aggregation. These degradation processes can occur during manufacturing, 
processing, transport, and long-term storage. Because of the negative impact of 
antibody aggregation on both manufacturing success and the efficacy and safety of 
the treatment, it is critical that we continue to develop multi-faceted approaches that 
tackle protein aggregation. In this thesis, we explored two approaches of combating 
aggregation: 1) modifications to the formulation (Chapter 2-4 and 6); 2) modifications 
to the antibody (Chapter 8).  
Through the investigation of protein-stabilizing excipients such as L-Arg and L-Glu, 
D2O and ionic liquid (CDHP) we shed light on previously unknown issues and 
demonstrated that such excipients can be incorporated in protein formulations to 
enhance protein stability. We showed that common stabilizing additives do not 
stabilize proteins in a general way; each protein must be tested, as the effects are 
often protein- and concentration-specific (Chapter 2). We demonstrated a novel 
approach for stabilizing protein formulations by modifying the solvent from H2O to D2O 
to strengthen intramolecular interactions and enhance the conformational stability of 
the protein. However, this also led to enhanced intermolecular interactions and 
increased aggregation (Chapter 3). We saw a boom in research on the biological 
applications of ionic liquids, triggering an invited review of their potential use as 
antibody-stabilizing agents (Chapter 4). This literature review concluded by identifying 
several ionic liquids with significant potential as formulation excipients – one of which 
was CDHP – a biocompatible and effective protein stabilizer. Following an 
investigation of the aggregation kinetics of mAbs (Chapter 5) which uncovered novel 
mechanistic insights into the aggregation process, we were successful in stabilizing 
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trastuzumab at high concentrations (3-fold higher than marketed product) in CDHP 
(Chapter 6) demonstrating that the stability of these commercial therapeutic products 
can be taken to new heights with ionic liquids. These results will promote the 
development of pre-filled syringes with high antibody concentrations that allow 
convenient administration of antibodies to patients from their homes.   
Our second approach to tackling antibody aggregation required an understanding of 
their production process. We developed a simple and cost-effective method to 
maximise antibody expression yield and optimise purification (Chapter 7). Following 
this, we engineered the top-selling therapeutic antibody adalimumab with additional 
N-linked glycans in the Fab domain and succeeded in improving its conformational 
stability further, without compromising its antigen or FcγR binding affinity (Chapter 8). 
Overall, the present work highlighted the unlimited potential to optimise the biophysical 
properties of therapeutic antibodies through formulation and engineering approaches.  
Our work stimulates further research into the optimisation of antibody stability and 
other important biophysical properties. In addition to screening other novel excipients 
with high-throughput methods and testing novel formulation modifications, there is 
more work to be pursued with antibody engineering. We showed that with the addition 
of a single extra glycan pair in the Fab domain, the stability of the entire domain is 
significantly improved without compromising antigen binding affinity. Moreover, there 
may be additional unexplored benefits of this additional glycan pair. Naturally occurring 
N-linked glycans are known to impact stability, effector function and pharmacokinetics. 
Engineering additional glycans may introduce new immune functions and properties 
to the engineered antibodies yet to be discovered.  
Future work may also involve characterising the identity of the added glycans in the 
Fab domain, to establish a possible relationship between the changes in stability and 
the composition of the glycan added. Modifying the composition of the added glycan 
via cellular engineering or enzymatic methods and observing its impact on stability is 
another area of future investigation.  
Furthermore, there are several other aggregation-prone regions in other domains such 
as the Fc domain, that can be engineered to enhance the stability of IgG1 antibodies. 
A combination of a few mutations in multiple APRs may result in more significant 
improvements to antibody stability. New or advanced computational techniques are 
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expected to play a key role in the development of more stable biologics such as 
antibodies. 
Protein aggregation is an ongoing hurdle to the development of biopharmaceuticals 
such as mAbs. The work presented in this thesis contributes to a detailed 
understanding of this complex process and provides methods to prevent it in 
therapeutic mAbs. As the antibody market continues to expand, research into ways of 
combating protein aggregation becomes increasingly important, especially as we 
move towards the development of novel antibody formats, which are often less stable 
than the original mAbs. Addressing protein aggregation will lead to reduced 
immunogenicity, improved pharmacokinetics, reduced tolerance to treatment and less 
manufacturing hurdles. The maximal potential of antibody therapeutics is yet to be 
unlocked.      
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Appendix 1A: Supplementary data from chapter 7 
Table S1. List of reagents and equipment used in the protocol and their source  
Product Catalogue 
Number 
Company Web Address Comments 
pFUSE vector series N/A InvivoGen www.invivogen.c
om 
Heavy and light antibody genes expressed in 
separate vectors that require co-transfection. 
mAbXpress vector series N/A ACYTE 
Biotech Pty 
Ltd. 
www.acyte.com Heavy and light antibody genes expressed in 
separate vectors that require co-transfection. 
Refer to: Jones, M. L. et al. A method for rapid, 
ligation-independent reformatting of recombinant 
monoclonal antibodies. J Immunol Methods. 354 
(1-2), 85-90, doi:10.1016/j.jim.2010.02.001, 
(2010). 
pVITRO1 vector N/A N/A N/A Heavy and light antibody genes are each driven 
by a separate promoter in a single vector.  Refer 
to: Dodev, T. S. et al. A tool kit for rapid cloning 
and expression of recombinant antibodies. Sci 
Rep. 4 5885, doi:10.1038/srep05885, (2014). 
GS vector series N/A Lonza www.lonza.com Multi-cistronic vector with heavy and light antibody 
genes co-expressed and translated as single 
transcript. 
Multi-cistronic vector 
series 1 
N/A N/A N/A Multi-cistronic vector with heavy and light antibody 
genes co-expressed and translated as single 
transcript. Refer to: Li, J. et al. A comparative 
study of different vector designs for the 
mammalian expression of recombinant IgG 
antibodies. J Immunol Methods. 318 (1-2), 113-
124, doi:10.1016/j.jim.2006.10.010, (2007). 
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Multi-cistronic vector 
series 2 
N/A N/A N/A Multi-cistronic vector with heavy and light antibody 
genes co-expressed and translated as single 
transcript. Refer to: Ho, S. C. et al. IRES-mediated 
Tricistronic vectors for enhancing generation of 
high monoclonal antibody expressing CHO cell 
lines. J Biotechnol. 157 (1), 130-139, 
doi:10.1016/j.jbiotec.2011.09.023, (2012). 
pVITRO1-Trastuzumab-
IgG1/κ 
61883 Addgene www.addgene.or
g 
Mammalian expression vector containing 
trastuzumab antibody genes with hygromycin 
resistance gene; pVITRO1-Trastuzumab-IgG1/κ 
was a gift from Andrew Beavil. 
Fast-Media Hygro Agar fas-hg-s Jomar Life 
Research 
www.liferesearch.
com 
Used to prepare low salt LB agar containing 75 
µg/ml hygromycin. 
Fast-Media Hygro TB fas-hg-l Jomar Life 
Research 
www.liferesearch.
com 
Used to prepare low salt TB broth containing 75 
µg/ml hygromycin.  
Glycerol, BioXtra, ≥99% G6279 Sigma-Aldrich www.sigmaaldric
h.com 
Prepare to 80% with water and autoclave. Store at 
room temperature. 
Jestar 2.0/LFU Plasmid 
Maxi Kit 
G221020 Astral 
Scientific 
www.astralscienti
fic.com.au 
Plasmid Maxi Prep Kit; elute or resuspend DNA in 
water (pH 7.0-8.5). 
FreeStyle 293-F Cells R790-07 Life 
Technologies 
www.lifetechnolo
gies.com 
HEK-293 cell line adapted to suspension culture in 
serum-free media. 
FreeStyle 293 Expression 
Medium 
12338-018 Life 
Technologies 
www.lifetechnolo
gies.com 
Serum-free media specially formulated for 
maintaing 293-F cell line and high protein 
expression. 
Kolliphor P188 K4894 Sigma-Aldrich www.sigmaaldric
h.com 
Non-ionic surfactant; pluronic F-68; prepare to 
10% in water and filter-sterilize using 0.22 μm 
filter. Store at 4oC. 
DMEM, high glucose  11995-065 Life 
Technologies 
www.lifetechnolo
gies.com 
 
 
Heat-Inactivated Foetal 
Bovine Serum 
10082-147 Life 
Technologies 
www.lifetechnolo
gies.com 
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Polyethylenimine, Linear, 
MW 25,000  
23966 Polysciences, 
Inc. 
www.polyscience
s.com 
Prepare to 1 mg/ml in water. Adjust to pH 7.0 with 
1 M HCl (solution becomes clear) and filter-
sterilize using 0.22 μm filter. Store at -80oC until 
use. 
OptiPro SFM 12309-050 Life 
Technologies 
www.lifetechnolo
gies.com 
Transfection formulated serum-free media 
Hygromycin B Solution ant-hg-1 Jomar Life 
Research 
www.liferesearch.
com 
 
Dimethylsulphoxide 
(DMSO) 
AJA2225 Thermo Fisher 
Scientific 
www.thermofishe
r.com 
Tryptone (casein 
peptone) 
LP0042B Thermo Fisher 
Scientific 
www.thermofishe
r.com 
Prepare to 20% in PBS and filter-sterilize using 
0.22 μm filter. Store at 4oC.  
Phosphate Buffered 
Saline (PBS) Tablets, pH 
7.4, 100 ml 
09-2051-
100 
Astral 
Scientific 
www.astralscienti
fic.com.au 
 
HiTrap Protein A High 
Performance, 1 x 5 ml 
column 
GE17-
0403-01 
Sigma-Aldrich www.sigmaaldric
h.com 
AKTApurifier 100 28406266 GE Healthcare www.gelifescienc
es.com 
Automated FPLC system, which can include a P-
960 sample pump and Frac-920 fraction collector. 
Glycine-HCl G2879 Sigma-Aldrich www.sigmaaldric
h.com 
 
Citric Acid, monohydrate BIOC2123 Astral 
Scientific 
www.astralscienti
fic.com.au 
Sodium Citrate, trisodium 
salt dihydrate  
BIOCB003
5 
Astral 
Scientific 
www.astralscienti
fic.com.au 
1 M Tris-HCl solution pH 
9.0 
BIOSD814
6 
Astral 
Scientific 
www.astralscienti
fic.com.au 
Amicon Ultra Centrifugal 
Filters (30 MWCO) 
UFC80300
8/UFC903
008 
Merck Millipore www.merckmillip
ore.com 
Used to buffer exchange and concentrate purified 
protein. 
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Pierce Bicinchoninic Acid 
(BCA) Assay Kit 
23227 Thermo Fisher 
Scientific 
www.thermofishe
r.com 
 
BLItz System 45-5000 fortéBIO www.blitzmenow.
com 
Instrument used for bio-layer interferometry (BLI) 
measurements. 
Protein A biosensors 18-5010 fortéBIO www.blitzmenow.
com 
 
Acrylamide/Bisacrylamide 
(37.5:1), 40% solution 
786-502 Astral 
Scientific 
www.astralscienti
fic.com.au 
Ammonium Persulfate 
(APS) 
AM0486 Astral 
Scientific 
www.astralscienti
fic.com.au 
TEMED AM0761 Astral 
Scientific 
www.astralscienti
fic.com.au 
Coomassie Brilliant Blue 
R-250 
786-498 Astral 
Scientific 
www.astralscienti
fic.com.au 
Precision Plus Dual-Color 
Protein Standard 
1610374 Bio-Rad www.bio-rad.com 
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Appendix 1B: Supplementary data from chapter 8 
 
Figure S1. HCD spectrum of the chymotryptic peptide LSTASSLDYWGQGTNVTVSSASTK for the L116N mutant 
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Figure S2. ETD spectrum of the chymotryptic peptide LSTASSLDYWGQGTNVTVSSASTK for the L116N mutant. 
Figure S3. HCD spectrum of the de-glycosylated chymotryptic peptide GQGTNVTVSSASTKGPAVFPLAPSSK for the L116N mutant. 
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Figure S4. HCD spectrum of the chymotryptic peptide LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
Figure S5. ETD spectrum of the chymotryptic peptide LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
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Figure S6. CID spectrum of the de-glycosylated chymotryptic peptide LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
Figure S7. ETD spectrum of the de-glycosylated chymotryptic peptide LSTASSLDYWGQGTLVNVSSASTK for the T118N mutant. 
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Figure S8. HCD spectrum of the chymotryptic peptide GQGTLVTVSSNSTK for the A122N mutant. 
Figure S9. ETD spectrum of the chymotryptic peptide GQGTLVTVSSNSTK for the A122N mutant. 
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Figure S10. CID spectrum of the de-glycosylated chymotryptic peptide LSTASSLDYWGQGTLVTVSSNSTK for the A122N mutant. 
Figure S11. ETD spectrum of the de-glycosylated chymotryptic peptide LSTASSLDYWGQGTLVTVSSNSTK for the A122N mutant. 
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Figure S12. HCD spectrum of the chymotryptic peptide KVDNALQSGNSNESSVTEQDSKDSTY for the Q160N mutant 
Figure S13. ETD spectrum of the chymotryptic peptide KVDNALQSGNSNESSVTEQDSKDSTY for the Q160N mutant 
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Figure S14. CID spectrum of the chymotryptic peptide NSGALTSGVHTFPAVK for the L178K mutant. 
Figure S15. ETD spectrum of the chymotryptic peptide NSGALTSGVHTFPAVK for the L178K mutant. 
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Figure S16. HCD spectrum of the chymotryptic peptide PAVNQSSGLY for the L178N mutant. 
Figure S17. ETD spectrum of the chymotryptic peptide PAVNQSSGLY for the L178N mutant. 
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Figure S18. HCD spectrum of the chymotryptic peptide NSGALTSGVHTFPAVLQSSGNY for the L183N mutant. 
Figure S19. ETD spectrum of the chymotryptic peptide NSGALTSGVHTFPAVLQSSGNY for the L183N mutant. 
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Figure S20. ETD spectrum of the chymotryptic peptide SLSSVVTVPSSSLGNQTY for the T198N mutant. 
Figure S21. ETD spectrum of the de-glycosylated chymotryptic peptide SLSSVVTVPSSSLGNQTY for the T198N mutant. 
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Figure S22. Single cycle kinetic sensograms of monomeric AdmAb variants binding to soluble homotrimeric TNF-. Humira® (A), 
AdmAb WT (B), L178K (C), L178N (D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
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Figure S23. Single cycle kinetic sensograms of monomeric AdmAb variants binding to FcγR1A. Humira® (A), AdmAb WT (B), L178K 
(C), L178N (D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
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Figure S24. Single cycle kinetic sensograms of monomeric AdmAb variants binding 
to FcγR2B. Humira® (A), AdmAb WT (B), L178K (C), L178N (D), L116N (E), T118N 
(F), A122N (G), Q179N (H), L183N (I) and T199N (J). 
). 
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Figure S25. Single cycle kinetic sensograms of monomeric AdmAb variants binding to FcγR3A. Humira® (A), AdmAb WT (B), L178K 
(C), L178N (D), Q160N (E), L116N (F), T118N (G), A122N (H), Q179N (I), L183N (J) and T199N (K). 
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